Speaker and Chair Biographies for 2012


Below are listed the biographies of the speakers and chairs participating in the 2012 programme.  These will be continually updated as we receive new biographies.

Stephen Arnott

Anne Assmus

Mark Bamforth

Catherine Beech

Jeremy Billson

Steve Bloor

Bruce Booth

Jasper Bos

Charles Brigden

Chris Britten

Iain Buchanan

Yulia Butscheid

Hamish Cameron

Gilles Capart

Sir William Castell

Mark Chadwick

Margarita Chavez

Dina Chaya

Yen Choo

Gavin Clark

David Colpman

Nigel Courtenay-Luck

Jane Dancer

Paul Davie

Sir Andrew Dillon

James Dipple

Darrin Disley

Paul Drohan

Jack Elands

Mike Evans

Josep Falcó

Lubor Gaal

Ian Gilham

Denise Goode

Richard Goodfellow

Mike Gutch

Tim Haines

Debbie Harland

Steven Harris

Peter Harrison

Paul Higham

John Hodgson

Christopher Hollowood

Sofia Ioannidou

David Jackson

Burkhard Jansen

Keyji Johnsen

Charlie Johnson

Kevin Johnson

Chris Jones

Frank Kalkbrenner

James Kew

Gareth King

David Knowles

David Laskow-Pooley

Melanie Lee

Reid Leonard

Stephanie Lesage

Jan Lichtenberg

Edward Littler

Wilma Lukas

Suzanne Mandala

Howard Marriage

Francis Marsland

Fiona Marston

Niall Martin

Julie Masse

Stuart Medina

Gwen Melincoff

Sir Jonathan Michael

Richard Mole

Bruno Montanari

Neil Murray

Ian Nicholson

James Noble

Richard Owen

Dave Parry

Alex Pasteur

David Phillips

Richard Pither

Andrew Porter

Alexander Pretsch

Richard Pye

David Roblin

Greg Rossi

Bruce Savage

Simon Saxby

Govert Schouten

Graziano Seghezzi

Sunil Shah

Tom Shepherd

Ken Shimokawa

Alex Sim

Nick Skaer

Andy Smith

Gunnar Staaf

Christina Takke

Douglas Thomson

Claire Thompson

Adrian Towse

Anthony Walker

Matthew Walls

Fintan Walton

Sally Waterman

Ilka Wicke

Eric Marijn Wielhouwer

 

Stephen Arnott, Managing Director, Quy BioScience

Stephen Arnott has worked within the healthcare environment for over 20 years and has extensive experience licensing novel IP and introducing new products to market. He has been Managing Director of Quy Biosciences Ltd since January 2011, tasked with developing the company's veterinary division, VetCell, and determining a route to market for the human application of using MSC's to treat soft skeletal injuries. VetCell is conjunction with the Royal Veterinary College has been treating equine tendon and ligament injuries with stem cells for ten years and has data to show that treatment reduces re-injury rate by over 50%.

Anne Assmus, Manager Business Development, MorphoSys

Anne has been working for MorphoSys AG since August 2009 and is mainly responsible for technology In- and Out-Licensing. Before joining MorphoSys, Anne worked in Marketing of Novozymes, a Danish Industrial Enzyme Company. Anne studied biology at the University of Heidelberg and International Business at Copenhagen Business School, where she was a Scientific Assistant in the Research Centre for Biotech Business.

Mark Bamforth, President & CEO, Gallus BioPharmaceuticals

Mark Bamforth is Founder, President and CEO of Gallus BioPharmaceuticals, a premier contract manufacturer. He raised the financing to acquire an existing, licensed site. Today, a highly experience team of 200 is delivering clinical and commercial biopharmaceuticals. Mark utilizes 22 years of experience running global operations and a Pharmaceutical CMO business for Genzyme. Prior, Mark was a chemical engineer in the whisky industry and a petroleum engineer exploring for North Sea oil. Mark serves on the MassBio Board and is a Saltire Foundation Founding Trustee, enabling Scottish entrepreneurs to learn in high growth USA companies. Mark has a BS in Chemical Engineering and an MBA.

Dr Catherine Beech, CEO, Oval Medical Technology

Dr Catherine Beech joined Oval Medical in 2009 as Commercial Director and has recently taken over the position of CEO. Catherine was formerly the European Medical Director of a multi-national pharmaceutical company and so has a broad range of expertise in founding, growing and exiting biotechnology and life science businesses. She has a background in early stage venture capital and was a co-founder and Director of Life Sciences at the Cambridge Gateway Fund, a £35 million venture capital fund investing in early-stage biotechnology companies. Catherine was awarded an OBE in the Queen’s Birthday Honours List in June 2008 for services to innovation and technology and was the Founding Chair of the Bioindustry Association’s Fledgling Company Committee.

Jeremy Billson, Vice-President of Business Development, Argenta

Jeremy is Vice-President of Business Development at Argenta and has over 17 years experience in business development and research functions within the pharmaceutical and biotech industry.
Jeremy joined Argenta from Research Intelligence, a biotech business intelligence service provider which he founded. Prior to this, he was Associate Director of Business Development at Summit PLC and Business Development Manager at Medivir UK.

Steve Bloor Biography, CEO, Videregen

A senior level executive with over 20 years' experience in the medical device and regenerative medicine industry having worked within both start up and multinational medical companies. A proven track record of leadership and senior management including roles as Vice President of R&D (Covidien) and Chief Scientific Officer (TSL plc), with direct responsibility for R&D, Regulatory, Clinical and Compliance functions.

Steve has specialist expertise in MedTech, regenerative medicine and translation of technologies from laboratory to commercial scale manufacture, development and launch of new products and technologies, clinical strategy execution and regulatory approvals in the EU and US. Now leveraging this wide-ranging knowledge in the industry to lead a regenerative medicine spin-out (as CEO of Videregen), and as a consultant to advise and help spin-out and early phase start-up companies successfully realise the full potential of their technologies or products through regulatory approval and commercialisation.

Bruce Booth, Partner, Atlas Venture

Bruce is a Partner with Atlas Venture, focusing on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies.  He currently sits on the Boards of Avila, Bicycle, Miragen, Nimbus, OnQity, ProtAffin and Zafgen. He also works or has worked closely ARCA Biopharma (NASDAQ:ABIO), Archemix, NxStage Medical (NASDAQ:NXTM), Prestwick (sold to Biovail), Proprius (sold to Cypress), and Stromedix.   Previously, Bruce was an investor with Caxton Health Holdings, and before that he was a consultant with McKinsey & Company on pharmaceutical R&D issues.   Bruce serves as a Trustee of the New York Academy of Medicine and a member of the UCB Pharma Scientific Advisory Board. As British Marshall Scholar, Bruce earned a Doctorate in Immunology from Oxford University, and received his B.S. summa cum laude in Biochemistry from Pennsylvania State University. He also writes a blog on venture capital and life science topics (http://www.lifescivc.com), and can be followed on Twitter @LifeSciVC. Bruce lives in Wellesley, MA with his wife and three wonderful kids.

Jasper Bos, Director, Merck Serono Ventures

Jasper Bos, PhD is Director with Merck Serono Ventures, the corporate venture capital fund of Merck Serono SA. Prior to joining Merck Serono SA, Jasper served as Investment Manager at IFHA, a growth capital fund backed by Dutch institutional investors and Goldman Sachs, where he managed investments in emerging economies in the healthcare and insurance sectors. Before joining IFHA, he worked as Health Economics and Strategy Manager at the Netherlands Vaccine Institute.  Jasper is a Board Member of EpiTherapeutics and Galecto, and an Observer to the Board of Vaximm. Jasper holds a PhD. in Pharmacy from the University of Groningen, the Netherlands

Charles Brigden, European Development & Licensing Director, Amgen International

Charles Brigden is the European Business Development & Licensing Director for Amgen International. Having joined Amgen in 2004 as Therapeutic Area Lead for Oncology, his most recent role was Country Medical Director for the UK & Ireland. Prior to joining Amgen, Charles worked for Eli Lilly & Company as a Clinical Research Physician. Before joining industry, Charles trained as a medical doctor in NHS teaching hospitals. He is a Fellow of the Royal College of Surgeons, a Member of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and holds an MBA from Columbia & London Business Schools.

Chris Britten, Business and Commercial Development Director, Astellas Pharma Europe Ltd

Chris is currently Director, Business and Commercial Development at Astellas Pharma Europe Ltd., the European arm of one of Japan’s leading pharmaceutical companies.  In this role he works closely with both global brand teams and R&D colleagues to build Astellas’ presence in the region.  Prior to joining Astellas, Chris spent three years leading the life science advisory team at Deloitte Corporate Finance, advising companies across the sector on M&A, partnering, fund-raising, valuation and corporate strategy.  He previously spent several years at GlaxoSmithKline in roles of increasing responsibility across drug discovery, project management, corporate venturing and business development.

Iain Buchanan, CEO, NOXXON

Iain Buchanan was appointed CEO of NOXXON in September 2010 having worked closely with the board of directors since 2007 and as a non-executive member of the supervisory board since 2009. He brings to the company over 30 years of commercial experience in the pharmaceutical and biotech industries. Iain joined NOXXON from Novexel in Paris where he acted as CEO since the Company's formation in 2004 until its sale to AstraZeneca earlier this year. Prior to Novexel, Iain held a variety of management positions of increasing responsibility across various companies. These include Vertex Pharmaceuticals (Europe) Limited where, as Managing Director, he was responsible for building a Vertex presence in Europe from 1994 to 2004, at Cilag A.G. (a division of Johnson and Johnson based in Zug, Switzerland) where he managed the licensee business internationally from 1987 to 1994 and at Biogen S.A. in Geneva, Switzerland from 1981 to 1987 where he oversaw commercial activities in Europe. Iain began his career in Product Management at Merck Sharp & Dohme (UK) Limited in 1978.

Iain holds a Bachelor of Science in Physiology from the University of St Andrews, Scotland and is a non-Executive Director of Synairgen plc based in Southampton UK.

Yulia Butscheid, Head of Strategy and Business Development, Biognosys

At Biognosys Yulia is responsible for the development of the company's long-term strategy, marketing and business development. Yulia started her career as a founder of a biotech start-up in Belarus in the field of molecular diagnostic of infectious diseases. After completing her PhD she worked in various roles in clinical development and marketing at Novartis Pharma in Germany. Prior joining Biognosys Yulia was an Investment Manager at Creathor Venture where she was in charge of the Life Science portfolio and new investments in Biotech / Pharma fields. Yulia graduated in Environmental Medicine and Immunology, and obtained her PhD degree in Human Biology. She also holds a MBA from INSEAD.

Hamish Cameron, Venture Partner, SV Life Sciences

Dr Hamish Cameron is as a Venture Partner at SV Life Sciences and currently a Director at TopiVert, Delenex and VH Squared. Before joining SVLS he was CEO of Cambridge Antibody Technology ("CAT"). Prior to that, he held a series of senior R&D positions at AstraZeneca/Zeneca including Head of the Cardiovascular Therapy Area, Senior Vice-President Medical Research and was a member of the R&D Leadership Team. Dr Cameron started his industry career with Janssen, after working in clinical practice and research in the UK. Hamish trained as a physician and holds MBBS and BSc (Hons) Pharmacology degrees from the University of London. He is a member of the UK Royal College of Physicians and a Fellow and past Board member of the Faculty of Pharmaceutical Medicine.

Gilles Capart, Managing Director, BruCells

Gilles participated in the creation of the company in 2001 in order to develop applications of the therapeutic vaccine technology of the three major university hospitals in Brussels. Before that, he was Vice President of Investments of the UCB Group.

Mark Chadwick, CEO, Physiomics plc

Mark joined Physiomics from EnviroGene in December 2010.  Previously he was VP of BD at Excelsyn, where he grew turnover to £14m and EBITDA to £1m. Prior to that he led the Development Services Business Unit at Excelsyn, growing the customer base from scratch to over 80 in 3 years.  Before that, Mark spent 10 years in Cambridge from Cambridge Genetics Limited, through two mergers to become Director of Commercial Operations at BioFocus.
Mark’s a former Fellow of Corpus Christi College Cambridge, He holds an MBA from Imperial College London, a PhD in Molecular Biology from The University of Newcastle.

Margarita Chavez, Director, Venture Investments, Abbott Biotech Ventures

 

  • 15 years of deal-making experience
  • With Abbott Biotech Ventures since 2010, closing several investments in US and Europe
  • Joined ABV from Abbott Global Licensing & Acquisitions, executing on a number of acquisitions and divestitures since 2007
  • Deal lawyer since 1997, advising companies, venture funds and investment banks on venture financings, M&A and IPOs
  • JD 1997 (licensed to practice law in California since 1997); BS 1994

 

Dina Chaya, Venture Partner, NeoMed Management

Dina Chaya is a Venture Partner of NeoMed Management. She has worked as an investor in the venture capital healthcare industry in Europe and the US since 2001, including an operational role in a medical devices business during 2006. Prior to joining NeoMed, she was a Director of Growth Capital at 3i plc in London and an Associate at Index Ventures in Geneva. Significant recent investments include Endosense SA, EUSA Pharma Inc and Novexel SA. Dina graduated from Cambridge University and has a Ph.D. in molecular and cellular biology from Paris VI University. She is a CFA charter holder.

Yen Choo, Founder, CEO and CSO, Progenitor

Dr Choo is Founder, CEO and CSO of Progenitor Labs Ltd. He is also founder and Executive Chairman of Plasticell Ltd, a stem cell technology and cell therapy company. Prior to his interest in stem cells Dr Choo was founder and CSO of Gendaq Ltd, a zinc finger engineering company that was acquired by Sangamo Biosciences (NASDAQ:SGMO). Previously he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge. Dr Choo holds a PhD in Molecular Biology from the University of Cambridge. He serves on the UK Stem Cell Steering Committee, which oversees national stem cell research and the UK Stem Cell Bank.

Gavin D Clark, BSc, CLP, Chief Business Officer, MGB Biopharma Limited

Gavin is a co-founder at MGB Biopharma. He was formerly responsible for WW Licensing Infectious Diseases at Glaxo – GlaxoWellcome 1994-99, there closing several deals including the first Paratek deal, Otsuka Quinolone Grepafloxacin, "Super Macrolide" Research Collaboration with PLIVA, and diagnostic deals for influenza and herpes. After GlaxoWellcome he was VP Business Development at Tibotec and a key player in the team which drove to the J&J acquisition. He has consulted since 2002 for a number of biotech companies in US/EU/Asia Pacific and serves as Non Executive Director at Angel Biotechnology Holdings plc.

David Colpman, Senior Vice President, Business Development, Shire Pharmaceuticals Group

David Colpman is a senior member of Shire’s business development team focused on building the global Speciality and Regenerative Medicine business through licensing and M&A.

During the last twelve years at Shire, David has completed around 12 licensing deals. In addition, he has run numerous M&A, product divestment and acquisition projects. Specific achievements include in-licensing the GI product Lialda/Mezavant with current sales of over $350M, leading the teams that bought Transkaryotic Therapies for $1.6BN, Movetis for $550M, and Advanced BioHealing for $750M. In 2007 David divested a business to Almirall for $213M.

David acts as advisor to the Venture Group, Sunstone Capital, and was formerly a member of the board of Ace BioSciences.

Prior to joining Shire he led GlaxoWellcome’s UK Business Development team and prior to that he was Head of Licensing and Alliances at Novo Nordisk in Denmark. David is a pharmacist by training; he spent part of his early career working in Japan and has a basic command of the Japanese language.

Nigel Courtenay-Luck, CSO, Saturn Biosciences

Professor Nigel Courtenay-Luck has over thirty years' experience in Biotechnology, specialising in the drug development of novel biological molecules for the treatment of cancer. He has gained experience at all levels of drug development from pre-clinical to Phase III. Nigel co-founded Antisoma Research Ltd in 1991, and has served on a number of boards including the BIA scientific advisory board and Fusion Antibodies Ltd main board, on which he is still active. In addition Nigel is a senior lecturer in the division of medicine, Hammersmith Hospital (Imperial College, London) and a faculty professor at the Medical University of South Carolina (MUSC). Nigel, together with Raymond Spencer, co-founded Saturn Biosciences, a virtual company which is developing a highly novel second generation pan cancer antibody-Interleukin 12 fusion protein which is aimed at improving efficacy over current treatments for a greater number of malignant melanoma patients and with a greatly reduced dose and cost of treatment compared with current antibody therapies.

Jane Dancer, COO, F-star GmbH

Jane Dancer joined F-star as their Chief Operating Officer in April 2012. Prior to that she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)). Jane spent the first part of her career in the agrochemical industry where she held research and project management roles in Aventis Crop Science, AgrEvo UK Ltd and Schering Agrochemicals Ltd. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD and degree in Natural Sciences from the University of Cambridge.

Paul Davie, Chief Executive Officer, InhibOx

Paul has a long and successful track record in commercial roles in computer-aided drug discovery. He held support and sales roles at Chemical Design before going on to build and manage the European sales, marketing, support and consulting operations at Oxford Molecular. Paul went on Accelrys to build the Consulting Division and serve as European General Manager, before becoming Chief Operating Officer at InforSense. He founded and was CEO at Secerno, a successful database security company, before returning to research informatics with InhibOx. Paul has an MBA and studied chemistry at Oxford University.

Sir Andrew Dillon, CEO, NICE

Andrew Dillon joined the NHS in 1975 and held a number of senior management positions, including General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust, before joining the National Institute for Health and Clinical Excellence as its founding Chief Executive in 1999.

James Dipple, MD, Milton Park

James Dipple holds over 30 years' experience in commercial property. James began his career working within agency and consultancy, before moving into senior roles with Strutt & Parker and Speyhawk. James originally came to MEPC in 1997 to lead the modernisation of Milton Park, before leaving the business in 2003 to pursue new opportunities with Hines and then later with Easter Group Ltd. James then rejoined MEPC to take over the running of Milton Park as Managing Director in April 2008. James is a keen cyclist, enthusiastic sailor and dedicated rugby fan.

Dr Darrin M Disley, CEO, Horizon Discovery Ltd.

Dr Darrin M Disley is the CEO of Horizon Discovery Ltd. and is responsible for corporate development, business strategy and investor relations. Darrin is a parallel business entrepreneur and has been involved in the start-up and growth of ten high-tech business ventures. He is an experienced general manager with a track-record for raising investment for and managing the growth of early-stage technology companies. Darrin holds a PhD in Biotechnology from the University of Cambridge; has been the author of six papers, 7 patent applications and 32 conference abstracts and; has been an advisor on biotech commercialisation strategies to key technology centres in Europe, USA, India and Africa.

Paul V. Drohan, SVP Commonwealth and Ireland, Genzyme Therapeutics

Paul Drohan is a 23 year veteran of the biopharmaceutical industry. He has led organisations in South Africa, Canada, Australia/New Zealand, Ireland and the UK. The hallmarks of his success have been i) building successful teams, ii) understanding the unique approach to different markets, and iii) ensuring a sustainable competitive advantage by simplifying processes and consolidating services.

During his tenure in industry he has been determined to bring value to patients. Orphan diseases have been at the centre of his work over the past 15 years.

He is currently the General Manager & Snr Vice-President of genzyme UK & Ireland where he is also Chairman of Genzyme Therapeutics Ltd in the UK. Paul also is a member of the OBN (Oxfordshire Bioscience Network) Advisory Board and is a past Board Member of the Bio Industry Association in the UK.

Jack Elands, CEO, Amakem

Jack Elands has been the Chief Executive Officer of Amakem since its inception in 2010. Previous to his role as CEO at Amakem, Jack served as the CBO of Silicos, an informatics platform-based biotechnology company. Prior to that, Jack served as the CEO of Vitec, a specialty biochemical company focused on antimicrobial surface chemistries and products, and the VP of Business Development at Sidec AB, a Swedish company focused on the discovery and development of protein based drugs. Jack started his pharmaceutical career at Marion Merrell Dow (later HMR, now Sanofi-Aventis). He has published extensively in papers and posters on topics ranging from biomolecular screening to protein tomography to life science informatics and functional genomics and has contributed to several patents. He received his undergraduate in medical biology from University of Utrecht in 1985. Jack was awarded his doctorate in Neuropharmacology from the Rudolf Magnus Institute at University of Utrecht in 1989.

Mike Evans, Chief Executive, Oxford Gene Technology

Mike Evans joined Oxford Gene Technology (OGT) in March 2005 and has led the transition from a licensing-led business model to a highly successful products and services business — delivering innovative clinical genetics and diagnostic solutions to advance molecular medicine. Dr Evans most recently held the position of Executive Vice President, Marketing and Strategy, Amersham Discovery Systems Division, and was previously Executive Vice President of the Bioassays Business. In 2000 Dr Evans joined Ascot plc as Managing Director, Fine Chemicals, responsible for two businesses within the Ascot plc group and was a member of Ascot's Executive Committee. Dr Evans holds a BA, MA and DPhil from the University of Oxford. He is a non-executive director of The Automation Partnership plc.

Josep Falcó, CEO, ImmunNovative Developments.

In January 2011 Josep joined ImmunNovative Developments, a spin-off biotech company of University of Barcelona and Hospital Clínic of Barcelona, as CEO. Josep has more than 10 years of experience in pharmaceutical industry. Josep has worked at Sanofi as Senior Scientist in Medicinal Chemistry in the areas of oncology and CNS, and in Grupo Ferrer as Team Leader and Project Manager in the areas of CNS and antibacterials. Josep also worked in Fundació Bosch i Gimpera as Senior Consultant in Centre for Entrepreneurship in 2010.
Josep holds a Degree in Chemistry (1997), a Degree in Chemical Engineering (1998), a PhD in Chemistry (2001) and a MBA (2009).

Lubor Gaal, Head of Europe, Search and Evaluation, Strategic Transactions Group

Lubor is the Head of Europe, Search and Evaluation, Strategic Transactions Group for Bristol-Myers Squibb, based at the UK headquarters in Uxbridge (London). He is responsible for the acquisition and licensing of drug programs or companies in support of the company's BioPharma strategy.

Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d in France and CBO of Vectron Therapeutics AG in Germany. In the US, Lubor worked for Berlex Laboratories, where he was responsible for worldwide licensing for Cardiovascular and Neuroscience for Schering AG. Before joining Berlex, he worked for Burrill and Company in San Francisco, where he advised biotechnology and pharmaceutical companies on business development strategies and execution. Lubor has extensive experience in evaluating and negotiating transactions with small and large companies, having worked in the U.S. and in Europe over the last two decades. Lubor received his Ph.D. from the University of California at Berkeley and his B.Sc. in Neuroscience from the University of Sussex in Brighton, U.K.

Dr Ian D Gilham

Dr Gilham joined the Board of Axis-Shield in November 2001 from GlaxoSmithKline (GSK), where he held the position of Vice President - Pharmacogenetics. At GSK, he was responsible for the delivery of pharmacogenetic tests, as well as novel diagnostic tests used in targeting GSK's medicines. Prior to joining GSK, Ian held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics. In January 2007 Ian was appointed Chief Operating Officer and was promoted to the position of Chief Executive Officer in January 2008. Ian left Axis-Shield in November 2011 after completing the sale of Axis-Shield to Alere Inc.

Denise Goode, Senior Director, AstraZeneca

Denise Goode, joined AstraZeneca in 1994 and has been dealmaking for over 10 years.

After graduating in biological sciences and qualifying as a Chartered Accountant, Denise's Pharmaceutical career started in finance. As a result, Denise has worked on all aspects of strategic reviews, finance, and global product transactions. She is currently Executive Regional and Corporate Business Development Director in AstraZeneca's Strategic Partnering and Business Development team. Her successes include leadership & delivery of the AZ/BMS collaboration for saxagliptin & dapagliflozin and a subsequent related Japanese deal; in-licenses of Vimovo & AZD-1067; the in-license of Crestor and associated Japanese co-marketing arrangements with Shionogi; the divestment of the global Dental business; & the original 2004 C.A.T. alliance. She has also worked on many academic alliances with major Universities around the World and on R&D collaborations.

She is currently working on Real World Evidence alliances to support AstraZeneca's leading position in relation to Payer Evidence.

Richard Goodfellow, CEO, Scancell Holdings plc

Dr Richard Goodfellow has over 25 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company’s flotation on the London Stock Exchange and successfully negotiated numerous deals. Dr Goodfellow is also a founder of Paradigm Therapeutics, a Cambridge based functional genomics company and is a former Director of Enact Pharma plc.

Mike Gutch, Managing Director, MedImmune Ventures

Mike had experience as both a corporate and private venture capital investor prior to joining MedImmune Ventures in September 2011. Before MedImmune Ventures, Mike was a Director with H.I.G. BioVentures, and prior to that was a Principal with Lilly Ventures, the corporate venture capital arm of Eli Lilly & Company. While at Eli Lilly, Mike was also part of the Corporate Financing and Investment Banking group, where he focused on M&A and licensing transactions. Mike earned his Ph.D. in Cellular and Molecular Pathology from the State University of New York and his MBA in finance from Indiana University.

Tim Haines, Partner, Abingworth

Tim Haines, Partner, has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Current and past board positions include Astex Therapeutics (ASTX: NASDAQ), Chroma, Fovea (Acquired by Sanofi Aventis), HBI (acquired by Meda), IMI, PowderMed (Acquired by Pfizer), KSpine, Stanmore Implants, Lombard Medical (AIM) and XCounter (AIM). Tim has a BSc from Exeter University and an MBA from INSEAD.

Debbie Harland, Partner, SR One

Deborah joined SR One in 2005 to establish the firm’s European investment office. She brings to SR One extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 20 year tenure in the pharmaceutical industry. Deborah is currently a member of the Board of Directors of Mission Therapeutics Limited, Protaffin AG, Bicycle Therapeutics Limited, Syntaxin Limited, and f-star GmbH and is an observer on the board of 7TM Pharma. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007) and Pharmakodex Limited (sold to Orexo) and an observer on the Board of Ablynx (IPO, Euronext Brussels 2007). Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.

Steve Harris, Chief Executive, Circassia

Steve Harris is a successful bioscience entrepreneur with extensive experience of founding and leading biotechnology and specialty pharmaceutical companies. Prior to establishing Circassia, Steve was a founding member of the management team that grew Zeneus Pharma into a leading specialty pharma company after acquiring Elan’s European business for $110m. As CFO, Steve played a key role in refocusing and turning the business around, and subsequently as CEO managed the company’s acquisition by Cephalon for $390m. Prior to Zeneus, Steve spent seven years at PowderJect Pharmaceuticals plc as CFO. As a key member of the management team he helped grow the business from a loss-making private biotechnology business into a fully integrated, profitable public company and fifth largest vaccines business in the world. As CFO he oversaw the financial management of PowderJect’s subsequent acquisition by Chiron for $1 billion.

Peter Harrison, CEO, Bioventix plc

Peter Harrison is Chief Executive Officer of Bioventix plc, an antibody technology company that works in the field of clinical diagnostics. He has worked in the field of antibody technology since 1986 and has extensive experience of the development and commercialisation of antibody technologies. In 1986 he joined Celltech Ltd to manage their contract antibody production business and in 1991 he joined KS Biomedix Ltd and helped to establish sheep monoclonal antibody technology at their Farnham research laboratory. Following the acquisition of KS Biomedix Limited by Xenova plc in 2003, he led a management buy-out that resulted in the formation of Bioventix and he has led the subsequent commercial development of the Company.

Paul Higham, CEO, immatics

Paul Higham was appointed as CEO of immatics in August 2008. Previously, he served as Director Commercial Development at Ark Therapeutics Group plc where he was responsible for commercial strategy and all business development activities. In addition, he was in charge of establishing the operations and gene-based medicine production facilities of Ark Therapeutics in Finland.

Prior to joining Ark Therapeutics in 2001, Paul Higham worked as International Commercial Vice President for GI, Metabolic and Pain at GlaxoWellcome plc from 1996 to 2001, where he was responsible for all aspects of business development, strategic marketing, sales and finance. From 1985 to 1996, after completing his studies in Applied Biology, he held various sales and marketing positions of increasing responsibility with Bayer AG and eventually became General Manager of Bayer Pharmaceuticals for Sweden and Denmark.

John Hodgson, Managing Editor, Scrip Intelligence

John Hodgson is Managing Editor of Scrip Intelligence, the daily global pharma newsletter, responsible for a global team of writers, editors and analysts on the drug development industry. Before that he was co-founder and director of Critical I, a business intelligence consultancy advising biotech start-ups, venture capital funds, scientific foundations, universities, and European government bodies on business planning, fund-raising, risk management and technology trends. He has followed the biotechnology sector since the early 1980s with Trends in Biotechnology and Nature Biotechnology.

Chris Hollowood, Partner, SV Life Sciences

Chris joined Apposite in 2007 and is working with the Life Sciences investments. He started his investment career as a fund manager with Neptune Management, with responsibility for Healthcare sector investments, before moving into Healthcare focused venture capital and corporate advisory at Bioscience Managers. He attained his first degree in Natural Sciences, specialising in Chemistry, and a PhD in Organic Chemistry, both from Cambridge University. Between his first and second degree, Chris worked in the pharmaceutical industry as a medicinal chemist at GlaxoWellcome (GlaxoSmithKline) and Pfizer.

Sofia Ioannidou, Associate, Edmond de Rothschild Investment Partners

Sofia Ioannidou is an Associate in the Life Sciences team of Paris-based Edmond de Rothschild Investment Partners (EdRIP), having joined the company in 2009. She is an observer on the boards of EdRIP companies Cellnovo and PDC Biotech. Prior to joining EdRIP, she was an Associate Consultant at L.E.K. Consulting in London, where she performed scientific and commercial due diligence assignments for clients in the Life Sciences sector. Sofia started her career as a Research Scientist in Drug Development within the Boston, US-based company Eyetech Pharmaceuticals. Sofia obtained a BSc and an MSc in Molecular and Cellular Biochemistry from the University of Oxford, UK, and a PhD in Cell Biology from Cancer Research UK.

David Jackson, CEO, Oxtex

David joined Oxtex as the founder CEO in August 2011, raising £0.5M of initial seed investment for the Oxford University spin out.  Over the last 25 years, prior to joining Oxtex, he has held a number of senior positions in both public and privately held companies, including Chief Operating Officer of Oxford Molecular, Chairman of FWPharma Systems, and more recently  as CEO of Ijento, a global software supplier in marketing analytics.  David is also currently the non-executive Chairman of Brain in Hand Ltd, an early stage company developing technology to support people living in the community with impaired executive brain function.

Burkhard Jansen, CEO, Avienne

Burkhard Jansen, MD, is a skin and cancer drug development executive with a background as a professor of dermatology and clinical pharmacology with FDA experience. Prior to co-founding and leading Avienne (Lower Austria and Vienna, Austria) and Novelix (San Diego, USA), Burkhard was VP, Clinical Development, at Oncogenex (Vancouver, Canada). Oncogenex entered into a $430 million partnering deal with Teva in December of 2009 based on programs Burkhard helped to build. Prior, he was the Head of Experimental Oncology and Molecular Pharmacology at the Medical University of Vienna in Austria.

Keyji Johnsen, Founder, MATOS Pharma

Keyji spent nine years in the Schering/Bayer organization. After joining Nihon Schering KK as Oncology Product Manager, he experienced various operational and strategic marketing roles with the firm. As a manager of Market Intelligence, he was responsible for primary/secondary market research and assessment of licensing candidates. Post-merger, he was the manager of New Products, concurrently assessing licensing candidates and representing Japan in Global Launch Teams. He has experience in multiple specialty medicine fields such as oncology, CNS, ophthalmology and specialty GI. Keyji has Ph.D. from University of Bristol and MBA from Manchester Business School.

Charlie Johnson, CEO, ADC Biotechnology

Charlie Johnson holds a degree in Applied Chemistry from Liverpool John Moores University and his expertise is further built on more than 20 years working within the pharmaceutical industry. During this time, he has been based in the UK, Italy and Switzerland while holding positions with Zeneca (now AstraZeneca), Avecia Pharmaceuticals,UQUIFA and Carbogen Amcis. At Avecia Pharmaceuticals he was a founding member and Business Manager for the High Potency Actives and ADCs business. At UQUIFA (Milan) he again held a Business Management position for Highly Potent APIs in both the CRAMs and Generic sectors. His last position at Carbogen Amcis (Basel) was as Director, High Potency Division leading CRAMs and Generic businesses at multiple locations in Europe and Asia. In February 2012, he took up the position as CEO at ADC Biotechnology (North Wales) to lead the newly formed start-up whose technology is focused on next generation processing technologies for the high growth Antibody Drug Conjugate (ADC) sector.

Kevin Johnson, Partner, Index Ventures

Kevin Johnson is a Partner at Index Ventures working out of the London office. Prior to that he was CEO of PanGenetics, an antibody development company based in the Netherlands, and one of the Index Ventures portfolio. Kevin was one of the team at Cambridge Antibody Technology (CAT), heading up research from 1994 onwards. In 1997 he was appointed to the Board, where he held the posts of Research Director and Chief Technology Officer.

Kevin led both the development of CAT's platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development.  Two of these are now marketed, Humira (Abbott Pharmaceutical) and Benlysta (HGS, GSK).

He was also part of the management team that floated CAT on the London Stock Exchange (main market). Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.

Chris Jones, CEO, GlySure

Mr Jones has more than 20 years of experience in the medical device and diagnostic industry. Prior to joining GlySure in 2008, he was CEO of Tensys Medical and led the development of the first clinically acceptable, continuous, non-invasive blood pressure monitor. Mr Jones also spent nine years with Nellcor Inc, a division of Tyco, most recently as VP of Marketing responsible for the pulse oximetry and critical care businesses.

Prior to that he spent six years in sales and marketing management positions at BioGenex Laboratories. Mr Jones is a graduate of Yale University with a Bachelor of Science Degree in Molecular Biophysics and Biochemistry.

Frank Kalkbrenner, Investment Manager, Boehringer Ingelheim Venture Fund GmbH

Frank Kalkbrenner is Investment Manager at the Boehringer Ingelheim Venture Fund GmbH since July 2010. He joined Boehringer Ingelheim in 1999 and held several positions in the department of pulmonary research. In 2005 he took over the responsibility for the licensing department. In this function he has been responsible for the licensing activities of the German Boehringer Ingelheim organization as well as for competitive assessment. After working for ten years in academic research he began his industrial career in 1997 by joining Schering AG as scientist in experimental dermatology.

James Kew, Research Director, GlaxoSmithKline

James Kew joined the GSK Centre of Excellence for External Drug Discovery (ceedd) in 2010 as Research Director. He has worked on ceedd alliances with Prosensa and Chroma Therapeutics as well as on the identification and progression of new alliance opportunities. Prior to joining the ceedd, he spent 15 years within CNS Drug Discovery, most latterly as Director of Biology within the GSK Schizophrenia & Cognitive Disorders Discovery Performance Unit (DPU) and, prior to joining GSK, from 1995-2002 at Hoffmann-La Roche in Basel. Dr Kew has experience of drug discovery from target identification through to clinical proof of concept.

Gareth King, CEO, Critical Pharmaceuticals

Gareth is the CEO of Critical Pharmaceuticals, having joined the company in 2008 with a background in biotechnology and pharmaceutical business development, discovery and clinical research. Gareth started his career as a research scientist at Harvard Medical School and discovery project leader at AstraZeneca. Gareth moved into business development through a series of increasingly responsible commercial roles at Incyte Pharmaceuticals, Cyprotex and Pharmaceutical Profiles before joining Critical Pharmaceuticals.

David Knowles, Chairman, ProcartaBiosystems Ltd

David worked for over 20 years in major pharmaceutical companies both in Europe and the US and established an international reputation in anti-infectives R&D. In 1999, he joined the UK biotech sector, simultaneously taking on variousexecutive, non-exec and advisory roles in an attempt to learn rapidly about the business environment. As CSO of RiboTargets plc, he successfully transformed the scientific basis of the company from one based on the discovery of anti-infective molecules targeting discreet RNA structural motifs into one predominantly focused on the discovery and development of anti-cancer agents. RiboTargets went public through a reverse merger with British Biotech and he subsequently became Director of R & D for the combined organization. He joined the board of Procarta in 2009 and is currently also a non-executive director of ABsynthBiologics.

David Laskow-Pooley, CEO, London Pharma

David has been involved with London Pharma since 2010. He has enjoyed an extensive career in Pharmaceuticals, Diagnostics and Devices commencing with GSK, Abbott, Life Technologies, Amersham International, and OSI Pharmaceuticals where he has operated at executive level. He has experience in Development, Operations, Commercial and overall General Management. More recently he has focused upon start ups, initially spinning out Surface Therapeutics from Oxford University. Now with London Pharma, an early stage company with late stage products, repositioning molecules through its own sub-lingual spray delivery system.

Dr Melanie Lee, Chief Executive Officer, Syntaxin Ltd

Dr Lee was formerly President of New Medicines and Executive Vice President R&D with UCB, having served as R&D Director at Celltech before its merger with UCB. Dr Lee brings a wealth of drug research and development experience to Syntaxin, through her early academic career at Cancer Research UK (as ICRF), a decade in research with GlaxoSmithKline, and her later leadership of biopharmaceutical R&D at Celltech and UCB. Dr Lee also sits as a Non-Executive Director on the Board of BTG plc.

Reid J. Leonard, Executive Director, Worldwide Licensing, Merck Research Ventures Fund

Dr. Leonard is Executive Director, Worldwide Licensing for Merck and Managing Director of the Merck Research Ventures Fund. Based in Boston, Reid interacts regularly with biotechnology companies and academic institutions to identify and evaluate partnership opportunities that will enhance Merck's pipeline. A key component of this role is to maintain close contact with leading life science venture firms and other stakeholders in the New England innovation cluster. Reid also supervises scientific scouting for Canada, Latin America, and India.

Reid recently assumed the additional role of Managing Director of the Merck Research Venture Fund (MRVF), a strategic investment vehicle through which Merck will help to shape the diversity and quality of external innovation. In this capacity, Reid is responsible for the overall implementation and coordination of Merck's investments through the MRVF, working closely with colleagues from Merck Corporate Development, Finance, and External Scientific Affairs.

Prior to his career in business development, Dr. Leonard conducted basic research and drug discovery on ion channels at Merck. Reid is a graduate of Brandeis University, with a dual B.A. in biology and psychology. He earned a Ph.D. in biology (neuroscience) from Purdue University and completed postdoctoral training in molecular pharmacology at Caltech. Reid joined Merck Research Laboratories, Rahway NJ, in 1989 and spent ten years at the bench practicing drug discovery. In 1998, Reid moved into the External Scientific Affairs group where he has contributed to the search, evaluation, and execution of numerous biotech and academic partnerships to advance Merck's pipeline.

Stephanie Lesage, Chief Operating Officer/Project Leader, Oxford Biomaterials Ltd

With an initial scientific degree from the University of Paris XI in France, Stephanie graduated with a Masters degree in Textile Engineering from a French Engineering school. She then obtained a second Masters degree in Biomaterials from the University of Bordeaux in France to specialise in medical implants. Stephanie joined Oxford Biomaterials Ltd in 2009, initially focusing on the development of the company’s nerve repair technology. At the beginning of 2010, she initiated OBM’s Vascular project and took on the responsibilities of Chief Operating Officer and Project Leader of the company.

Jan Lichtenberg, CEO, InSphero

Jan started InSphero with his Co-Founders in 2009 in Zurich, Switzerland, in order to provide pharmaceutical customers with reliable and affordable 3D cell-based assays. Since its start, InSphero has grown into a 20+-staff company working with 7 of the global top 10 pharmaceutical and cosmetics companies. Before joining InSphero, Jan was VP of R&D and Product Management at Hocoma, a medical robotics company, and Head of R&D at Uwatec, a Johnson family company. Jan is a microtechnology engineer by training and studied in Germany, Switzerland, the US and Singapore.

Eddy Littler, CEO, Domainex

Eddy began his career in academia in Canada and Manchester researching virology before joining the Wellcome Research Labs in Beckenham as Head of Molecular Sciences. He joined GlaxoWellcome as Head of Antiviral Research. In 2000 he left GSK to join Medivir as Head of Discovery and of the UK site.  Amongst other projects Eddy was an integral part of Medivirs hepatitis C protease project now in phase III trials with J&J. Eddy joining Domainex as CEO in 2006 leading the company through two investment rounds.

Wilma Lukas, Senior Search & Evaluation Officer, In-Licensing, Debiopharm SA

Dr Lukas has over 25 years of experience in drug discovery, R&D, licensing and business development. After earning a Ph.D. in Biology completed by an MBA, she gained pharmaceutical expertise at GSK and Merck- Serono before joining a start-up that was later on successfully acquired by MDC. Dr Lukas joined Debiopharm in 2007. She is in charge of the search and evaluation process and identifies pre-clinical and clinical opportunities to in-license in line with Debiopharm’s strategy, business model and portfolio. She is responsible for European territories including Russia, Israel and Eastern countries.

Suzanne Mandala, Strategic Licensing & Acquisitions, External Scientific Affairs, Merck & Co. Inc

Suzanne Mandala received her BA degree from Swarthmore College (Pennsylvania) and her PhD from the University of California, Santa Cruz. She was a postdoctoral fellow in the Department of Human Genetics at Yale University. Suzanne joined Merck in 1989. Suzanne managed a diverse portfolio of projects in immunology, inflammation, and hematology as a director in the Immunology Department until 2008, when she assumed a position in External Scientific Affairs.

In her current position as senior director in the Worldwide Licensing, Suzanne heads the group of strategic licensing and acquisitions leads responsible for identifying and scientifically assessing licensing opportunities for all therapeutic and functional areas.

Francis Marsland, VP Corporate Development, Europe, Biogen Idec

Francis Marsland qualified as a solicitor in the UK and worked for four years at Freshfields before moving into industry, with Johnson Matthey plc. Francis moved into the pharmaceutical sector in 1998 as sole counsel for Recordati, a quoted Italian pharma company. He joined Biogen in 2001 as Director, Legal Affairs and from 2004 onwards acted as Chief International Counsel managing the International Legal Affairs department. In his current role Francis serves as a strategic liaison for Biogen ldec Europe+, interacting with Business Development, Corporate Strategy and M&A, Corporate Communications, Investor Relations, Finance and Government Affairs. He is also Site Leader of the Zug office.

Fiona Marston, CEO, Absynth Biologics

Fiona is an entrepreneurial Chief Executive who has successfully established and grown biotechnology businesses. She previously co-founded the anti-infectives company Novacta Biosystems and was Chief Executive until late 2007. In her early business career Fiona founded and managed Healthcare Ventures Limited, a European incubator company, for the Rothschild Bioscience Unit and J&J Development Corporation. In this role she helped found Metris Therapeutics Limited and Novarticulate BV. Fiona has led Absynth Biologics since 2008 to advance its S. aureus vaccine and its collaborative development of S.aureus therapeutic antibodies with Morphosys, which form the basis for Absynth’s pipeline and platform.

Niall Martin, COO, MISSION Therapeutics

From his PhD, Niall Martin joined Zeneca Pharmaceuticals as a post doctorate scientist in the non-lipid cardiovascular disease Bioscience group. In 1993 Niall moved to France to become a Team Leader within the Thrombosis group at Laboratoire Fournier, a Dijon-based pharmaceutical company.

On his return to the UK in 1999, Niall became Director of drug discovery at KuDOS Pharmaceuticals, Cambridge, UK where he established the drug-screening capabilities in KuDOS. Most notably, Niall set up and headed the KuDOS programme against PARP that yielded the pioneering new drug, olaparib which is now in Phase II and III trials with AstraZeneca for breast and ovarian cancers.

Niall then became head of KuDOS from 2008, upto the closure by AstraZeneca of the KuDOS site in 2010. Niall is a founding member of MISSION Therapeutics that has recently raised £6 million in Series A funding. Niall has joined MISSION as it’s Chief Operating Officer.

Julie Masse, Business Developer, BRAINco Biopharma

Julie joined BRAINco in May 2010, her current responsibilities are out-licensing of drug discovery program, to do so she has had to implement a strategy combining the identification, evaluation and exploitation of business opportunities with the development of strategic marketing activities. Before, she also worked as project manager for BRAINco where she was in charge of early stage drug discovery projects including planning, outsourcing and co-ordination of research activities.

Stuart Medina, CEO, ProRetina

Stuart Medina founded ProRetina in 2007 and was named CEO of the company in June 2009 after conclusion of the Series A round. He has prior experience in the investment and biotech industries. In 2003 he co-founded Metas Biotech, a consulting firm providing advice to Spanish biotech companies in finance and business development. He was an investment analyst and portfolio controller at UF eBusiness, a corporate investment unit of Spanish utility Unión Fenosa. Previously he conducted business development work at Genzyme Corp. in the US and was also the CFO of its Spanish subsidiary from 1997 to 2001.

Gwen Melincoff, Senior Vice President of Business Development, Shire Strategic Investments

Ms. Melincoff has over 20 years of leadership experience in the biotechnology and pharmaceutical industries, spanning research operations, marketing, product management, project management, and licensing and business development.

From September 2004 to the present, Ms. Melincoff has been part of the Business Development team at Shire Pharmaceuticals, first as Vice President of Business Development, and recently as Senior Vice President of Business Development. During her tenure, she has been involved in numerous licenses, product divestments, co-promotion and collaboration agreements, and mergers and acquisitions. She was responsible for the collaboration with New River Pharmaceuticals that led to the $2.6 billion acquisition of the company within two years of the first transaction.

Ms. Melincoff has a B.S in Biology, a Master's of Science in Management and Health Care Administration, and has attained the designation of the Certified Licensing Professional (CLPTM).

Sir Jonathan Michael, Chief Executive, Oxford Universities NHS Trust

Sir Jonathan Michael was appointed Chief Executive of Oxford Radcliffe Hospitals in 2010 (now Oxford University Hospitals). He joined the Trust from BT Health where he held the position of Managing Director.

Sir Jonathan qualified as a doctor at St Thomas' Hospital Medical School. In 2000 he became the Chief Executive of Guy's and St Thomas' Hospitals NHS Trust.

He has held a number of national roles including Chairmanship of the Board of NHS Innovations (London), Chairmanship of the Association of UK University Hospitals and Chairmanship of the Board of the NHS Foundation Trust Network. Sir Jonathan was knighted in the New Year's Honours in 2005 for services to the NHS.

Richard Mole, COO, Inocul8 Ltd

Richard has over 15 years' experience with commercial product development, from academic research bench, through product development and evaluation, manufacturing and regulatory approval. He has extensive experience identifying, nurturing, negotiating and legalising strategic partnerships including co-development and licensing relationships. Following his applied PhD studies, Richard worked for three years for the University of Nottingham after which he joined a spinout company, Biotec Laboratories, where he rose to become Product Manager and Head of R&D, and was responsible for taking four medical diagnostic products through to the market. In 2007, Richard completed an MBA after which he joined the Genecom team commercialising research from a number of veterinary research institutes within the UK. In 2009, Richard helped form Inocul8 and is the company’s Chief Operating Officer.

Bruno Montanari, Director, CAPE

Bruno Montanari joined Crédit Agricole Private Equity's Venture Capital team in January 2010, where he is currently a Director. He began his career in 1999 in London as an Investment Banker in the Healthcare Groups of Deutsche Bank and Merrill Lynch, later joining the venture capital community first with CDP Capital, and later Atlas Venture, responsible for several European portfolio companies in the biotech and medtech areas as board member or observer. Bruno holds a PharmD from the Université René Descartes Paris V and a Masters in Strategic Management from HEC, France. He currently sits on the board of directors of several companies: Cytheris, Novate, Poxel, Themis, Xention and was as well a director of EOS imaging.

Dr Neil Murray, CEO, RedX Pharma

Dr Neil Murray is the CEO at Redx Pharma, which specialises in early stage drug development. The company adapts existing compounds to create promising new medicines across a broad range of therapeutic areas. Dr Murray is also involved in PharmEcosse Ltd, a clinical-stage company investigating scar prevention, and Essential Science Ltd, a consulting practice which provides expert support to early stage companies. Having gained a PhD in Synthetic Organic Chemistry from the University of Dundee, his career has included senior positions with high profile companies including Solutia, Vernalis, Sigma-Aldrich and Glaxo-Wellcome.

Ian Nicholson, CEO, Chromatherapeuttics

Mr. Nicholson has served as Chief Executive Officer of Chroma Therapeutics Limited since September 2004. Prior to joining Chroma, he was Senior Vice President of Business Development for Celltech Group plc, responsible for all global licensing activities. He has held a variety of senior commercial positions with Oxford Asymmerty International plc, Lonza AG and Amersham International plc. He currently sits on the board of the Biotechnology Industry Association and Bioventix limited. Mr Nicholson holds a BSc (Hons) from University College, London and a MBA from Boston University.

James Noble, CEO, Immunocore

James has been involved with Immunocore's T cell receptor technology since 1999, when Avidex Limited (the predecessor company to Immunocore) was founded. He has over two decades of experience in biotechnology and has served on public and private boards of companies in the UK, the USA and Germany. He is currently Deputy Chairman at GW Pharmaceuticals plc, an AIM-listed biotech company, and is also CEO of Adaptimmune, Immunocore’s sister company focused on adoptive T cell therapy.

Richard Owen, Chief Scientific Officer, PlaqueTec

Richard is an inventor of PlaqueTec’s technology and a co-founder of the company (2008). His role is Chief Scientific Officer and he is responsible for developing PlaqueTec’s clinical strategy, running its Biomarker Development Program and working with external partners to ensure that its technology delivers patient benefit. Prior to PlaqueTec, he worked at PA Consulting where, as lead biologist, he helped companies translate new technology into new products. Before PA, he developed diagnostic assays for the industrial sector at Celsis plc, and before that he developed clinical diagnostic assays at DAKO Ltd. He has a PhD in molecular microbiology and a degree in genetics and microbiology.

Dave Parry, Cyclofluidic

Dave joined Cyclofluidic as its COO and first employee early in 2009. Dave started his career as a medicinal chemist with Celltech where he rapidly developed an interest in drug discovery technologies making the move to Chiroscience in Cambridge to head up their combinatorial chemistry group. After the acquisition of Chiroscience by Celltech he continued to strengthen both his scientific and management skills leading the Exploratory Chemistry section at the Cambridge site. When UCB acquired Celltech Dave had the opportunity to play a key role in small molecule discovery technologies and joined Cyclofluidic from UCB where he was most recently Director, Technology within Research.

Dr Alex Pasteur, Partner, MVM Life Science Partners

Dr Alex Pasteur joined MVM Life Science Partners in 2005, is a member of the boards of Vantia Ltd and Xention Ltd, and is a member of the London-based investment team.

Prior to joining MVM, he was a member of the life sciences investment team at the Cambridge Gateway Fund. Alex was a consultant with OC&C Strategy Consultants Ltd in London. He has a Ph.D. in Chemistry and a first degree in Natural Sciences from Cambridge University.

David Phillips, Partner, SR One

David joined SR One in 2008 to both strengthen SR One's investment activities as well as pioneering a new function to incubate and spin-out technologies from GSK. He brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. David has significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors. David has a BSc (Hons) in Pharmacology from the University of London and is a member of the Charted Institute of Marketing. He is based in London.

Richard Pither, CEO, Cytox Ltd

Dr Richard Pither is CEO of Cytox Ltd, a company working to improve the diagnosis and clinical management of Alzheimer’s Disease, to bring Personalized Medicine in dementia closer to reality. Richard has been involved in the development of novel diagnostic and prognostic solutions for Alzheimer’s Disease for over ten years. Richard has held senior R&D positions in global Pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech and Amersham plc. Richard has a BSc in Cellular and Molecular Pathology from Bristol University. His PhD, also at Bristol, was gained in the field of immunology and vaccine design, followed by post-doctoral research at Harvard.

Andy J. R. Porter, Director, Antoxis

Prof Andy Porter is currently the Chair at Antoxis Ltd. Andy also has a small number of additional non-executive Board positions within the biotechnology sector, and has established a specialist angel fund, Grampian Bio-Partners, investing in early stage Scottish biotechnology. GBP companies currently have products in Phase 2 and 3 trials. He was originally the founder and CSO of Haptogen Ltd, acquired by Wyeth Inc in October 2007. In 2005 he was made the Ernst and Young Plc, Science and Technology Entrepreneur of the Year. He has been a Fellow of the Royal Society of Edinburgh since 2006. Andy also sits on the Executive Committee of the Scottish Life Science Association, BBSRC Super Follow-on-Fund and until recently the Scottish parliament’s Science Advisory Committee.

Dr Alexander Pretsch, CEO, SeaLife Pharma Mag.

Dr Alexander Pretsch B.Sc. holds degrees in marine biology, biomedicine and biotechnology and is CEO of SeaLife Pharma, an Austrian marine biotech company near Vienna. He has a strong focus on marine drug discovery and development. During his PhD he discovered a novel algal antiviral compound and launched it as OTC within three years to the market. With SeaLife Pharma he has a strong focus on bioactive compounds of marine microbes for the antiinfective and anticancer use. With his team he was awarded as entrepreneur of the month, was winner of the Genius innovation award, nominated for the Econovius State Price of Austria, and won international biotech venture summits. Beside his career as entrepreneur he is a university lecturer and consultant for international companies. From 2009 to 2011 he held the position of Chief Scientific Officer of the Chinese Global Health Biotechnology Group, active in the field of anti-infective products, and was responsible for the research and development.

Richard Pye, PhD, Head of Investor Relations and Communications, Summit Plc

Dr Pye joined Summit in 2004 as a Senior Scientist and later moved into the corporate side of the business in 2007. Dr Pyecurrently hasresponsibility for investor relations and communications,whilst also being involved with general corporate development. His broad range of experience and skills includes the completion of successful fundraisings, M&A and divestment activities. Dr Pye holds a PhD in Organic Chemistry and prior to joining Summit was a Post-Doctoral Research Associate at Oxford University.

David Roblin, Chief Medical Officer, Creabilis

David was formally Senior Vice President and Head of Research and Site Head for Pfizer’s European R&D HQ in Sandwich, Kent. Significant previous roles include Head of Anti-Infectives in Bayer Medical Affairs. In his pharmaceutical career he has held leadership roles across several therapy areas involving research, development and commercial responsibilities. His units have delivered several medicines to the market-place including ciprofloxacin, moxifloxacin, sildenafil (for pulmonary vascular disease), mariviroc and growth hormone injectable devices. He also Chaired the Research Directors Group of EFPIA and was a co-founder of the Innovative Medicines Initiative; a ground-breaking 2 billion Euros public-private partnership with the European Commission.

He currently holds positions as Chief Medical Officer to Creabilis Biotech, Bio-Industry Advisor to NOCRI in the NHS and Medical Director of Destiny Pharma. He sits on The Royal Society’s Scientific Policy Advisory Group and he is also an honorary senior lecturer at Brighton & Sussex Medical School.

He has a first class degree in Biochemistry and later qualified with Honours in Medicine from St George’s Hospital. David practiced medicine at a variety of London teaching hospitals before joining the pharmaceutical industry in 1995. He became a Fellow of the Royal College of Physicians in 2004 and a Member by Distinction of the Faculty of Pharmaceutical Medicine in 2007.

Greg Rossi, Vice President of Payer Evidence, AstraZeneca

Greg Rossi received his doctorate in Molecular Biology and Protein Chemistry from the University College London (UCL) in 1993. Since then he has worked in the biotechnology/pharma industry.

Between 1996 and 2007 Dr Rossi was at Amgen Inc where he held a number of roles in regulatory affairs, clinical development and global product strategy. He was involved in the clinical development and registration of a number of products with responsibilities including negotiations with global reimbursement authorities and US payers. Between 2005 and 2007 Dr Rossi was responsible for co-leading the development and commercialization strategies of Amgen’s therapeutic oncology pipeline in phase 2 and 3 clinical development.

In 2007 Dr Rossi joined Genentech Inc/Roche Pharmaceuticals where he was responsible for outcomes research, health economics and global pricing. These responsibilities included providing input into the design of phase 2, 3 and 4 studies, conduct of observational research studies, development of global pricing policies, as well as the generation of Health Technology/Reimbursement Dossiers for coverage and reimbursement submissions.

In August 2011 Dr Rossi was appointed Vice President of Payer Evidence at Astrazeneca with responsibilities for coverage and reimbursement submissions, real world evidence (outcomes) studies, and ensuring development programs address evidence requirements of global payers.

Dr Rossi is author over 25 clinical research manuscripts and numerous abstracts.

Bruce Savage, CEO, Alchemy Pharmatech

Bruce has a track record in the Pharma industry and has created and driven many life science start-up/early stage companies. A visiting professor in entrepreneurship at a business school.

Simon Saxby, CEO, Selcia

Simon Saxby joined Selcia as CEO in April 2011 from RecipharmCobra Biologics where he was Vice-President Biologics. Simon’s previous roles as CEO include Cobra Biomanufacturing plc and Alpha Biologics Sdn.Bhd.. He has 13 years' experience as a Board Director and has led successful M&A activities for two companies. Simon has a scientific background in immunology, and during his 31 years in the life sciences industry he has been a founder and fundraiser for companies in the UK, Malaysia and the USA where he spent five years leading the development of a CMO business for Unisyn Technologies. Prior to that Simon was a scientific founder of Murex Diagnostics, a founder director of Quantum Biosystems Ltd, and he has held senior management positions with KS Biomedix plc, Xenova plc and Scynexis Europe Ltd.

Govert J Schouten, Ph.D., CEO, Mucosis BV

Dr Govert J Schouten joined Mucosis as Chief Executive Officer in May 2008. Prior to that, he served as Vice President of Business Development at Crucell where he was responsible for global vaccine business development. He holds a Ph.D. in virology from Leiden University, the Netherlands.

Graziano Seghezzi, Partner, Sofinnova Partners

Graziano Seghezzi brings nearly a decade of European venture capital investment experience to Sofinnova Partners, where he has been a partner focused on life sciences investment since joining the firm in 2006.

Graziano has been instrumental in targeting, investing in, and nurturing the growth of a number of Sofinnova Partners’ portfolio companies, including: Creabilis Therapeutics (Italy), a specialty dermatology company developing products in multiple clinical areas such as psoriasis and atopic dermatitis; Crescendo Biologics (UK), a seed-stage company targeting the application of highly innovative antibody fragment technologies to the development of new therapeutics; GlycoVaxyn (Switzerland), a biotechnology company dedicated to the development of novel vaccines; and Omthera (USA), specialized in cardiovascular disorders with a best-in-class omega-3 drug. Graziano is a board member of each company.

Prior to joining Sofinnova Partners’ Paris-based team, Graziano was principal at Index Ventures in Geneva, Switzerland, where he invested in biotechnology and biopharmaceuticals companies. Before this, he worked for Sofinnova Partners, identifying new investment opportunities in Italian pharmaceutical and medical device companies out of Milan, Italy. Graziano began his career as a biomedical researcher at New York University’s School of Medicine, where he gained five years of hands-on experience studying the molecular mechanism of angiogenesis in oncology and cardiovascular diseases.

Graziano has a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from the RSM, Erasmus University (Netherlands).

Sunil Shah, Director, Piramal Discovery Solutions

Sunil Shah is the director of O2h (now Piramal Discovery Solutions). Sunil co-founded O2h with his brother Prashant Shah and O2h recently became a part of Piramal group of companies in January 2011. He was previously the Director of Business Development at Cambridge Biotechnology (now Biovitrum). He has consulted into a range of biotechnology companies and major pharmaceuticals such as Pfizer, GSK, and BASF via Private consulting and the Life Sciences group of PA Consulting. Prior to co-founding O2h, he was the co-founder and Director of a technology company. The Non-Executive board positions he holds include those with Opal Drug Discovery Ltd and IOTA Pharmaceuticals Ltd. He holds an MBA from Cambridge University and a BSc in Biochemistry and is a member of the Royal Society of Chemistry.

Tom Shepherd, Chief Business Officer, Kymab

Dr Shepherd is Chief Business Officer of Kymab, Cambridge and has over 30 years’ experience in the pharmaceutical industry in the USA, France, UK and Australia. He has led multiple pharmaceutical and technology licensing transactions and strategic company-building acquisitions. He has also raised significant amounts of equity capital to grow early stage companies into sustainable commercial operations. Dr Shepherd was previously CEO of CXR Biosciences in Scotland and Neurotech S.A. in Paris and Vice President Business Development at Valeant Pharmaceuticals and Intrabiotics Pharmaceuticals in California. He was awarded a Ph.D. in biochemistry from the University of Strathclyde in 1981.

Dr Shimokawa, Senior Investment Director, Astellas Venture Management

Dr Shimokawa is a Senior Investment Director at Astellas Venture Management (AVM). Prior to AVM, he was an Associate Director at Licensing & Alliances (L&A) Astellas Pharma, and involved in the M&A of a Japanese Biotech Company, and a couple of license-in deals. Before L&A, he was a Global Project Leader (GPL) of CNS and bone projects in Astellas. During his career, he successfully brought "Bonoteo", an osteoporosis drug, to the Japanese market, and staged up number of compounds to P2/3, P1 and P0 globally. He received a Ph.D. in Chemistry from the University of Pennsylvania and started as a senior chemist at Yamanouchi Pharma.

Alex Sim, Founder & CEO, AMS Biotechnology

Alex Sim has been involved in translating cutting edge life science research into successful revenue generating products for 30 years. With Amersham International he led the team that developed Hybond and was involved in the commercialisation of multiple technologies that have had impact on genomics and proteomics. In 1988 Alex established AMS Biotechnology (AMSBIO). He has raised venture funding, sold a variety of companies and continues to contribute to the success of small innovative SMEs. AMSBIO provides specialist biotools including tissues, stem cells, cell based assays and services for antibody production, expression and stable cell line generation.

Gunnar Staaf, CEO, Crystallics

Gunnar is the CEO of Crystallics a CRO specialized in solid state and pre-formulation for the pharmaceutical industry. Gunnar has over 18 years of senior commercial and executive positions with Eli Lilly, Novartis, Astellas and Serentis. In December 2009, Gunnar joined Avantium as the CEO of the Pharma division. In April 2011, he completed a MBO of Avantium Pharma to create Crystallics. Gunnar is an economist by training from the University of Reading, UK and holds an MBA from Warwick Business School, UK.

Christina Takke, Partner, Forbion Partners

Christina Takke is Partner at Forbion Capital Partners and joined the team at ABN AMRO Capital Life Sciences as analyst in 2000. At Forbion Christina is responsible for scouting and analysis of new investment opportunities as well as the general deal execution. Christina serves on the Supervisory Boards of Amakem, arGEN-X, Simibio and Pieris. Previously, she was on the board of Bioceros and was closely involved with GlycArt. Christina began her scientific career with a master’s degree in biology from the Technical University of Darmstadt. She subsequently joined the group of Prof Dr Campos-Ortega at the Institute of Development Biology of the University of Cologne.

Claire Thompson, Director of Pharma Development, Oxford Pharmascience Group

From a degree in Biochemistry at the University of St. Andrews, Claire moved into the Pharmaceutical arena via a PhD at School of Pharmacy, University of Nottingham.

Claire spent six years with Pfizer and GSK developing novel molecules and formulations for therapeutic areas such as asthma, cancer, HIV, insomnia, malaria and pain. In 2009, she joined the CRO Molecular Profiles as Associate Director, identifying and setting up new service areas and managing the delivery of outsourced projects for Virtual, Biotech and Pharmaceutical Clients.

Claire is now Director of Pharmaceutical Development with Oxford Pharmascience, a Virtual Pharmaceutical company which develops cutting edge technologies to enable medicines to be safer and easier to take.

Claire has been on the Board of the Academy of Pharmaceutical Sciences since 2008.

Douglas Thomson, CEO, Ixo Therapeutics

Douglas originally trained and worked as an analytical chemist in marine environmental protection in Scotland.  He first joined industry in FMCG manufacturing and progressed to biologics manufacturing setting up and running, from 1994 - 1999, an animal vaccine manufacturing company based in Malta.

He joined Microscience Limited in South-East England as Director of Business Development, establishing and leading the Business Development team from 1999 to 2004. He was part of the senior executive team that raised approximately £30m of venture finance during this period. He was directly responsible for deal-making with pharmaceutical and biotech partners as well as commercial analysis and evaluation. In 2005, he raised funds for a new venture in Singapore securing approximately £8m of equity and grant funding.  He was CEO of SingVax until late 2007 and left to join Aquapharm as Commercial Director and latterly as COO.

He holds positions with a number of leading biotech companies. His main role is to lead IXO Ltd a start-up from the Natural Environment Research Council in the UK.

Adrian Towse, Director, Office of Health Economics

Adrian’s current research includes the use of 'risk-sharing' arrangements between health care payers and pharmaceutical companies, including value-based pricing approaches; the economics of pharmacogenetics for health care payers and the pharmaceutical industry; economic issues that affect both R&D for and access to treatments for diseases prevalent in the developing world; the economics of medical negligence; and measuring productivity in health care. A Visiting Professor at the University of York, Adrian also is a Visiting Senior Researcher at the Department of Public Health and Primary Care at the University of Oxford. For ten years, he served as the Non-Executive Director of the Oxford Radcliffe Hospitals NHS Trust, one of the UK’s largest hospitals. Adrian joined the OHE in 1993. Adrian holds an MA (Hons) in Politics, Philosophy and Economics from Keble College, Oxford; an MPhil in Management Studies from Nuffield College, Oxford, and the Oxford Centre for Management Studies; and is a Member of the Chartered Institute of Management Accountants.

Anthony Walker, Partner, Alacrita

Anthony Walker leverages 12 years of building and managing a biotechnology company together with over 12 years as a management consultant to the chemical, pharmaceutical and biotechnology industries. His experience includes due diligence, technology/market appraisal, business planning, licensing, raising venture capital finance, and M&A.

Prior to forming Alacrita, Anthony was CEO of Onyvax, a company he co-founded in 1997, raising over £35 million from blue chip life science investors including 3i and SR One. Before that, he spent ten years as a management consultant, specialising in the pharmaceutical and biotechnology industries. He consulted to big pharma and biotech, and also produced expert reports for five IPOs. He is a non-executive director of Proteome Sciences plc.

Matthew Walls, Chief Executive Officer, Epistem

Matthew joined Epistem in February 2007 as Chief Executive Officer. Matthew is an experienced CEO most recently with Oxford BioSignals Limited, where he led the strategic collaboration with Rolls Royce Plc and Covance Inc. Matthew spent the early part of his career with ICI Plc, progressing through to AstraZeneca Plc prior to its plant crop biotechnology group merger with Novartis to form Syngenta Plc. Matthew has led the growth of several technology and biotechnology companies as CEO, including Internexus Limited and Zylepsis Limited. Matthew holds a non-executive post at Continum Limited and Riyada Oxford Investments Limited and is a chartered accountant and a member of CIMA.

Dr Fintan Walton, CEO, PharmaVentures

Dr Walton is the Founder and CEO of PharmaVentures. After completing his doctoral research on the genetics of cell proliferation at the University of Michigan (US) and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Although Dr Walton's main focus is his role as Chief Executive Officer of PharmaVentures, he is available for some consultancy assignments.

Sally Waterman, COO, PolyTherics

Sally Waterman joined PolyTherics in October 2009 as COO with responsibility for the oversight of the science programmes and provision of the supporting infrastructure. Sally’s previous roles include Director of Research & Development at Protherics (now part of BTG) and also at KS Biomedix (acquired by Xenova), VP of Non-clinical Development at Vernalis (previously called Vanguard Medica), and Director of Scientific Operations at the CRO, Pharmakopius (since acquired by PRA). Her early career was spent in regulatory affairs in GD Searle, Wyeth and Sterling Winthrop.

Sally has been a member of several Boards, including Discerna, the first spin-out company from the Babraham Bioscience Technologies Limited. She has a BSc degree in Biological Sciences and obtained a PhD from the University of Reading for her research with Campylobacter jejuni.

Ilka Wicke, Director, Boehringer - Ingelheim Venture Fund

Ilka joined Boehringer Ingelheim in 1996 as Head of an interdisciplinary research laboratory specializing in new drug discovery approaches. She later joined the Corporate Licensing Division of Boehringer Ingelheim where she gained over 10 years' extensive experience in the evaluation, negotiation and the management of global licensing transactions. Subsequently Ilka joined the Corporate Licensing Group as head of the business advisory teams for oncology, urology and metabolism where she was responsible for the identification and evaluation of pre-clinical and clinical licensing opportunities as well as structuring and negotiating technology and licensing agreements. She later joined the transaction group of Corporate Licensing where she was responsible for the negotiation and conclusion of a variety of global licensing agreements. Ilka has a PhD in organic chemistry from the Johann Wolfgang Goethe University in Frankfurt. Following her graduation she spent a year as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy approaches to stimulate antitumour responses.

Eric Marijn Wielhouwer, Director, Syntecnos

Eric has recently published his first article and is co-applicant on 2009 Biochip patent application. Eric is director and co-founder of Syntecnos. As an entrepreneurial scientist, Eric studied Biology (with specialization in Molecular & Cellular Biology) at Leiden University, including courses Master Class BioBusiness & Entrepeneurship. In the past, Eric studied Medical Biology (HLO, B.A.Sc, with a research internship at Genetics Dept. of St. Jude Children Re-search Hospital, Memphis, USA); Biotechnology (MLO, Analyst, Genetherapy internship at Crucell (formerly In-trogene BV)). His fields of interest are whole embryo screening, pre-toxicity safety & side effects, 3D tissue cul-ture, microfluidics, process automation, bioBusiness in the life science sector.


 

Speaker and Chair Biographies for 2011

Below are listed the biographies of the speakers and chairs participating in the 2011 programme.  These will be continually updated as we receive new biographies.

Charlie Alexander

John Aston

Julian Baines

Gordon Barker

Anthony Baxter

John Beadle

Margaret Beer

Christopher Berry

Colin Blakemore

Phil Boyd

Michael Brennan

Richard Broadhead

Iain Buchanan

Martin Buckland

Carlos Buesa

Roel Bulthuis

Linda Cammish

Sue Charles

Yen Choo

Andy Crossley

Russ Cummings

Jane Dancer

Jack Elands

Tim Fell

Richard Goodfellow

Shaun Grady

Tim Haines

Deborah Harland

Ian Harrison

Martin Heidecker

Ruben Henriquez

Jon Holmes

Raquel Hughes

Sofia Ioannidou

Chris Jones

Roel Kamerling

Gareth King

Johan Kördel

Olivier Litzka

Alain Lostis

Ernest Loumaye

Colin Love

Ian Nicholson

Keith Martin

Michael McArthur

Keith McCullagh

Helen McKeever

Michael McLean

Gwen Melincoff

Bryan Morton

Eckhard Niemeier

James Noble

Peter Nolan

Deborah O'Neill 

Tibor Papp

Nigel Pitchford

Denise Pollard-Knight

Dirk Reyn

Elizabeth Rollinson

Mike Romanos

Les Russell

Peter Sandbach

Gregg Sando

Bruce Savage

Clive Savory

Richard Seabrook

Sunil Shah

Nick Skaer

Jason Slingsby

David H. Solomon

Will Spooner

Sue Staunton

James Steel

Jenny Taylor

Helen Tayton-Martin

Nicola Thompson

John Tite

Hans von Celsing

Fintan Walton

Naiyin Wang

Mike Ward

Jeremy Warren

Paul Watt

Gunnar Weikert

Will West

Alan Whitmore

Paul Whyte

Sarah Wordsworth

Malcolm Young

Charlie Alexander, Director, Business Development, Shire Pharmaceuticals Group

Charlie joined Shire in April 2007 with responsibilities including both in-licensing and out-licensing. His experience spans biotech, large pharma and consultancy. Immediately prior to joining Shire he worked as a consultant in providing strategic and commercial services to biotechs and mid-cap pharma. Before this his initial Business Development experience was with Xenova, a Slough-based biotech. Amongst other things her was responsible for seeking territorial deals for Xenova’s oncology portfolio and ultimately closed a deal for Xenova’s lead compound. He started his career at GSK spending a significant part of his time there working in new Product Development/Strategy.

John Aston, Ex Chief Financial Officer, CAT

John Aston is currently a non-executive director of Polar Capital Global Healthcare Growth and Income Trust and of International Biotechnology Trust. He was Chief Financial Officer of Astex Therapeutics from January 2007 to May 2010 and prior to that was Chief Financial Officer of Cambridge Antibody Technology (CAT) between 1996 and 2006. There he played a central role in the development of CAT into one of Europe's leading biotechnology companies, including its successful listing on the London Stock Exchange and subsequently on NASDAQ, and its sale to AstraZeneca in June 2006 at a valuation of $1.3 billion. He was a member of the BIAs Finance and Tax Committee for eight years and its chair for over three years. In 2008 he worked with the Bioscience Innovation and Growth Team as Chair of the Finance and Investment Working Group and as a member of the Steering Group, and in 2009 chaired the Finance & Investment working group for the Office of Life Sciences. Prior to joining CAT John was a director in investment banking with Schroders in London and previously worked for British Technology Group (BTG) and Price Waterhouse. He is a qualified Chartered Accountant and has a degree in Mathematics from Cambridge University.

Dr Gordon Barker, Chief Executive Officer, Conformetrix

Gordon co-founded Conformetrix in October 2008 where his responsibilities range from business development to tea-boy. Prior to joining Conformetrix, Gordon has worked for several biotech SMEs & technology transfer organisations, managing licensing and spin-out company formation in the medical device, CRO and therapetics sectors.


Dr Anthony Baxter, Chief Executive Officer, Cyprotex

Dr. Anthony Baxter is the Chief Executive Officer of Cyprotex Discovery Ltd and has over 25 years experience in management and research within the pharmaceutical, biotech chemistry service and instrumentation industries, mainly in the areas of drug discovery, medicinal chemistry and combinatorial chemistry. Before joining Cyprotex, Dr. Baxter successfully held positions as the CSO of Oxford Asymmetry International prior to its merger with Evotec, as founding CEO of Argenta Discovery Ltd and as CEO of deltaDOT. He has also held positions as Research Manager at Ciba UK Central Research Laboratories (1990-1994) where he managed Ciba blue-sky research interests and as Team Leader at Glaxo Group Research (1983-1990). Dr. Baxter has been actively involved in assisting in the scientific success of the development of several marketed drugs and in the discovery of advanced clinical development candidates for Curis, Serono, GSK, Ciba and Argenta. 

Dr John Beadle, Chief Executive Officer, PsiOxus

Dr John Beadle was Entrepreneur in Residence at Imperial College London, where he helped to establish Myotec Therapeutics as a spin-out business. He became CEO of Myotec in late 2008, rapidly securing seed financing followed by a £5.6 million series A funding round from Imperial Innovations and Invesco Perpetual in early 2010. During this time, John was also Executive Chairman and CEO of Hybrid Biosystems, securing further seed financing for this Oxford based start-up. In 2010, John’s leadership of these two private companies led to their combination to form PsiOxus Therapeutics Ltd. John was previously the co-founder of the vaccine company PowderMed. In 2004 he helped to raise £20 million from leading UK and US Venture Capital Funds and was then Chief Medical Officer and board director leading to the trade sale of PowderMed to Pfizer for over US$300 million in 2006. John has previously held roles at PowderJect, Pfizer and Glaxo SmithKline where he was most recently VP of Global Medical Operations. John was trained in Medicine at the University of Witwatersrand and received his MBA with distinction from the London Business School;

Dr Margaret Beer, Senior Director & Head, Licensing & External Research, MSD

Margaret Beer studied at the Universities of Reading and London before carrying out her research work on serotonin pharmacology. She joined Merck, as a bench neuroscientist, in 1984 following her return to the UK from Stanford University. She is one of the founding members of the team responsible for the development of Merck’s anti-migraine drug MAXALT and was involved in the project during the basic research stage through to the launch in 1997. Her other main areas of research interest include depression, anxiety and multiple sclerosis. Margaret joined Merck’s Worldwide Licensing and External Research, Europe, group in 2003. This group was established in 2002 specifically in recognition of the scientific excellence in Europe and the wealth of potential licensing opportunities. Margaret assumed leadership of the group in 2008. She is the co-author of 100 original research articles, review articles, and abstracts, and has presented widely at international professional meetings.

Dr Christopher Berry, Partnering & Innovation, sanofi-aventis

Dr Chris Berry is currently in the Contracting, Partnering & Innovation office within sanofi-aventis R&D. He is responsible for building research collaborations in the areas of anti-infectives, biologics and regenerative medicine. In addition he is also responsible (with sanofi-aventis’ UK Medical Director) for opportunity scouting in the UK across all therapeutic areas. He has over 10 years experience in research alliance building and management. He was previously Head of Thrombosis and Haematology in Synthélabo Recherche (one of sanofi-aventis’ predecessor companies), which was the culmination of 16 years in discovery research which began in 1984 when he joined Synthélabo’s Pain and Inflammation group, after a brief flirtation with academic research. He obtained his PhD in Pharmacology at King’s College, London in 1981, and an MBA at the Open Business School in 2003.

Prof. Colin Blakemore, Professor of Neuroscience, University of Oxford

Professor Colin Blakemore, FMedSci, FRCP (Hon), FIBiol (Hon), FRS, is Professor of Neuroscience at the University of Oxford and a Fellow of Magdalen College Oxford.He also holds a professorship at the University of Warwick and is chair of the Neuroscience Research Partnership in Singapore.He was is chair of the Food Standards Agency's new General Advisory Committee on Science. From 2003-2007 he was chief executive of the Medical Research Council.Professor Blakemore studied Medical Sciences at Cambridge and completed a PhD at the University of California, Berkeley. After working for 11 years in Cambridge, he moved to Oxford as Waynflete Professor of Physiology in 1979, and from 1996-2003 he was also director of the Centre for Cognitive Neuroscience.His research has been concerned with many aspects of vision, early development of the brain and plasticity of the cerebral cortex.He has been president and chair of the British Association for the Advancement of Science, and president of the British Neuroscience Association, the Physiological Society and the Biosciences Federation.Colin Blakemore is a frequent broadcaster on radio and television, and writes books and articles about science for a general audience.

Phil Boyd, Chief Finance Officer, Syntaxin

Phil joined Syntaxin as Chief Financial Officer in March 2007. Prior to Syntaxin he was Senior Vice President, Finance and UK Finance Director for Evotec AG a German biotechnology company from 2001 to 2007. Phil looked after the financial requirements of the company’s UK subsidiary and running a small team in the German head office. After a degree in Biotechnology and a scholarship year at Vanderbilt University, Nashville (USA), Phil undertook research for a PhD in plant molecular biology at Leeds University (UK). Following his scientific education, Phil joined Unilever as a graduate financial trainee. He completed his accountancy training whilst working for four years in a variety of financial and management roles in a Unilever subsidiary, and was a prize winner in the CIMA exams. In 1992 Phil moved to Kraft Foods where he worked as a financial analyst for the UK Foodservice Division. Phil next joined PricewaterhouseCoopers (at that time Coopers and Lybrand Management Consulting) in 1994 and spent five years working on consulting assignments in a wide variety of industries, specialising in areas of operational and financial management. He then returned to an industry finance role in 1999 as the Finance Director of Cambridge Discovery Chemistry, a medicinal chemistry service provider to the Biotechnology and Pharmaceutical industries, which was subsequently acquired by Millennium Pharmaceuticals, Inc. Phil stayed on at the Company after the acquisition, focusing on integrating the operations and the divestment of a small US subsidiary before moving to Evotec in 2001.

Michael Brennan, Head of Corporate Development, Proximagen Group plc

Michael joined Proximagen in November 2008 and started his career in the City and has 14 years experience in various corporate finance and corporate broking roles, latterly as a Director in Corporate Finance with Evolution Securities. During this time he worked on over 30 corporate transactions as lead director including IPOs, rights issues, placings and various takeovers and M&A work. Michael overseas all of Proximagen’s corporate development activities.

Dr Richard Broadhead, Sales & Marketing Manager, Oxford Expression Technologies

Richard obtained a BSc in Biological Sciences from the University of Birmingham and then went on to obtain a PhD from the University of Aberdeen. Richard joined Oxford Expression Technologies in 2008 and is OET’s Sales and Marketing Manager. His experience spans both the academic and commercial spheres of science. Richard brings significant global sales and marketing experience to the company and also has extensive relevant technical experience acquired through laboratory research in the fields of proteomics and protein expression.

Iain Buchanan, Chief Executive Officer, NOXXON Pharma AG

Iain Buchanan was appointed CEO of NOXXON in September 2010 having worked closely with the board of directors since 2007 and as a non-executive member of the supervisory board since 2009. He brings to the company over 30 years of commercial experience in the pharmaceutical and biotech industries. Iain joined NOXXON from Novexel in Paris where he acted as CEO since the Company's formation in 2004 until its sale to AstraZeneca earlier this year. Prior to Novexel, Iain held a variety of management positions of increasing responsibility across various companies. These include Vertex Pharmaceuticals (Europe) Limited where, as Managing Director, he was responsible for building a Vertex presence in Europe from 1994 to 2004, at Cilag A.G. (a division of Johnson and Johnson based in Zug, Switzerland) where he managed the licensee business internationally from 1987 to 1994 and at Biogen S.A. in Geneva, Switzerland from 1981 to 1987 where he oversaw commercial activities in Europe. Iain began his career in Product Management at Merck Sharp & Dohme (UK) Limited in 1978.Iain holds a Bachelor of Science in Physiology from the University of St Andrews, Scotland and is a non-Executive Director of Synairgen plc based in Southampton UK.

Dr Martin Buckland, Chief Business Officer, Astex

Martin Buckland joined Astex as Chief Business Officer in September 2004 and was appointed to the Board in July 2008. He has more than 20 years of commercial and business development experience in the pharmaceutical industry and joined Astex from Elan Pharmaceuticals where he previously held the position of VP Global Business Development. His prior experience includes a variety of business development and commercial management roles with Quintiles, Xenova and Celltech. He has a BA in Chemistry and a DPhil from the University of Oxford, and an MBA from the Open Business School.

Dr Carlos Buesa, Chief Executive Officer, Oryzon

Dr Buesa earned his PhD in Biochemistry from the University of Barcelona in Spain. He has produced more than thirty papers and patents internationally, was a member of the cellular signaling research team in the Pharmacy Faculty at the University of Barcelona, held an EU post-doctoral fellowship in the Faculty of Medicine at the University of Ghent in Belgium, and later became Senior Investigator with the Flemish Institute of Biotechnology (VIB), also in Belgium. In 2000, he founded Oryzon, one of the strongest-growing biotech companies in Spain, and since 2001 he has served as Chief Executive Officer and Chairman of the Board of Directors. In addition, he sits on the board of other biotech companies like Neurotech Pharma and Oncnosis Pharma. He has taken the executive education programme (PADE) at the IESE Business School. Currently he is President of the Association of Catalan Biotechnology Companies CataloniaBio, and he is a member of the governing body of ASEBIO and of the Executive Committee of BioRegió de Catalunya, a new regional development model that has been set up with the aim of improving people's quality of life through better coordination of the biotechnology activity being carried out in Catalonia.

Roel Bulthuis, Head, Merck Serono Ventures

Roel Bulthuis is Head of Merck Serono Ventures, the strategic venture capital group of Merck Serono. Through the ventures group, Merck Serono is committed to actively invest in emerging biotech companies which have the potential to provide innovative products in Merck Serono’s core therapeutic areas, or access to innovative technologies. In addition to the venture fund, Roel is also responsible for all ‘externalization’ transactions at Merck Serono, including ‘fostering’ deals, spin-offs and other alternative financing models. Roel joined Merck Serono in 2006 and is based in Geneva, Switzerland. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before joining Fortis Bank, Roel worked at Devgen NV in Gent, Belgium, as a business analyst. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.

Dr Linda Cammish, Chief Executive Officer, Nanotherics

Linda has 25+ years experience in the life science sector, with 20+ years of this being in a commercial environment. Her strong life science background includes a Ph.D. from Cambridge University (with research conducted at the Laboratory of Molecular Biology) and her business education includes an MBA from Henley Business College. She also has considerable practical, hands-on experience in growing businesses in the high technology life science sector involving products and services (including reagents, hardware, software as well as drug discovery services and technology access programmes) for the academic, pharmaceutical and biotechnology markets. She combines this technical and business education with extensive practical experience in senior business development, sales and marketing roles in companies including Millipore, PerSeptive Biosystems, Applied Biosystems and Abcam.

Sue Charles, Managing Partner, College Hill Life Sciences

Sue was formerly co-founder and CEO of Northbank Communications, a highly-regarded Life Sciences consultancy that was acquired by College Hill in October 2007. She has more than 20 years’ communications experience, across financial, corporate, science and marketing communications, and is regarded as an industry leader in Life Science communications. In addition to communications experience, Sue has spent time as CEO of a biotech spin-out and has had a number of non-executive positions. She has a first class degree in Biochemistry from Oxford and an MBA from Cranfield Business School. Sue’s expertise is at the interface of innovation and wealth creation, in particular advising clients where transformational science will have a high profile impact. Notably she led the global media relations on the announcement of Dolly the cloned sheep. Her experience spans both private and publically-listed biotech companies as well as pharma and not-for-profit. She works closely with boards and senior management to craft messages and outreach programmes that will maximise value creation. As Managing Partner, Sue offers senior level counsel across the College Hill Life Sciences portfolio and maintains team leadership on a select number of clients Current and past experience includes: Ablynx, Abraxis BioScience, Affymetrix, Akubio, Amersham Life Sciences, Astex Therapeutics, Axxima Pharmaceuticals, Benitec, Bicycle Therapeutics, BioInvent International, BioProgress, Biota, Biotica, British Council –Darwin Now, BTG, CABI International, CAT (MedImmune/AZ), Cellmark Diagnostics, Cerenis Therapeutics, Cimtech, Cyclacel, Diamand Light Source, DTI-BMB Initiative, DxS, Funxional Therapeutics, Elastagen, HUGO/HGM, Illumina, Imperial Innovations, Inpharmatica (Galápagos), Index Ventures, International Biotech Trust, Karus Therapeutics, Living Cell Technologies, Medical Futures, Merck Serono, Merlin BioSciences, Midatech, Molecular Partners, Morphochem, Nestlé Nutrition, Novartis, Oxagen, Oxford BioMedica, Oxford Gene Technology, Oxonica, PanGenetics, Physiomics, PowderMed (Pfizer), Prosensa, PPL Therapeutics (Dolly), Pronota, QIAGEN, RespiVert, Roche, Santaris Pharma, SETsquared Partnership, Sigma-Aldrich, Siogen Biotech, Smiths Detection, SmithKline Beecham, SR Pharma/Atugen (now Silence Therapeutics), Sugen Europe, SV Life Sciences, Syngenta Biopharm, Trigen and Wellcome Diagnostics.

Dr Yen Choo, Chief Executive Officer, Plasticell Therapeutics

Dr Choo is the founder of Plasticell Therapeutics and has been Chief Executive and Chief Scientist of the company since its inception. He also sits on the UK Stem Cell Steering Committee which regulates national stem cell research and the UK Stem Cell Bank. Prior to his interest in stem cells he was founder and Chief Scientist of Gendaq (1999-2001), a zinc finger engineering company acquired by Sangamo Biosciences and whose technology is now marketed by Sigma-Aldrich. Previously he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge (1995-2000), where he pioneered the engineering of protein-DNA interactions using combinatorial methods. Dr Choo holds a PhD in Molecular Biology from the University of Cambridge and for his thesis received the Prize for Young Scientists awarded by GE Healthcare and Science (1996), and the Max Perutz Student Prize awarded by MRC-LMB (1995).

Andy Crossley, Corporate Broker, Peel Hunt

Andy Crossley worked as a UK Small Cap fund manager at Invesco Perpetual for almost 20 years running unit trusts, investment trusts and a VCT. He is a memeber of the London Stock Exchanges Aim Advisory Group, the AIC VCT Forum and has been a director of Baronsmead VCT plc, managed by ISIS, for over ten years. In April 2011 he became a “gamekeeper turned poacher” and joined Peel Hunt, the UK small and mid-cap broker, to help them continue to grow their corporate advisory business.

Russ Cummings, Chief Investment Officer, Imperial Innovations

Russ Cummings joined the Group from Scottish Equity Partners Limited where as director in the Information Technology Group he was responsible for investment in high growth technology companies. Russ worked at 3i Group plc where he was a director in their UK Technology Group (and previously worked at Rolls-Royce Motors as a development engineer). Russ manages the investment portfolio and decision-making process. Russ serves on the boards of the following Group technology companies: Circassia Holdings Limited and Nexeon Limited. Russ has a BSc in Mechanical Engineering from Imperial College.

Dr Jane Dancer, Vice President, Business Development, Cellzome

Jane Dancer is Vice President of Business Development at Cellzome. Since joining Cellzome at the beginning of 2008, she has been involved in negotiating two major collaborations with GSK and extending and expanding Cellzome’s existing collaboration with Johnson and Johnson. Prior to joining Cellzome, Jane was at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) where she was responsible for in- and out-licensing agreements in relation to technology and products and was part of the team that negotiated the strategic alliance with AstraZeneca which subsequently led to the acquisition of CAT. Jane has a PhD in plant biochemistry and an MBA from Cambridge.

Dr Jack Elands, Chief Executive Officer, Amakem NV

Jack Elands is the CEO of Amakem NV. He is a pharmacologist and has a PhD from the University of Utrecht, the Netherlands. Previously Jack was CEO and head of business development at several biotechs. He started his pharma career at Marion Merrell Dow (later HMR and now Sanofi Aventis). He worked on several drugs now on the market. His experience is in business development, strategic marketing, general management, investing and fundraising.

Tim Fell, Chief Operations Officer, CellCentric Ltd

Following his D.Phil in Semiconductor Materials Tim migrated to the biological sciences in 1992 to work with DNA microarray pioneer Prof Ed Southern at Oxford University. In 1999 he co-founded Oxford Gene Technology (Operations) Ltd where as Technical Director, and later as General Manager, he developed a DNA microarray fee-for-service business. In 2002 UK anti-infective drug discovery company Arrow Therapeutics Ltd acquired the business and he joined the management team as CTO. His last role was with the London Technology Network, which he joined in 2005 as a Technology Consultant with a remit to stimulate collaboration between global business and the academic research base in the South East of England. Tim has an MBA from the London Business School. He joined CellCentric in March 2006.

Dr Richard Goodfellow, Chief Operations Officer, Scancell Holdings plc

Dr Richard Goodfellow has over 25 years international experience in the pharmaceutical industry, both in Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals. Dr Goodfellow was a co-founder of Paradigm Therapeutics and was on the board of Enact Pharma plc until its sale to Protherics. He has been a Board Director at Scancell for the past 10 years and is currently COO.

Shaun Grady, Vice President SPBD, Astra Zeneca

Shaun leads the AstraZeneca Strategic Partnering and Business Development (SPBD) function responsible for delivering the AZ’s externalization strategy, including early and late stage and on-market licensing and partnering, M&A, and divestments. His background includes roles at ICI, Zeneca, and AstraZeneca, as well as roles in legal, HR, US and business development. Major projects include: AstraZeneca merger, creation of Avecia and Syngenta, acquisition of CAT and MedImmune, the spin out of Marlow Foods (Quorn) and Albireo. Shaun’s interests include: rugby football, soccer, and sports writing.

Dr Tim Haines, Partner, Abingworth

Tim Haines has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc (sold to Depuy) and General Manager Baxter UK. Current and past board positions include Astex Therapeutics, Fovea (sold to sanofi-aventis), HBI, IMI, PowderMed (sold to Pfizer), Stanmore Implants and XCounter (AIM). Tim has a BSc from Exeter University and an MBA from INSEAD. At Abingworth, he identifies and creates new businesses and provides support for portfolio companies.

Dr Deborah Harland, Partner, SR One

Deborah joined SR One in 2005 and leads SR One's investment activities in Europe. She is a member of the Board of Directors of Onyvax, Protaffin and Syntaxin and is an observer on the board of 7TM Pharma. Prior to SR One, Deborah was part of GSK's Worldwide Business Development team where she evaluated opportunities in the CNS and GI therapeutic areas. Debbie holds a BSc. (Hons.) in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London, and an MBA from Henley Management College.

Ian Harrison, Chief Scientific Officer, Alchemy Healthcare

Founder Ian Harrison, CSO, is an elected fellow of the Royal Pharmaceutical Society and past Chief Pharmacist, Hammersmith Hospital. He was an Honorary Lecturer in Clinical Pharmacology at the Royal Postgraduate Medical School (now part of Imperial College). Ian has co-authored two textbooks on medicines and prescribing, and has undertaken marketing support work for pharmaceutical companies in relation to respiratory products. He has a research degree in pharmaceutics (Kings College, London) and a MBA (Cranfield University), subsequently qualifying as a PRINCE2 project management practitioner. Ian has worked full time on nasal drug delivery since 2007.

Dr Martin Heidecker, Investment Manager, Boehringer Ingelheim

Martin has been working at Boehringer Ingelheim since 2007 in a Senior Business Analyst and later in a Director capacity within the Global Business Analysis department. His responsibility incorporated all global strategic Marketing support in the arena of CNS and women’s health. This remit was later extended to include responsibility for the global Oncology Business Analysis as well. Prior to joining BI, Martin held several positions within the global Business Intelligence Department of Solvay Pharmaceuticals focussing primarily on compounds in early clinical stages. From 2002 – 2005 Martin worked as an investment manager at Bayern Kapital. During this time he led co-investments in early stage drug development, medical devices, and bioinformatic companies. Martin holds Master’s degrees in Biology and Economics. In his Ph.D thesis he was focusing on membrane transport proteins.

Dr Ruben Henriquez, Chief Executive Officer, Sanifit

Ruben joined Sanifit in 2008 and focused on getting the company, a young university spin-out, ready to raise funds needed to take its discoveries into clinical trials. In the Biotech field he has held management appointments with responsibilities for R&D Business Development and Corporate Strategy. Prior experience includes fund raising and negotiating licensing deals (including the deal with Johnson & Johnson for Yondelis) for Zeltia, an oncology company quoted in the Spanish exchange. A science Ph.D. and MBA trained in USA and Switzerland, he started his industry career at Novartis in Preclinical Research.

Jon Holmes, Chief Executive Officer, Michelson Diagnostics

Under Jon’s skilful and visionary leadership, Michelson Diagnostics Ltd has rapidly grown from a fledgling start-up in 2006, to the thriving company it is today. He has masterminded five rounds of investment, and his strategy for growth has enabled the company to achieve all of its milestones to date on time and on budget. Jon was previously Business Director of the Biomedical Group at Sira, the instrumentation R&D company, and was Director of the Smart Optics Faraday Partnership.

Raquel Hughes, Management Consultant

A qualified Management Accountant, mentor to small businesses and lecturer on the Stock Market at schools and colleges, Raquel developed her knowledge of the listing regime whilst at the London Stock Exchange. She used her considerable expertise to great effect in the creation and management of Exchange regulated products to commercially exploit the ever-changing London capital markets and is currently consulting to a company seeking pre-flotation funding. An experienced business manager who negotiated with and influenced HM Treasury, regulators and trade groups Raquel served on HM Treasury’s Islamic Finance Experts Group until 2009 and is a member of FTSE’s EMEA Committee, which determines the constituents of the FTSE 100 index.

Dr Sofia Ioannidou, Associate, Edmond de Rothschild Investment Partners

Sofia Ioannidou is an Associate in the Life Sciences team of Paris-based Edmond de Rothschild Investment Partners (EdRIP), having joined the company in 2009. Prior to joining EdRIP, she was an Associate Consultant at L.E.K. Consulting in London, where she performed scientific and commercial due diligence assignments for clients in the Life Sciences sector. Sofia started her career as a Research Scientist in Drug Development within the Boston, US-based company Eyetech Pharmaceuticals. Sofia obtained a BSc and an MSc in Molecular and Cellular Biochemistry from the University of Oxford, UK, and a PhD in Cell Biology from Cancer Research UK.

Chris Jones, Chief Executive Officer, Glysure

Mr. Jones has more than 20 years of experience in the medical device and diagnostic industry. Prior to joining GlySure in 2008 he was CEO of Tensys Medical and led the development of the first clinically acceptable, continuous, non-invasive blood pressure monitor. Mr. Jones also spent nine years with Nellcor Inc, a division of Tyco, most recently as VP of Marketing responsible for the pulse oximetry and critical care businesses. Prior to that he spent six years in sales and marketing management positions at BioGenex Laboratories. Mr. Jones is a graduate of Yale University with a Bachelor of Science Degree in Molecular Biophysics and Biochemistry.

Roel Kamerling, Managing Director, HealthTIES

Since 2002 Roel Kamerling has worked at stimulating technology based innovation. By reaching out with a personal approach from the TU Delft to industry, other universities, knowledge institutes and university medical centers, more and more knowledge is turned into a product suitable for market introduction.Roel Kamerling is currently program manager for the MedTech cooperation program Medical Delta (Delft, Leiden, Rotterdam) and managing director for the EU cooperation project HealthTIES (with Barcelona, Debrecen, Oxford and Zurich) . Before this he served for 4 years as business director for the nanotechnology research project NIMIC and various other public-private partnerships.

Dr Gareth King, Chief Business Officer, Critical Pharmaceuticals

Gareth joined Critical Pharmaceuticals in 2008 as Chief Business Officer responsible for the commercialisation of Critical Pharmaceuticals unique drug delivery technology and 'biobetter' products. Gareth has always focused on the science and commercialization of drug discovery and early clinical development having started his career as a postdoctoral research fellow at Harvard Medical School and a discovery project leader at Zeneca Pharmaceuticals (AstraZeneca). Gareth moved into business development with Incyte Pharmaceuticals before leading business development at Cyprotex and Pharmaceutical Profiles.

Dr Johan Kördel, Senior Investment Director, Lundbeckfond Ventures

Johan joined Lundbeckfond Ventures in 2010. He is a member of the board of Directors of Syntaxin Ltd., KaroBio AB and EQL Pharma AB. Prior to joining Lundbeckfond Ventures, he was a co-founder and CEO of Sound Biotech ApS and co-founder and Senior Vice President of Research as well as Business Development of Biovitrum AB. Before these positions he worked 10 years in R&D at Pharmacia, Sweden. He has a Ph.D. and is an associate professor in Physical Chemistry at the University of Lund, Sweden.

Dr Melanie Lee, Chief Executive Officer, Syntaxin

Dr Lee was formerly President of New Medicines and Executive Vice President R&D with UCB, having served as R&D Director at Celltech before its merger with UCB. Dr Lee brings a wealth of drug research and development experience to Syntaxin, through her early academic career at Cancer Research UK (as ICRF), a decade in research with GlaxoSmithKline and her later leadership of biopharmaceutical R&D at Celltech and UCB. Dr Lee currently Chairs Cancer Research Technology, an early drug R&D and technology licensing company of CRUK.

Dr Olivier Litzka, Partner, Edmond de Rothschild Investment Partners

Olivier Litzka has been a partner with Paris-based Edmond de Rothschild Investment Partners (EdRIP) since 2006. He invests primarily in European biotechnology and medtech companies as well as some investments in the United States. In addition to Noxxon Pharma, he serves on the boards of Novexel, Probiodrug, Endosense, SuperSonic Imagine and JenaValve Technologies. Before joining EdRIP, Olivier Litzka spent six years with 3i's life science venture capital practice, based first in Munich and then in Paris. In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting for several years, both in Munich and Paris. Litzka holds a Ph.D. in molecular microbiology from the Institut für Mikrobiologie at the University of Munich and did his scientific research work over several years in Munich and Oxford.

Alain Lostis, General Partner, Aelios

Alain Lostis has had an international career for the past eleven years with the Baxter group in the USA, Belgium, the Netherlands and Switzerland. Lostis’s last position at was as a board member of Baxter Europe, responsible for all mergers and acquisitions. He participated in all sectors where Baxter was involved in Biopharmaceuticals, renal therapy, medical devices and cardiology. Alain Lostis was the founder and CEO of a high technology company in the Netherlands for which he raised €6 million in capital. In 2002 Alain Lostis founded Eumedix Technology & Finance raising substantial capital and performing mergers and acquisitions in association with Chausson Finance. Alain Lostis regularly serves as an advisor to investment funds, and has been a member of a fund investment committee at the Caisse des Dépôts et Consignation (CDC). In 2004 he co-founded Aelios Finance He started his career in investment strategy and mergers and acquisitions with Booz Allen & Hamilton in Paris and New York. He holds an agricultural Engineering degree from INA-PG and an MBA from Columbia University in New York.

Dr Ernest Loumaye, Chief Executive Officer, Preglem

Dr. Loumaye is a co-founder of the Company. He has been a member of the Board of Directors and Chief Executive Officer of the Company since its inception in 2006. He has 9 years’ experience as Head of Clinical Development for Reproductive Health (RH) at Serono in Geneva and Boston. While at Serono he contributed actively to the worldwide registration of three important biotechnology products. In 2003 Dr. Loumaye joined Ipsen in Paris as Vice President, Medical Sciences, Endocrinology, Research & Development. His positions at Serono and Ipsen gave him 5 years of experience in strategic R&D portfolio design and implementation follow-up in endocrinology. Dr. Loumaye is a visiting Professor of Reproductive Endocrinology at Louvain University, Brussels, where he held a fulltime clinical and academic position until 1991. He holds MD, PhD and OB/GYN degrees from Louvain University, Belgium, specializing in Obstetrics and Gynaecology. He was a research fellow at the National Institute of Child Health and Human Development, in the US and is the author of over 90 publications in peer-reviewed journals. He is a Belgian citizen and was born in 1952.

Dr Colin Love, SVP of Development, BioVex

After twenty years developing and launching biotechnology products, Colin joined BioVex as Development Director. BioVex is now a ten year old private biotech company that is developing a new class of treatments for cancer, based on Herpes Simplex virus. The Company is headquartered in Boston with laboratories in Oxford and University College London. Colin is responsible for the product development functions at BioVex where three products have been progressed from discovery through to phase III clinical trials. Previously he was Director of Manufacturing Development at Celltech Chiroscience working on the development of both biologicals and NCE's. He has worked in product development for Medeva, Ares Serono and Amersham International. He has experience in the development and approval of both diagnostic and biopharmaceutical products. Colin was Director of Project Management when Hepacare TM, a third generation recombinant Hepatitis B vaccine, gained EMEA approval. He completed his PhD at the University of Glasgow on the influence of steroid hormones on breast cancer.

Dr Keith Martin, Chief Executive Officer, Apitope

Keith Martin has over 25 years' experience in pharmaceutical R&D, business development and new venture experience. He was previously founder and president of KetoCytonyx Inc where he was responsible for securing seed and Series A funding of €4.6 million and completed a Phase I lead programme. Previously Keith was Global Director of Life Sciences at BTG where he was responsible for an extensive portfolio of product candidates and licensee marketed products. Prior to this, he was Deputy Head of Biology at BASF Pharma where he developed six CNS compounds from the bench through to Phase I and was a key member of the team that developed two products to full market approval. Keith has been the recipient of the Wellcome Trust Fellowship in Mental Health at the University of Nottingham Medical School and a NATO Exchange Fellowship to Princeton University Psychology Department. Keith has published over 150 papers, reviews & abstracts and is an inventor on 10 patents.

Dr Michael McArthur, Chief Scientific Officer, ProCarta BioSystems

Dr. McArthur is a Biotechnologist with a track record in the successful creation of novel and powerful technology platforms. While he was Director of Molecular Biology at Regulome Corporation which developed a multi-faceted platform capable of functionally annotating the human genome. Since returning to the UK he has established a variety of proprietary techniques, which are at the core of Procarta Biosystems, to manipulate bacterial gene expression and adapted the approach to tackle the drug-resistant pathogenic bacteria prevalent in our clinics.

Dr Keith McCullagh, Chairman, Xention

Keith G McCullaghis Chairman of Xention Pharma Ltd and its operating subsidiary, Xention Ltd. Prior to joining Xention, from 2003 to 2008 he was Chief Executive of Santaris Pharma A/S, an RNA medicines company, and from 2009 to 2010 Chairman of Clavis Pharma, an oncology research business. From 1986 to 1998 Dr McCullagh was Chief Executive of British Biotech plc, a company he built into one of Europe’s leading biopharmaceutical businesses. Prior to founding British Biotech, he was UK Research Director for GD Searle & Co, Inc, now part of Pfizer. Dr McCullagh is also Chairman of Provesica Ltd, a urology research company demerged from Xention in 2010, Chairman of Pharmacy 2U Ltd, the UK’s largest warehouse pharmacy and Vice Chairman of Affitech AS, a Scandinavian antibody therapeutics company. He holds a degree in veterinary medicine from the University of Bristol and a PhD in pathology from the University of Cambridge.

Helen McKeever, Pre-Clinical Programme Manager, Almac

Helen joined Almac in August 2009 as Preclinical Programme Manager. In this role she assumed overall responsibility for the successful implementation of programmes under the new RAPIDDTM service offering, ensuring seamless progression from initial API production through non-clinical safety assessment and thereby accelerating entry into clinical development. She has more than 20 years experience within the CRO industry, working in both the clinical and non-clinical arenas, with the last 12 years spent within Programme Management and Business Development.

Dr Michael McLean, Chief Executive Officer, Pro-Cure Therapeutics

Mick became CEO of Pro-Cure Therapeutics, a company developing novel treatments against cancer stem cells, in May 2009. He has a track record of leading organisations from start-up through growth and change, and previously lived for two years in Paris, France, where he was CEO of two cancer vaccine start-ups and joined Link Technologies (Scotland) as Chairman in April 2007. Before moving to Paris at the end of 2005 he was based in Boston as President of Avecia's DNA Medicines business, which he led from its inception in the mid-1990's to being the leading manufacturer of cGMP oligonucleotide therapeutics.

Gwen Melincoff, Senior Vice President Business Development, Strategic Investment Group, Shire Pharmaceuticals

Ms. Melincoff has over 20 years of leadership experience in the biotechnology and pharmaceutical industries, spanning research operations, marketing, product management, project management, and licensing and business development. From September 2004 to the present, Ms. Melincoff has been part of the Business Development team at Shire Pharmaceuticals, first as Vice President of Business Development, and recently as Senior Vice President of Business Development. During her tenure, she has been involved in numerous licenses, product divestments, co-promotion and collaboration agreements, and mergers and acquisitions. She was responsible for the collaboration with New River Pharmaceuticals that led to the $2.6 billion acquisition of the company within two years of the first transaction. Ms. Melincoff has a B.S in Biology, a Master’s of Science in Management and Health Care Administration, and has attained the designation of the Certified Licensing Professional (CLP™).

Bryan Morton, Chief Executive Officer, EUSA

Bryan Morton has a BSc in Pharmacology from Aberdeen University and an MBA from Durham University. He began his pharmaceutical career in sales and has held positions of increasing responsibility in medical information, marketing, sales management, business development and general management during a 30 year career in the healthcare industry, largely with Merck and Co. Inc. and Bristol Myers Squibb. During this time he has lived and worked in the UK, USA, Australia and Belgium and in 2003 he founded Zeneus Pharma through the acquisition of Elan’s European sales and marketing business for $120m in a private equity deal. Following the sale of Zeneus Pharma for $360m in late 2005, Bryan founded EUSA Pharma in 2006 with backing from Essex Woodlands Health Ventures.

Ian Nicholson, Chief Executive Officer, Chroma Therapeutics

Mr. Nicholson has served as Chief Executive Officer of Chroma Therapeutics Limited since September 2004. Prior to joining Chroma, he was Senior Vice President of Business Development for Celltech Group plc, responsible for all global licensing activities. He has held a variety of senior commercial positions with Oxford Asymmetry International plc, Lonza AG and Amersham International plc. He currently also sits on the Boards of the Biotechnology Industry Association and Bioventix Limited. Mr Nicholson holds a B.Sc. (Hons) degree from University College, London and an MBA from Boston University.

Dr Eckhard Niemeier, Director of Business Development, MorphoSys

Eckhard joined MorphoSys in January 2008. He is responsible for all business development activities related to MorphoSys’ proprietary pipeline of antibody therapeutics including in- and out-licensing as well as portfolio management and competitive intelligence. Prior to joining MorphoSys, he worked for several years in consulting for McKinsey & Company advising pharmaceutical companies on a broad variety of topics including R&D strategy, organization and commercial operations. Before this, he worked for Human Genome Sciences, Inc. in R&D.

James Noble, Chief Executive Officer, Immunocore

As the former CEO of Avidex Limited, James has in-depth knowledge of Immunocore’s mTCR technology as well as a wealth of prior experience in the international biotech community. Former CFO of British Biotech, prior to leading Avidex for 7 years, James also sits as a non-executive director on the boards of GW Pharmaceuticals plc and Astaire Group plc (both listed on AIM) and the privately-held Axellis Limited plus quoted 3D Diagnostic Imaging plc. He is also CEO of Adaptimmune Limited.

Peter Nolan, Senior Vice President, Commercial Development, Oxford Biomedica

Peter Nolan, age 58, was appointed to Oxford BioMedica's board in May 2002, having been a senior member of the Company since its foundation. He is also a Director of the UK Biolndustry Association and is a past chairman of the Oxfordshire Bioscience Network. He has broad experience and knowledge of the biotechnology sector. Prior to joining Oxford BioMedica, he served as head of the Biotechnology Unit at the UK Department of Trade & Industry for eight years. In that role he was responsible for establishing and managing complex collaborative research programmes involving industry, research councils and other government departments. Previously he held senior positions in the Laboratory of the Government Chemist and also the Metropolitan Police Laboratory in London where he was a senior forensic scientist.

Dr Deborah O'Neill', NovaBiotics

Deborah founded NovaBiotics in August, 2004. An immunologist by training with over a decade's experience in the field of natural antimicrobials, Deborah studied at University College London and then worked in internationally acclaimed laboratories in San Diego and Ghent before moving to Aberdeen. It was here where, in order to fully develop the commercial potential of novel antimicrobial peptide therapies, the business was started.

Tibor Papp, Head of Corporate Advisory, PharmaVentures

Dr Papp is an experienced corporate strategy advisor having spent 18 years in the healthcare / life sciences industry in the areas of commercial and operational strategy, investment management, portfolio development, business transformation, licensing / M&A, and risk management. He has advised leading pharmaceutical, medical device and private equity clients about product, market and M&A deal strategies in pharmaceuticals, biotechnology, medical devices, drug delivery systems, and medical supplies globally. Tibor is also an experienced surgeon, with a PhD from the University of Aberdeen and an MBA from the University of Oxford.

Nigel Pitchford, Partner, DFJ Esprit

Nigel is a Partner with DFJ Esprit. He joined as a result of the 3i European venture portfolio acquisition in 2009. Previously, Nigel had been with 3i for 12 years, becoming a Partner in 2006 and ultimately leading the venture team’s healthcare activities across Europe and the US.In 2010 Nigel led the DFJ Esprit new investment into translational genomics and personalized medicine company, Horizon Discovery, and sits on the board of this exciting business. He is a director of Oxford Immunotec and manages the DFJ Esprit investments in Kiadis, HBI and Pulmagen.Nigel studied chemistry at the University of Oxford, before completing a PhD at the University of Durham. He also has an MBA from Warwick Business School.

Denise Pollard-Knight, Managing Partner, Phase4 Ventures

Denise has been responsible for leading (Nomura) Phase4 Ventures investment activities since joining Nomura in 1999 and has over 14 years experience as a venture capitalist. Phase4 Ventures recently completed an MBO in a transaction that was backed by Harbourvest Partners, a Fund of Funds firm with over $35bn under management. Denise is actively involved in US and European investments most recently Proteolix and OncoMed. She is currently a Director of portfolio companies OncoMed, Albireo, Cerimon and Nabriva (Chairman) and is an independent director on the board of Idenix. Prior to joining Nomura, Denise was an investment manager in the Bioscience Unit of Rothschild Asset Management, a group managing investments in private and public biotechnology companies and previously held senior management positions in R&D and in strategic consulting. She holds a PhD and BSc (Hons) from Birmingham University and was a Fulbright Scholar at the University of California, Berkeley. Denise is a member of the Board of Trustees and Council of the British Heart Foundation and holds a Diploma in Company Direction from the Institute of Directors. She is a Director of Phase4 Ventures Ltd. Denise was the 2008 Women in the City award winner for the Financial Services category and Nomura Phase4 Ventures was the EVCJ Venture Capital House of the Year also in 2008.

Dirk Reyn, Chief Executive Officer, Movetis

Dirk Reyn is managing director of Shire-Movetis NV and has worked in the industry for 23 years.Following 10 years in a number of sales and marketing functions with Eli Lilly in Belgium, USA and France, Dirk joined Johnson & Johnson in 1992. After different roles with increasing responsibility, he led the International Marketing department for the Gastrointestinal Franchise and was the driving force behind the global marketing and commercial strategy for different GI products between 1992 and 1999. He was selected to create the first Johnson & Johnson CRM (Customer Relationship Management) Competence Centre (2001-2002) and then became Vice President New Business Development for Janssen-Cilag in Europe (2002- 2006). Together with three other founders, he started Movetis in December 2006. October 2010 Movetis was acquired by Shire. Shire-Movetis NV in Turnhout is to become the GI R&D and EU Commercial Centre of Excellence for Shire.

Dr Elizabeth Rollinson, Director, PhotoBiotics

(Biography to follow shortly)

Dr Mike Romanos, Chief Executive Director, Crescendo Biologics

Mike Romanos is CEO and founder of Crescendo Biologics. He has 25 years’ biotech and pharmaceutical industry experience in most areas of drug discovery science and technology, and several therapeutic areas. Previously Mike held international executive positions in GlaxoSmithKline R&D, making significant contributions to GSK’s drug development pipeline, and broadly to discovery strategy and technology. He played a key role in establishing GSK’s advanced antibody lead discovery capability which generated the pipeline of in-house monoclonal antibodies, several of which are in clinical development. Mike has a degree in Natural Sciences from Cambridge, a PhD in molecular biology from Imperial College.

Les Russell, Chief Executive Officer, OrganOx

Les has been involved with OrganOx since its formation in 2008 and has led the company through 2 funding rounds, closing its Series B funding earlier this year. He has broad general management experience in medical devices and biopharmaceuticals having worked as Business Development Director for Baxter Healthcare and Cambridge Life Sciences plc and earlier as Technology Development Manager for Ciba Corning Diagnostics. Les was instrumental in securing licence agreements with several major diagnostics companies for Cambridge Life Sciences plc and also in its subsequent sales to Medirace plc and Byk Gulden GmbH. After being recruited as Managing Director at Chromogenex plc, he led a successful turnaround of the company resulting in its AIM flotation in 2005.

Peter Sandbach, Head of Communications, Roche

Peter Sandbach leads communications for the Partnering function of Roche, the Swiss pharmaceuticals and diagnostics group. With Roche making upwards of 50 deals each year with external companies to strengthen its R&D portfolio, Peter is constantly handling communications at the pharma-biotech interface. Prior to that he managed issues surrounding genetically modified crops for Syngenta, previously Novartis. Peter started his career in biotech communications at the UK-based consultancy that introduced Dolly the cloned sheep to the world.

Gregg Sando, Chief Executive Officer, Cell Medica

Gregg Sando is the founder and CEO of Cell Medica. After a career in investment banking based both in London and New York, he completed his Immunology MSc degree at the medical school of Imperial College. Recognising the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in cooperation with a small group of the leading clinicians and immunologists who were pioneering this new mode of medical treatment. (MSc Imperial College, MBA University of Chicago, BA Biochemistry Harvard University).

Bruce Savage, Director, QSIant

Bruce is a serial scientific entrepreneur. He founded Cytocell, a molecular diagnostics company in 1991 raised £8.0m employed 53 people with sales of £1.1m. Company was split up and sold off in 2001. He assisted with the founding of BioAnaLab, a company offering analytical services to pharma industry for biologics. Here he raised £540k. The company was recently acquired by Millipore giving the investors an excellent return. In 2005 he co-founded CMP Therapeutics a company based on a natural immune modulator developed in an MRC unit. Here he raised £5.0m and took the compound from the lab into Phase II trials in 5 years. He started his career in drug development in Roche and then spent many years in sales & marketing positions in a wide range of bioscience/biotech companies.

Dr Clive Savory, Senior Lecturer, Open University

Dr Clive Savory has specialised in the management of innovation processes in the NHS, especially the transfer of technology in and out of the NHS. He is currently researching in the adoption of healthcare technology by NHS organisations and is currently undertaking an NIHR-funded project on the topic.

Richard Seabrook, Head of Business Development, The Wellcome Trust

Richard leads the Business Development Team, Technology Transfer Division which undertakes due diligence and project management of translation awards, strategic translation awards and seeding drug discovery funding.The Team has responsibility for intellectual property management and its translation such as through licensing or new company formation. Previously, Richard held project management and business development roles in the biotechnology sector and has extensive experience of early-stage funding of life science technologies, commercial transactions, Board, SAB and government agency advisory roles.

Sunil Shah, CEO, O2h

Sunil Shah is the CEO of O2h. He was previously the Director of Business Development at Cambridge Biotechnology (now Biovitum). He has consulted into a range of biotechnology companies and major pharmaceuticals such as Pfizer, GSK, and BASF via Private consulting and the Life Sciences group of PA-Consulting. Prior to co-founding O2h, he was the co-founder and Director of a technology company. The Non Executive board positions he holds include those with Opal Drug Discovery Ltd and IOTA Pharmaceuticals Ltd. He holds an MBA from Cambridge University and a BSc in Biochemistry and is a member of the Royal Society of Chemistry.

Dr Nick Skaer, Chief Executive Officer, Orthox

Nick Skaer, CEO, Orthox Ltd. Nick founded Orthox Ltd. in 2008, securing £1.6 million seed funding from the Wellcome Trust, to commercialise regenerative cartilage and bone repair devices using a revolutionary silk biomaterial, Spidrex®. A bioscience graduate of Oxford and Strasbourg Universities, Nick developed Spidrex® with Oxford Biomaterials Ltd., the company of which he was CEO for the four years prior to founding Orthox. During this period, he raised over £3.5 million in private equity finance and public grants to fund the Spidrex® development programme, and was founding Director of two other equity financed Oxford Biomaterials spin out ventures, Neurotex Ltd. and Suturox Ltd.

Dr Jason Slingsby, MBA, Chief Executive Officer, Protaffin Biotechnologie

Jason is co-founder and CEO of ProtAffin. He has worked over the last 13 years at the listed biotech companies Oxford BioMedica (UK), Sosei Co. Ltd (UK/Japan) and Intercell (Austria). He was awarded a 1st class honours degree in Biochemistry at Magdalen College, Oxford University, a PhD in Inflammatory Disease Genetics from Imperial College London and an MBA with Distinction from London Business School.

David H. Solomon, President & Chief Executive Officer, Zealand Pharma

Dr. Solomon joined Zealand Pharma September 1st, 2008. Dr. Solomon has extensive experience in pharmacology research, having served as a faculty member at Columbia University's College of Physicians and Surgeons in New York, NY as well as leadership positions at several biotechnology, pharmaceutical and medical device companies, including Remedy Pharmaceuticals and Critical Diagnostics, both in New York. From 2003-2006, Dr. Solomon led healthcare investing at Carrot Capital Healthcare Ventures. Most recently, Dr. Solomon served as Chief Operating Officer of Vital Sensors, Inc. Dr. Solomon studied medicine and received his doctorate at Cornell University Medical College and the Sloan-Kettering division of its Graduate School of Medical Sciences, in New York City.

Will Spooner, Technical Director, Eagle Genomics

Will has been developing bioinformatics tools under the Ensembl umbrella for 9 years, 2 at Eagle, 4 as an independent consultant on projects such as Gramene and WormBase, and 3 at the Sanger Institute. He was until early 2009 a visiting scientist at the European Bioinformatics Institute, sponsored by the Cold Spring Harbor Lab. Will holds a PhD in Earth System Modelling from the University of Southampton.

Sue Staunton, Business Services Partner, James Cowper LLP

Sue Staunton is a business services partner. She also has a particular interest in working with technology businesses and their owners and, as such, heads our our technology team.
Sue works with clients on the development and implementation of their corporate strategies. She also has a great deal of experience in working with businesses in financial crisis to establish strategies to assist them to move forward successfully.

James Steel, Director of Corporate Finance, KBC Peel Hunt

James Steel is a director of corporate finance at KBC Peel Hunt, a leading middle market financial advisory and broking firm. Prior to joining KBC Peel Hunt in 2009 James was a senior investment banker within Piper Jaffray's European healthcare group and has considerable experience in advising both public and private companies on a wide range of corporate matters including financings and mergers and acquisitions.

Dr Jenny Taylor, Programme Director of the Genomics and Pathology Theme, OBRC

Dr Jenny Taylor is Programme Director for the Oxford Biomedical Research Centre’s Genetics Theme. Oxford Biomedical Research Centre (BRC) is funded by the UK’s National Institute of Health Research to translate advances in biomedical research into clinical practice and is a partnership between the University of Oxford and the Oxford Radcliffe Hospitals NHS Trust. Its programme encompasses ten disease-specific themes and three cross-cutting themes, of which Genetics is one. The aims of the Genetics Theme are to evaluate cutting edge genomics technologies, (including next generation sequencing) for their clinical applications and to conduct a translational research programme that integrates genetics leading to novel molecular diagnostics. Dr Taylor has been Programme Director for the Oxford BRC Genetics Theme since its inception in 2007. Prior to that she managed the Oxford Genetics Knowledge Park’s translational research programme and also has experience of managing genetics research programmes in the biotech sector. She holds a BA in Biochemistry and a D.Phil. in Molecular Biology from the University of Oxford.

Helen Tayton-Martin, Chief Operations Officer, Adaptimmune

Helen Tayton-Martin is full-time COO of Adaptimmune Ltd. With a PhD in molecular immunology, a MBA from London Business School and 15 years of experience working within the Pharma, biotech and consulting environment in disciplines across preclinical and clinical development, Helen joined Adaptimmune from Avidex/MediGene Ltd. where she was responsible for commercial development of the increased affinity TCR engineering programme in cancer and HIV therapy. Helen is responsible for day-to-day running of Adaptimmune.

Dr Nicola Thompson, Director Scientific Opportunities, GSK-CEEDD

Nicki Thompson joined the GSK ceedd (Centre of Excellence for External Drug Discovery) in January 2010 as Director, Scientific Opportunities and is responsible for sourcing new alliances for the European ceedd. Prior to joining the ceedd, Dr. Thompson was Head of Discovery at Syntaxin (a U.K. based Biotech company), responsible for delivery of novel biopharmaceuticals in the areas of neurological, inflammatory and endocrine diseases through to Development. Dr. Thompson joined Syntaxin from GSK, where she worked in a variety of drug discovery roles with increasing responsibility from target identification through to candidate selection over a 20 year period. At GSK, Dr. Thompson was based in the Respiratory CEDD, where as head of the Allergic Mechanisms group, she lead a number of drug discovery programs and external alliances, focusing on allergic and inflammatory processes.

The ceedd

In order to access the best in the world innovation GSK established a small semi-autonomous scientific investment team of about 25 people in 2005 - the Centre of Excellence for External Drug Discovery, the ceedd. The ceedd considers itself a pioneer in the quest to find new medicines, going to great lengths to actively seek out and collaborate with world-class biotechnology companies.The ceedd was the first team in GSK R&D to be truly externally focused with no internal programs to manage, working across all therapy areas, tasked to form multi-program, risk reward sharing alliances. We thrive on the excitement of discovering innovative scientific platforms and compounds through our collaborations and nurturing them to their full potential to provide the world with differentiated medicines that will deliver significant benefits to patients.

Dr John Tite, Chief Executive Officer, Bicycle, Therapeutics

John joined Bicycle Therapeutics as CEO on formation of the company in July 2009, prior to this he was Vice President and Head of Discovery Biology for the GSK Biopharm CEDD in which capacity he was responsible for managing biology support for all biopharmaceutical discovery and development programmes from target to proof of concept. He has been involved in the discovery and development of therapeutic antibodies and vaccines for over 25 years. John is currently a member of the MRC-Technology Scientific Advisory Board, the MRC Developmental Pathway Funding Scheme (DPFS) and the CR-UK Drug Discovery Advisory Group.

Hans von Celsing, Chief Executive Officer, BiOxyDyn

Hans von Celsing serves since 2010 as Executive Chairman of BiOxyDyn Ltd. He has many years of experience in the medical and biotech technology industries as an entrepreneur and executive as well as venture capitalist. He built Elekta’s worldwide neuro and oncology business and started thereafter Neuroventures Capital and several other medical technology, including imaging, companies both in the US and in Europe. He currently serves on the boards of BiOxyDyn Ltd, Sonowand A/S and CLS AB and as an advisor to Mirada Medical Ltd and Still River Systems Inc.

Dr Fintan Walton PhD, CEO and Founder of PharmaVentures

Dr Walton is the Founder and CEO of PharmaVentures. After completing his doctoral research on the genetics of cell proliferation at the University of Michigan (US) and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Although Dr Walton's main focus is his role as Chief Executive Officer of PharmaVentures, he is available for some consultancy assignments.

Naiyin Wang, Investment Director, Shanghai Fosun Pharma, London

Trained as a medicinal chemist in China; Received PhD in molecular biology at Imperial College in London. Worked as researcher in many different disciplines. Gained commercial experiences by sales of chemicals including APIs and promoting packaging services from china to European companies; As part of team, try to raise fund for a 3D imaging device; Formed a company to do the technology transfer to Chinese pharmaceutical companies in the area of Biotechnology. Now, work as the investment director and chief representative of the Shanghai Fosun Pharmaceutical in our London office.

Mike Ward, Editor-in-Chief, Scrip Group

Mike Ward is editor-in-chief at the Scrip Group focusing on the business challenges facing all stakeholders in the pharma, biotech and medtech industries. He has been covering the life sciences industry for more than 25 years. He has extensive experience in investment banking, consultancy as well as writing about the industry for other leading publications such as Nature, the Economist and BioCentury as well as national newspapers including the Financial Times and International Herald Tribune. Between 1992 and 2002, Mike was a co-author of many of the European biotech industry reports published by the accountancy houses. In 2010 he was named European Mediscience Commentator.

Jeremy Warren, Chief Executive Officer, Nanosight

Jeremy Warren is an experienced businessman at CEO level with a background in sales and start-ups. Following a degree in Chemical Engineering, Jeremy worked for Unilever in production management where he qualified as a Chartered Engineer. He then set up a successful chemicals manufacturing business in Belgium, before completing an MBA at INSEAD. After a period in strategy consultancy with Booz Allen, Jeremy began a series of CEO roles in SME’s across a wide range of industries. This experience has centred on developing technology businesses with private equity finance.

Prof. Paul Watt, Chief Executive Officer, Phylogica

Dr Paul Watt completed his doctorate in Molecular Biology at Oxford University, and then had postdoctoral appointments Harvard and Oxford Universities, before being appointed, Adjunct Professor at the school of Paediatrics and Child Health of the University for Western Australia. Professor Watt has published more than 44 peer reviewed scientific papers (including several highly cited papers) and is primary inventor on 19 patent applications, several of which have been granted in the US and Europe. Professor Watt is founder and CEO of Phylogica, which is already entering into discovery alliances with large Pharmaceutical companies such as J&J, Medimmune/AstraZeneca, Pfizer and Roche.

Dr Gunnar Weikert, Chairman, Inventages

Gunnar is Chairman, CEO and Founder of Inventages. Before founding Inventages, He has more than 10 years of experience in the pharmaceutical industry. Prior to founding inventages, he was a senior vice president and global head for life science deals at Bayer AG. While at Bayer, he oversaw venture investments in technology companies and collaborations representing some of the biggest deals between big-pharma and biotechnology in the late 1990's. Gunnar holds an MD, a PhD in the field of metabolism from University of Düsseldorf, and an MBA.

Will West, Chief Executive Officer, CellCentric

Will has been CEO of CellCentric since November 2005 and involved with biotech and pharma for over 20 years. Following a post doc at NIBSC, he joined Procter & Gamble Healthcare, ultimately heading clinical development for Respiratory and GI, leading an international team and delivering programmes in Europe, the Americas, South Africa and China. Following an MBA at London Business School, he was Director of Product and Business Development at CellFactors plc, a tissue engineering biotechnology company. Other roles have included for The Wellcome Trust, the BIA and the UK Government’s BIGT initiative.

Dr Alan Whitmore, CEO/CMO, Lumemed

Dr Alan Whitmore BSc PhD (Lond) BM BCh (Oxon) MRCGP is a clinician scientist and former academic with 20 years' research and clinical experience in ophthalmology and general medicine. He has done work in ocular drug delivery, neurodegenerative disease and bioinformatics. Prior to moving into the business sphere he was Lecturer in Ophthalmic Pathology at the UCL Institute of Ophthalmology, where he ran his own laboratory. He was Institute Medical Advisor to the UCL Institute of Ophthalmology from 2003 to 2008. He invented a novel non-invasive drug delivery system and in 2008 co-founded Lumemed Ltd to develop it. He is currently its CEO and in this role has set up collaborations with High Force Research, The School of Pharmacy, e-Therapeutics PLC and Moorfields Eye Hospital. He successfully raised funding for and directed Lumemed’s recent proof of concept project, which was completed on schedule and on budget. He is also the Research Director of e-Therapeutics PLC.

Dr Paul Whyte, Chief Executive Officer, Future Injection Technologies

Paul joined FIT in 2010 to lead the commercialisation of the SafeClickTM auto-injector platform. He has experience in commercial leadership and consultancy roles spanning the pharmaceutical and emerging technology environments from partnering late stage pharmaceutical products to exploiting innovative emerging products and technologies. Prior to joining FIT, Paul headed-up Isis Enterprises’ Life Science Consulting team and before this was responsible for leading the commercial development and partnering of therapeutic medicines at Evolutec Plc as Director of Business Development. Previous commercial roles have included partnering Avidex Ltd’s cancer and anti-inflammatory therapeutics, Cancer Research Technology (CRT) and the formation of Antisoma plc and the licensing of CRT’s cancer portfolio. Paul’s early career includes Zeneca Diagnostics, vaccine research and development at Pierre Fabre Medicament and small molecule drug discovery at Astra Zeneca. Paul has an honours degree from Warwick University, a PhD in immunology and an MBA.

Dr Sarah Wordsworth, Health Economist, University of Oxford

Dr Sarah Wordsworth is a Senior Research Fellow in Health Economics, at the University of Oxford. For the past 16 years she has been performing cost-effectiveness analyses of new health care interventions for the NHS. She has particular expertise in evaluating novel genomic diagnostics in the area of inherited heart disease and cancers

Prof. Malcolm Young, Chief Executive Officer, e-Therapeutics

Professor Malcolm Young is a network analyst by scientific background. He has previously been Director of the Complex Systems Group; Director of the Institute for Neuroscience; Provost of the Faculty of Science, Agriculture and Engineering; and Pro-Vice Chancellor for Strategic Development at Newcastle University, after having been a Royal Society Research Fellow at the RIKEN Institute in Japan, and at Oxford University. The main goals of his research are to understand how biological function arises from structural aspects of complex biological systems, and how optimally effective interventions in malfunctioning complex systems can be designed. The latter area is the basis of what has come to be called Network Pharmacology, which e-Therapeutics was founded to pioneer.

 

Speaker and Chair Biographies for 2010


Below are listed the biographies of the speakers and chairs participating inthe 2010 programme.  These will be continually updated as we receive new biographies.

Patrick Baddeley

Charlie Bavington

Anthony Baxter

Marco Boorsma

Ian Brown

Neil Butler

Christophe Chassagnole

Andy Christie

David Colpman

Rod Cook

Nigel Courtenay-Luck

Paul Cuddon

Paul Davie

Liam Evans

Lubor Gaal

Ian Garland

James Gubbins

Tim Haines

Deborah Harland

Richard Honey

Graham Hughes

Michael Hunter

Eva Jack

Chris Jones

Richard Jones

Simon Jones

Barry Kenny

Simon Kerry

Jim Kinnier-Wilson

Dominique Kleyn

David Knowles

Rowland Kozlowski

Alexander Krantz

Alan Lamont

Melanie Lee

Steven Lee

Eddy Littler

Graham Lock

Colin Love

Anker Lundemose

Ken Macleod

Kaasim Mahmood

Gary Manchee

John March

Graeme Martin

Linda McCausland

Jim McDonald

Michael McLean

Christopher Meade

Andrew Mearns-Spragg

Phillip Monk

Ian Nicholson

Ian Paling

Rob Pinnock

Les Russell 

Jan Rutherford

Anand Sambasivan

Graziano Seghezzi

Chris Shelley

Nick Skaer

Tim Sparey

Sue Staunton

James Steel

Mark Sweetinburgh

Douglas Thomson

Rebecca Todd

Mark Tucker

Ena Vieira

Ian Wainwright

Colby Walker

Matthew Walls

Fintan Walton

Sally Waterman

Peter Wrighton-Smith

Patrick Baddeley, Partner, Manches

Partner, Patrick Baddeley, specialises in all aspects of corporate work, including mergers and acquisitions, refinancing and other transactions, particularly for clients in the life sciences field.

Dr Charlie Bavington, Managing Director, Glycomar

Founder of GlycoMar. He is a biochemist with over 8 years experience in marine biotechnology. A graduate of the University of Edinburgh, he completed his Ph.D. at the same university, studying proteoglycan metabolism in cartilage.

This was followed by postdoctoral research at Dunstaffnage marine lab studying invertebrate glycans and cell adhesion. Subsequently he worked for Integrin Advanced Biosystems Ltd, a marine biotechnology and testing company, holding the positions of Operations Manager and Research & Development Manager. His scientific interest is in glycobiology and its role in cell-cell interactions.


Anthony Baxter, Chief Executive Officer, Cyprotex

Dr. Anthony Baxter is the Chief Executive Officer of Cyprotex Discovery Ltd and has over 25 years experience in management and research within the pharmaceutical, biotech chemistry service and instrumentation industries, mainly in the areas of drug discovery, medicinal chemistry and combinatorial chemistry. Before joining Cyprotex, Dr. Baxter successfully held positions as the CSO of Oxford Asymmetry International prior to its merger with Evotec, as founding CEO of Argenta Discovery Ltd and as CEO of deltaDOT. He has also held positions as Research Manager at Ciba UK Central Research Laboratories (1990-1994) where he managed Ciba blue-sky research interests and as Team Leader at Glaxo Group Research (1983-1990). Dr. Baxter has been actively involved in assisting in the scientific success of the development of several marketed drugs and in the discovery of advanced clinical development candidates for Curis, Serono, GSK, Ciba and Argenta. 

Marco Boorsma, Senior Analyst, Forbion Capital Partners

Marco holds a master's degree in Molecular Biology from the University of Groningen (NL) and a PhD in Biotechnology from the ETH Zurich (CH). His PhD work focused on the development of bio-manufacturing systems was executed at Cytos Biotechnology (CH), the ETH and the MRC Laboratory for Molecular Biology in Cambridge (UK). In 2001 Marco took on the position of Lead Scientist with DSM Biologics (NL) working on recombinant manufacturing followed by 3 years as Director of New Business Development where he was responsible for the acquisition of new projects as well as out-licensing of DSM technology. In July 2007 Marco joined the investment team of Forbion Capital Partners.

Ian Brown, Chief Executive Officer, RepRegen Limited

Ian is the CEO of RepRegen Limited. Previously, Ian held senior executive positions with Chromogenix (previously Kabi Pharmacia) in Gothenburg Sweden, Instrumentation Laboratory in Milan Italy, Cordlife, SDP Technology and Avanti Capital. Ian has served as a non executive director on a number of boards and as Chair and deputy Chair. His experience includes M&A transactions, integration, start-ups, divestments and spin-outs, as well as private and public company capital raisings and IPO's. Ian has an MBA and is a Fellow of the Australian Institute of Company Directors, and is an alumnus of INSEAD in France and MBS in Australia.

Neil Butler, Chief Executive, Vivacta

A mechanical engineer with a career in medical and material science related businesses. Prior to Co-founding Vivacta in 2004 Neil was CEO of Oxford Biosensors from its formation in 99. Prior to this Neil held a number of positions over 13 years within the European and US operations of Rexam’s Coated Films business, where he was responsible for focusing the business on medical and electronic markets. Before Rexam he held Market Development and Product Manager positions with Celanese for 10 years.

Christophe Chassagnole, Chief Operations Officer, Physiomics

Dr Christophe Chassagnole joined Physiomics in May 2004 as Project leader to develop the companies cancer models. Since May 2007 he has served as Chief Operating Officer at Physiomics. He has been involved in Systems Biology projects during the last 15 years, with experience in both academic and industrial environments. He gained his PhD in biochemistry from the Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University. Before Joining Physiomics Dr Chassagnole worked in France as a Senior researcher for CRITT Bio-Industries (Toulouse) in the field of metabolic engineering.

Andy Christie, Hewitt New Bridge Street

Andy Christie has over thirty years experience within the HR industry. He has designed and run several in-house "Club Surveys". He now runs Hewitt New Bridge Street's Executive Total Reward Survey collating data from over 250 companies and covering over 4,000 executive roles as well as running a survey on Non-Executive Directors' Fees and a number of specialist surveys providing data for specific sectors including the Biotechnology sector covering total remuneration for all roles from graduate to chief executive.

David Colpman, Senior Vice President Business Development, Shire Pharmaceuticals Group

David Colpman is a senior member of Shire's business development team focused on building the global speciality business through licensing and M&A.

During the last ten years at Shire, David has completed around 10 licensing deals. In addition he has run numerous M&A, product divestment and acquisition projects. Specific achievements include in-licensing the GI product Lialda/Mezavant with sales potential of over $400M, leading the team that bought Transkaryotic Therapies for $1.6BN and in 2007 divesting a business to Almirall for $213M.

David acts as advisor to the Venture Group, Sunstone Capital and was formerly a member of the board of Ace BioSciences.

Prior to joining Shire he led GlaxoWellcome's UK Business Development team and prior to that he was Head of Licensing and Alliances at Novo Nordisk in Denmark. David is a pharmacist by training, he spent part of his early career working in Japan and has a basic command of the Japanese language.

Rod Cook, Partner, Biotech Personnel

Rod also has over thirty years' experience working in a variety of high technology companies. His last company role was as Head of Personnel for British Biotech, which he helped grow from a staff of 90 to over 330. Since the formation of Biotech Personnel, a substantial client base has been established with assignments varying from Board-level remuneration advice to a total interim HR service. He consults for Hewitt New Bridge Street on their UK Biotechnology Industry Remuneration Survey that he initiated in 1996.

Nigel Courtenay-Luck, Co-Founder & CSO, Saturn Biosciences 

Nigel Courtenay-Luck is the co-founder and chief scientific officer of Saturn Biosciences. Nigel has worked in cancer research for the last 28 years and was involved in the early pioneering studies, using monoclonal antibody therapy in cancer patients at the Hammersmith Hospital, London. He co-founded Antisoma in 1991, one of the most successful biotech companies in Europe, has a broad knowledge of drug development, having collaborated with oncology centres, worldwide and was CSO at Antisoma, until he left in November 2009. Nigel is also a senior lecturer, in the division of medicine, Imperial college London, and a full professor at the Medical University of South Carolina.

Paul Cuddon, Analyst, KBC Peel Hunt

Paul joined KBC Peel Hunt in 2007 following 8 years experience in the drug discovery industry. While completing a PhD at Cambridge he worked in big pharma with Merck, Sharpe and Dohme and spent three years in biotech with DanioLabs. He brings significant experience in academic and commercial due diligence to the sector.

Paul Davie, Chief Commercial Officer, Inhibox

Paul has a long and successful track record in commercial roles in computer-aided drug discovery. He held support and sales roles at Chemical Design before going on to build and manage the European sales, marketing, support and consulting operations at Oxford Molecular. Paul went on Accelrys to build the Consulting Division and serve as European General Manager, before becoming Chief Operating Officer at InforSense. He founded and was Chief Executive Officer at Secerno, a successful database security company before returning to research informatics with his consulting company, Davinger, through which he advises InhibOx. Paul has an MBA and studied chemistry at Oxford University.

Liam Evans, Chief Executive Officer, Hypha Discovery Ltd 

Liam began his career in drug discovery with Xenova Ltd, before undertaking PhD research on developing novel fermentation systems that stimulate the production of bioactive compounds by tropical mushrooms, based on observations in Ecuadorian rainforest , that represent a breakthrough in the biotechnological exploitation of these challenging fungi. After a period in agrochemical discovery with Syngenta, Liam co-founded Hypha Discovery in 2004 to commercialise the technologies developed during his doctoral studies, focusing initially in the area of small molecule pharmaceutical discovery. The company has already established a pre-clinical pipeline of oncology and anti-infective projects, led by the fully synthetic and potent anti-tumour series HD148. Hypha also provides natural product discovery services based on its MycoDiverseTM library of fungal extracts, either directly or via partner screening companies.

Lubor Gaal, Head of Europe, Global Search, Strategic Transactions Group, Myers-Squibb

Lubor is Head of Europe, Global Search, Strategic Transactions Group, Bristol-Myers Squibb. Lubor is responsible for the acquisition and licensing of compounds or drug programmes for all BMS therapeutic areas.

Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d and CBO of Vectron Therapeutics AG. In the US, Lubor was at Berlex Laboratories where he was responsible worldwide for Cardiovascular and CNS Licensing of Schering AG. Before joining Berlex, he worked for Burrill and Company, where he advised companies on business development strategies and execution.

Lubor received his Ph.D. in Molecular and Cell Biology from the University of California at Berkeley and his B.Sc. in Neuroscience from the University of Sussex in Brighton, U.K.

Ian Garland, Chief Executive Officer, Vernalis

Ian Garland was appointed as Chief Executive Officer in December 2008. From May 2007 until September 2008, Ian was CEO of Acambis plc. During this period he oversaw a series of important advances culminating in the company's acquisition by Sanofi-Aventis in September 2008 for £280m. From 2004 to 2007, Ian served as CFO of Arrow Therapeutics Ltd., a privately-held company engaged in the discovery and development of new anti-viral agents until its acquisition by AstraZeneca plc for US$150m in February 2007. Prior to this Ian was President and Chief Operating Officer of Celltech Pharmaceuticals Inc., with a turnover of around US$300 million which encompassed the US operations of Celltech Group plc. From 1988 to 1995 Ian worked at KPMG, specialising in the pharmaceutical sector, following qualification as a Chartered Accountant.

James Gubbins, Partner, Morrison & Forester

James Gubbins has more than 18 years of experience in the provision of advice on IPOs and other securities issues, private equity transactions, and mergers and acquisitions. His practice covers a range of industries, with particular experience in the life sciences and technology sectors, and his clients include corporates, private equity funds, and investment banks.

He is described by PLC Which Lawyer 2008 as a "high-profile corporate finance, transactional and joint venture partner with an enviable biotech and pharmaceutical track record."

Tim Haines, Partner, Abingworth

Tim Haines has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc (sold to Depuy) and General Manager Baxter UK. Current and past board positions include Astex Therapeutics, Fovea (sold to sanofi-aventis), HBI, IMI, PowderMed (sold to Pfizer), Stanmore Implants and XCounter (AIM). Tim has a BSc from Exeter University and an MBA from INSEAD. At Abingworth, he identifies and creates new businesses and provides support for portfolio companies.

Deborah Harland, Partner, SR One

Deborah joined SR One in 2005 and leads SR One's investment activities in Europe. She is a member of the Board of Directors of Onyvax, Protaffin and Syntaxin and is an observer on the board of 7TM Pharma. Prior to SR One, Deborah was part of GSK's Worldwide Business Development team where she evaluated opportunities in the CNS and GI therapeutic areas. Debbie holds a BSc. (Hons.) in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London, and an MBA from Henley Management College.

Richard Honey, Director, EVT Capital Partners

Since joining EVT Capital in 2001, Richard has led and completed numerous venture debt transactions. Richard joined EVT from Cavendish Corporate Finance. Prior to his involvement in mergers and acquisitions and venture capital transactions at Cavendish, Richard was a risk analyst at Credit Suisse Financial Products. He trained as an accountant with Deloitte & Touche in South Africa and California where he concentrated on work for financial institutions and funds. Richard is a member of the South African Institute of Chartered Accountants and has an undergraduate degree from the University of Cape Town

Graham Hughes, National Contact Point for Health, Beta Technology

Graham Hughes, from Beta Technology, is the UK National Contact Point for Health, the nominated representative in the UK providing free and impartial advice and support on the European Framework Programme to SMEs in the Health and Biotech sectors. Graham has been in the role for nine months and has already presented to and advised a wide range of UK companies. Prior to this, Graham had a long career in Clinical Biochemistry then the Medical Device industry, latterly at Abbott Diabetes Care where he held roles in R&D Manufacturing and QA.

Michael Hunter, Director of Drug Discovery, Oxagen Ltd

Dr Mick Hunter joined Oxagen as Research Director in 2001 and was involved in the change in strategy of Oxagen from a genetics platform based company into its current drug discovery and development focus. He participated in a $60M series B financing of Oxagen in 2005 and a recent $28M series C financing in 2009. He is currently Director of Discovery and Development Projects with responsibility for the department of drug discovery which focuses on inflammation. He is Development Project Director on the CRTH2 program with responsibility for preclinical, ADME, CMC, project management and quality functions.

Mick manages outsourced functions needed for prosecution of drug programmes up to proof of concept in human studies. He has managed the CRTH2 program from inception through to Phase IIb clinical studies.

Prior to joining Oxagen, he held positions at G. D, Searle Pharmaceuticals Ltd. and at British Biotech Pharmaceuticals (now Vernalis PLC).  He has managed teams of, biologists, chemists and biotechnologists involved in drug discovery and development projects, prosecuting targets to identify IND candidates and managing them through early clinical development in areas of respiratory, infection, cardiovascular and oncology. He has been involved in the discovery of several novel class investigational drugs and biologics and managed their entry into man (Phase I and Phase II clinical trials) He is familiar with regulatory environments and has managed biological pilot plants for GMP manufacture.
 
Dr Hunter received his BSc in Biochemistry from the University of Leeds and a PhD in Molecular Biology and Genetics from the University of Nottingham.

Eva Jack, Managing Director, MedImmune Ventures

Eva Jack recently joined MedImmune Ventures from MedImmune Business Development. She joined the company in 2004 and was in charge of initiating in-licensing and research collaborations with universities, medical research institutions and governments. In addition, she was responsible for some out-licensing of intellectual property portfolio to companies and other interested third parties. Prior to joining MedImmune in 2004, Jack held a variety of positions at Intel Corporation during her 13 years with the company. In her last position at Intel, she worked for Intel Capital, the company's venture fund, and was responsible for investments and research collaborations in biotechnology and health care. Jack began her career with Intel in Washington, DC as a lobbyist covering health care, immigration, labor law, and education and training issues. Jack holds a bachelors degree from the University of Virginia and a masters degree in health sciences from the Johns Hopkins University. Eva Jack is a board observer of LigoCyte, Inc.

Chris Jones, Chief Executive Officer, Glysure

(Biography to follow shortly)

Richard Jones, Chief Executive Officer, Oxford Contrast Molecular Diagnostics

Richard brings to Oxford Contrast a significant breadth of pharmaceutical and management experience. His career began in 1990 at Glaxo where he rapidly progressed, gaining broad commercial experience in roles in sales, marketing, finance, business analytics, sales management, country, commercial and general management.
He was responsible for a block of 15 countries as commercial director of Central and Eastern Europe (CEE) and general manager Ukraine, achieving the highest growth of any operating division globally within the Glaxo group. He has been involved in a number of blockbuster product launches; Serevent (1990), Flixotide (1992), Losec (1994), Seretide (1995) and more recently Lipitor (2006).

Richard has experience of new pharmaceutical start-ups at country level and was responsible for the integration of GlaxoWellcome and Smithkline Beecham within CEE. During his time at Pfizer he was responsible for the Lipitor National Defence Programme (UK Board report), an initiative to protect annual sales exceeding £450m.
Richard has experience of IPO, having taken Brightside through a successful AIM flotation, and the start-up of regulated entities within the financial services sector (TransSend Payments Ltd).

Simon Jones BSc ACA, Chief Financial Officer, Glide Pharma

Following a degree in physics, Simon joined Ernst and Young where he qualified as a Chartered Accountant. Simon held a number of senior posts with Unipart. He joined Oxonica in 2000 as CFO and was involved with several fundraising rounds and the commercial development of the company including negotiating IP in-licensing and out-licensing agreements and the first major sales contract for the lead product to market. Up until the time that he left Oxonica, Simon saw the company grow from six to 30 employees.

Dr Barry Kenny, Chief Business Officer, HEPTARES Therapeutics

Barry has over 24 years' research and management experience in the pharmaceutical and biotechnology industry. He was previously Vice President, Drug Discovery at Takeda Cambridge with overall responsibility for IND discovery. Prior to this, he was Commercial Director at Paradigm Therapeutics where he was responsible for several company-transforming deals, including the broad CNS collaboration with Takeda in 2005. He was also instrumental in the subsequent acquisition of Paradigm by Takeda in 2007.

Barry co-founded Cambridge Drug Discovery (CDD) in 1997, and was Director of Business Development for Biofocus following its merger with CDD in 2001, establishing a wide range of international deals and collaborations. Before this, he was at Pfizer Central Research and was responsible for the successful discovery and progression of several drug candidates into clinical development. He also spent eight years at Syntex Research Scotland, where he completed his PhD and post-doctoral studies.

Simon Kerry, Chief Executive Officer, Karus Therapeutics

Simon is a business professional with over fifteen years experience in creating and developing innovative life-science businesses. Before joining Karus as the company's first CEO, he was Director of Business Development at Ablynx NV (Ghent, Belgium), where he was responsible for securing a number of research, development and licensing agreements with major pharmaceutical companies and played an important role in the company's development from early-stage to one of Europe's most promising antibody companies.

Prior to Ablynx, Simon was co-founder and Vice President of Business Development at Isogenica Ltd (Cambridge, UK), a spin-out of Active Biotech AB (Lund, Sweden), where he was Director of Business Development. Simon has held other key commercial appointments at Actinova Ltd and Actigen Ltd (both Cambridge, UK), at the Centre for Applied Microbiology (Salisbury, UK) and within the Jasmin group of companies. Simon has a PhD in the use of microbial enzymes in organic chemistry and has secured an executive MBA from the highly-regarded Loughborough University Business School.

Jim Kinnier Wilson, Head of Life Sciences, Manches LLP

He is a biochemist with an MSc in Biochemical Engineering and has specialised in intellectual property, advising many life sciences clients since qualifying in 1987.

Dominique Kleyn, Chief Exeuctive Officer, London Genetics

Dominique joined London Genetics from Imperial College London, one of London Genetics' founding institutions. At Imperial College she was involved in new venture development and management, technology transfer, fund raising and collaborations. The latter include research arrangements with companies such as GlaxoSmithKline, Merck & Co, Johnson & Johnson and Syngenta. In addition, she was a non-executive founder director of Acrobot, Equinox Pharma, GMEC, London Genetics, MicroTestMatrices, Nova Thera (acquired by Medcell) and Protexeon (acquired by Air Products). Dominique has worked on device and diagnostic development at companies such as Unilever, in business development at the Wellcome Foundation, and in consulting at PricewaterhouseCoopers. She has a BSc in Microbiology, an MBA (2006) from Imperial College London and is a Chartered Licensing Professional.

David Knowles, President & CSO, CellCentric Ltd

David worked for over 20 years in major pharmaceutical companies both in Europe and the US and established an international reputation in anti-infectives R&D. In 1999, he joined the UK biotech sector, simultaneously taking on various executive, non-exec and advisory roles in an attempt to learn rapidly about the business environment. As CSO of RiboTargets plc, he successfully transformed the scientific basis of the company from one based on the discovery of anti-infective molecules targeting discreet RNA structural motifs into one predominantly focused on the discovery and development of anti-cancer agents. RiboTargets went public through a reverse merger with British Biotech and he subsequently became Director of R & D for the combined organization. Prior to his departure, oversaw the merger of British Biotech with Vernalis. David was then appointed CSO and R&D Director of Piramed Ltd, based in Slough. Piramed signed a lucrative pre-clinical deal with Genentech in November 2005 and was subsequently acquired by Roche in May 2008. David left Roche at the end of November 2008 and is currently President and CSO of CellCentric Ltd and a non-executive director of Procarta Ltd.

David is a past Member of Council of the American Society for Microbiology and on the editorial board of Current Opinions in Microbiology. He continues to serve on various biotech Scientific Advisory Boards.

Dr Roland Kozlowski, Chairman, OxEpi

Roland Kozlowski is a bioentrepreneur who has worked in the industry since the mid 90s with a reputation for creative solutions. Roland is CEO (and founder) of Lectus Therapeutics Ltd. Previously he was CEO of Sense Proteomic Ltd and prior to that worked with Oxford Molecular, notably on a key deal he negotiated with Astellas (then Yamanouchi). He has executed many transactions ranging from company sale, purchase, financing and in- and out-licensing. His research background is in pharmacology and, after a PhD at Cambridge, he ran research groups at Oxford and Bristol Universities where he is a Visiting Industrial Professor.
Roland has published extensively and is an inventor on granted patents. He is an non-executive director of London Genetics and has served on the BIA board and participates activity in policy formulation for UK biotech.

Alexander Krantz, Founder, President and CEO, Advanced Proteome Therapeutics Inc

Allen began his career as a professor in the Faculty of Chemistry at Stony Brook University and also held an appointment in the Department of Pharmacological Sciences in the Medical School. He helped establish Syntex Research Canada and served, first as Director, and then VP of Research, as well as a Syntex Distinguished Scientist, focusing on enzymes as drug targets. He then assumed the Executive Vice Presidency at RedCell, Inc. (the forerunner of ConjuChem, (TSX: CJC)), as well as Directeur Scientifique of the French subsidiary, and transformed the company's program, centering on specific human serum albumin conjugates as covalent carriers of drugs. He is also a Founder of Pharmena North America Inc., now Cortria Corporation. Following short stints as EVP of the Research Foundation/Director of Patents and Licensing at the University of South Florida, and then as Assistant Vice-Chancellor at UC Berkeley for University/Industry Liaison, Allen established operations in Boston for Advanced Proteome Therapeutics Inc.

Alan Lamont, Director (Science & Technology Alliances), AstraZeneca

Dr. Lamont currently serves as the Director and Head of the Science and Technology Alliances group at AstraZeneca, based at the company's site in Alderley Park. His group is responsible for identifying, evaluating and securing new enabling technologies and platforms to support AZ's discovery and development portfolio. Prior to joining AZ in 2006, he was VP Business Development at Acambis plc (Cambridge, UK), and before that, worked for a number of companies in both the UK (Catalyst Biomedica, Peptide Therapeutics and Roche) and the US (Cytel Corp, San Diego, U.S.A.).

Dr Melanie Lee, Chief Executive Officer, Syntaxin

Dr Lee was formerly President of New Medicines and Executive Vice President R&D with UCB, having served as R&D Director at Celltech before its merger with UCB. Dr Lee brings a wealth of drug research and development experience to Syntaxin, through her early academic career at Cancer Research UK (as ICRF), a decade in research with GlaxoSmithKline and her later leadership of biopharmaceutical R&D at Celltech and UCB. Dr Lee currently Chairs Cancer Research Technology, an early drug R&D and technology licensing company of CRUK.

Steven Lee, Chief Executive Officer, Summit Corporation plc

Dr Lee joined Summit plc as CEO in September 2004. Prior to this, he held a number of senior commercial and business development roles with major UK biotechnology companies including British Biotech plc, PA Consulting Group, Chiroscience Group plc and Datamonitor plc.

From 2001 until 2004, Dr Lee was Executive Director of Life Sciences at the commercialisation specialists IP2IPO Ltd (now IP Group plc). He has also acted as a consultant on product strategy to major pharmaceutical companies including Zeneca, Glaxo Wellcome, Novartis and Johnson & Johnson. Dr Lee holds a PhD in parasite epidemiology from Kings College London.

Eddy Littler, Chief Executive Officer, Domainex

Eddy joined Domainex in 2007. His experience spans large pharmaceutical companies including Wellcome and GlaxoWellcome where was the Head of Antiviral Research. Before joining Domainex he worked as Senior Director at Medivir UK including Head of Lead Identification and of the UK site. Eddy started his career in academia with several years research in Leeds, Canada and Manchester.

Graham Lock, Fry Heath & Spence

Graham is a UK and European Patent Attorney specialising in cases in the fields of chemistry, pharmacology, microbiology, genetic engineering, medical devices, biochemistry, dairy technology, nutrition, food engineering and simple mechanical engineering. Graham has substantial experience of licence negotiations, drafting and prosecuting patents and trade mark applications and filing and defending oppositions before the European Patent Office. 

Colin Love, SVP of Development, BioVex

After twenty years developing and launching biotechnology products, Colin joined BioVex as Development Director. BioVex is now a ten year old private biotech company that is developing a new class of treatments for cancer, based on Herpes Simplex virus. The Company is headquartered in Boston with laboratories in Oxford and University College London. Colin is responsible for the product development functions at BioVex where three products have been progressed from discovery through to phase III clinical trials. Previously he was Director of Manufacturing Development at Celltech Chiroscience working on the development of both biologicals and NCE's. He has worked in product development for Medeva, Ares Serono and Amersham International. He has experience in the development and approval of both diagnostic and biopharmaceutical products. Colin was Director of Project Management when Hepacare TM, a third generation recombinant Hepatitis B vaccine, gained EMEA approval. He completed his PhD at the University of Glasgow on the influence of steroid hormones on breast cancer.

Anker Lundemose, Executive Vice President of Corporate Development and Strategic Planning, OSI Pharmaceuticals, Inc. 

Dr. Anker Lundemose is currently Executive Vice President of Corporate Development and Strategic Planning at OSI and Managing Director of OSI Investment Holding GmbH. He was appointed Executive VP, OSI Pharmaceuticals, Inc. and President, (OSI) Prosidion, in March 2005 having been the CEO of Prosidion Limited since the Company became operational in February 2003.

Dr. Lundemose is co-founder of several companies including Prosidion Limited and Symphogen A/S. He has broad and extensive experience within Medical Sciences and business obtained from his positions held in both academia and the biotech and pharmaceutical industries. Previous positions include Chief Executive Officer at Pantheco A/S from December 1998 to August 2002; Associate Director, Business Development, Novo Nordisk from October 1997 to November 1998; Manager, Business Development, Novo Nordisk from January 1996 to September 1997 and Head of Diabetes Biology, Novo Nordisk from June 1994 to December 1995. He received an MD in 1988 from University of Aarhus, Denmark and continued at University of Aarhus to 1992 as a Post Doctoral Fellow. During this period, in 1992, he was awarded a Wellcome Trust Fellowship at University of Birmingham, England. A Ph.D. degree (Molecular Microbiology) was obtained in 1990 and a Doctor of Science (Dr.Med) degree in 1994, both from University of Aarhus, Denmark.

Dr. Lundemose holds a Diploma in "Management of Drug and Device Development" from Scandinavian International Management Institute and is a member of the Board of Directors of Prosidion Limited, OSI Pharmaceuticals (UK) Limited, OSI Investment Management and OSI Investment Holdings. 

Ken Macleod, Partner, Paul Capital 

Ken Macleod, Ph.D. joined Paul Capital in 2004 and is responsible for sourcing, evaluating and negotiating European and Asian investment opportunities for Paul Capital Healthcare. Dr. Macleod brings a strong operational background in the pharmaceutical and biotechnology industries, holding senior management positions over a 15-year career at Serono, Abbott Laboratories and Beecham Pharmaceuticals. Previously, Dr. Macleod was a Venture Partner at Schroder Ventures Life Sciences where he was responsible for deal sourcing, evaluation and negotiation of pharmaceutical investment opportunities. He earned his Ph.D. from the University of York, UK and his B.Sc. in Biology from the University of Manchester, UK.

Kaasim Mahmood, Principal, Advent Ventures

Kaasim joined Advent in June 2005 after spending four years at Cutfield Freeman & Co, a London based corporate finance boutique, where he worked on a wide variety of transactions including financings, mergers and acquisitions.

Kaasim is qualified as a medical doctor and has an MB BS from the Royal Free & University College Medical School, London.

Gary Manchee, Global Head of Business Development, Pharmidex

Gary is Global Head of Business development at Pharmidex having joined the company in December 2008.

Gary has worked in the pharmaceutical industry for over 30 years, starting as a bench scientist and progressing to Director of Drug Metabolism and Pharmacokinetics in Psychiatry, Respiratory & inflammatory, and Immuno-inflammatory disease areas within Drug Discovery at GSK.

Gary has been involved in the development of several key medicines including Ventolin, Zantac and Serevent and has progressed 35 new compounds into early and late stage development. He has also led cross-discipline research and development teams within cardiovascular and psychiatric disease areas.

Gary gained his PhD in 1995 studying species differences in drug metabolism and went on to collaborate with the University of Dundee to crystallise a major human phenolsulphotransferase enzyme. Gary is the co-author on 26 published papers.

John March, Chief Executive Officer & Chief Scientific Officer, BigDNA

I am the founder and Chief Executive of BigDNA Ltd, a vaccines development company (both platform & products) utilising a patented technology using bacteriophages (viruses of bacteria) as DNA vaccine delivery vehicles. I bring perhaps a slightly unconventional approach to biotech commercialisation (the company is named after my car number plate!), and I have been involved in all stages of the research and commercial development to date, morphing from scientist to businessman. BigDNA is fully funded for the next 3 years and has grown to 14 employees. We are targeting a major pharma trade sale within 3 years, by which time we expect to have completed phase I/II trials of our lead product.


Graeme Martin, President & CEO, Takeda Research Investment  

 

Dr. Martin is President and CEO of TRI with day-to-day responsibility for operations. He brings more than 28 years of pharmaceutical R&D experience, primarily in multinational Pharmas (Wellcome; Glaxo Wellcome: Hoffman La Roche). He was responsible for the discovery and preclinical development of Zomig®, marketed worldwide for the acute treatment of migraine. More recently, Dr. Martin served as Chief Technical Officer at Telik Inc. with responsibility for technology and business development before establishing a Bay Area biopharmaceutical consulting operation, Discovery-Insight. Dr. Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK. 

 

Linda McCausland, Head of Physical Sciences, Almac

Linda leads the group responsible for contract research, technology transfer and consultancy activities in the area of solid state chemistry and crystallisation process development, supporting the development of APIs from invention to launch.

Linda acts as an adviser to clients on solid state issues (e.g. form selection, form control, scale-up, interpretation of experimental data and intellectual property) in the manufacture of drug substance and drug product and has worked in this area for over 16 years. Linda is the inventor on several patents and has published numerous research papers in this area.

 

Jim McDonald, Finance Director, Oxford Nanopore Technologies

 

Jim McDonald is Finance Director at Oxford Nanopore Technologies. With both a legal and financial reporting background, Jim has over 30 years of professional experience across a wide range of businesses with a working knowledge of the financial reporting requirements and general business and tax regulatory frameworks in the US, UK and throughout the European Community. Jim began his career as a lawyer working for a Denver law firm representing banks and other financial institutions where he had a specific interest in commercial litigation and negotiating complex legal arrangements. He then spent nine years in the US with Arthur Andersen, before transferring to London and leading accounting, business advisory and tax services to a portfolio of international high technology and bio-medical clients. There he managed a broad range of projects that included purchase investigations, London Stock Exchange flotations, private placements, management buy-outs, corporate reorganisations, profit improvement and productivity exercises. More recently, Jim was Finance Director of MediSense UK Limited providing financial management support as the company went from being venture capitalist funded to being listed on the NASDAQ exchange and ultimately being acquired by Abbott Laboratories, a multi-national pharmaceutical and medical diagnostics company.

 

Michael McLean, Chief Executive Officer, Pro-Cure Therapeutics


Mick became CEO of Pro-Cure Therapeutics, a company developing novel treatments against cancer stem cells, in May 2009. He has a track record of leading organisations from start-up through growth and change, and previously lived for two years in Paris, France, where he was CEO of two cancer vaccine start-ups and joined Link Technologies (Scotland) as Chairman in April 2007. Before moving to Paris at the end of 2005 he was based in Boston as President of Avecia's DNA Medicines business, which he led from its inception in the mid-1990's to being the leading manufacturer of cGMP oligonucleotide therapeutics.

Chris Meade, Global Head Respiratory, Therapeutic alliances and Strategic partnerships, Boehringer Ingelheim

Chris has been working for Boehringer Ingelheim for 23 years, before that for Eli Lilly, His career has centred on immunology, respiratory diseases and inhaler technology. Having been involved in almost all stages of the research and development process for respiratory products, he has for the last 6 years enjoyed seeking out other people and helping them make successful partnerships with Boehringer Ingelheim, a company with around 40,000 employees and a strong commitment to the respiratory field. His most recent deals were the managed buy-out of the California company Actimis, and a license and research collaboration deal with a Japanese start-up, Evec.

Dr Andrew Mearns Spragg, CEO & Founder, Aquapharm® Biodiscovery Ltd.

Dr Spragg gained a first class honours degree in microbiology and PhD in marine biotechnology from Heriot-Watt University. Dr Spragg developed the company whilst holding a Royal Society of Edinburgh Enterprise Fellowship in biotechnology.

Aquapharm is a leading marine biotechnology company pioneering the discovery, isolation and development of novel bio-chemicals isolated from the biological diversity of marine microbes. The company is developing these natural products as new anti-infectives as well as further high value products for use in other commercial sectors such as natural cosmetic ingredients, nutraceuticals and industrial applications.

Since founding the business, Dr Spragg has successfully raised over £10M in equity finance. D Spragg is the recipient of the 2007 Gannochy Innovation Medal from the Royal Society of Edinburgh for achievements in biotechnology & innovation. In 2008, Dr Spragg's entrepreneurial achievements were recognised through winning the Ernst & Young Entrepreneur of the year 2008 in Health Care for Scotland.

Dr Phillip Monk, Chief Scientific Officer, Synairgen

Dr Phillip Monk was appointed to the Board as Chief Scientific Officer in September 2009. Phillip joined Synairgen in October 2006 as Head of Bioscience Development. Phillip was previously Director of the Respiratory and Inflammation Biology group at Cambridge Antibody Technology (‘CAT') and led the scientific development of CAT-354, an anti-IL-13 antibody being developed for the treatment of severe asthma. Prior to joining CAT, he worked at Bayer AG within the respiratory disease therapeutic area, focusing on the development of novel therapies for asthma, COPD and cystic fibrosis.

Ian Nicholson, Chief Executive Officer, Chromatherapeutics

Ian Nicholson joined Chroma in September 2004. Prior to joining Chroma, he was Senior Vice President of Business Development for Celltech, responsible for all global licensing activities, and additionally held the position of Acting CEO, Oxford GlycoSciences following its acquisition by Celltech. Prior to this he was Commercial Director at Oxford Asymmetry and has held a variety of senior commercial positions with Lonza and Amersham. He holds a BSc (Hons) degree from University College, London and an MBA from Boston University.

Ian Paling, Executive Chairman and CEO, CellCo Tec

Ian's background is in orthopaedics. From 1994 to 2007, Ian was the CEO of Corin Group PLC which, under his leadership grew to a highly regarded publicly quoted orthopaedic company with a world leading position in hip resurfacing.Prior to joining Corin, Ian, who has a B.Sc. and M.Sc. in metallurgy, worked for ten years in senior management roles for several OEM suppliers of orthopaedic devices. He is currently Non Executive Chairman of Inion Limited, a UK-listed orthopaedics company, a Non Executive Director of Metalrax PLC, and a Non Executive Director of Sphere Medical Holding PLC

Rob Pinnock, Director Scientific Liaison, Merck Sharp & Dohme

 

Rob's remit since joining Merck's licensing team in Sept 2007 is to identify partnering opportunities in the UK, Irish Republic & South Africa.
Rob has worked in neuroscience and cardiovascular disease therapeutic areas in Pharma, Biotech and academia over the last thirty years. These organizations include Pfizer, Parke Davis, the Medical Research Council & the University of Cambridge. Following a successful career in basic research & drug development in which collaborations became increasingly important, Rob has moved into the licensing and external scientific affairs group of Merck & Co in 2007.

 

Les Russell, Chief Executive Officer, OrganOx Limited 

 

Les co-founded OrganOx and secured initial funding in 2008. Previously, he was Managing Director of Chromogenex plc, an AIM-listed company manufacturing light devices for non-ablative surgical and cosmetic use. In a 2-year period, sales were increased from £2.4m to £4.5m and a loss of £150K reversed into a profit of £376K.

From 1995-2000, Les was Marketing Director for the Biotech Division of Baxter Export Corporation. Sales were increased from from $25m to $62m, based around of a strategy of new product introduction for both the biopharmaceutical and blood transfusion divisions.

Les has also been CEO of Gendel Limited, a company developing novel technologies for cancer therapy where he secured funding and planned and managed a 20 patient clinical trial for evaluation of CEFUS therapy in the treatment of basal cell carcinomas. Earlier, as Business Development Director at Cambridge Life Sciences plc, he was instrumental in the sale first to Medeva and then to Byk-Gulden GmbH and was also pivotal in the development of the Ciba-Corning Diagnostics 600 series of blood analysers.

 

Jan Rutherford, Partner, SEP

 

Jan joined SEP's investment team in London in January 2004, having previously spent three years at Dresdner Kleinwort Capital. Her nine years of experience in healthcare venture capital investment spans drug discovery and development, medical technology, healthcare IT and healthcare services, mainly in Europe. Prior to moving into venture capital, Jan spent 8 years in clinical development and business development, working for Merck, Novartis and Quintiles, predominantly in the field of oncology. SEP is currently investing from its £160m mixed technology SEP III fund and typically invests between £1m and £10m in funding rounds of up to £30m.

 

Anand Sambasivan, Partner, Darwin Strategic Limited

Anand Sambasivan is a Partner at Darwin Strategic Limited, recentlyfounded to provide underfunded listed companies with Equity Credit Facilties. Darwin Strategic is majority held by The Evolution Group, a leading small cap Investment Bank in the UK. Previously, Anand spent seven years as an Investment Banker at Credit Suisse and Banc of America Securities in New York and London. Focused primarily on the Financial Institutions sector, Anand's transaction experience includes IPO, other security issues, private equity transactions and mergers and acquisitions.

 

Graziano Seghezzi, Partner, Sofinnova Partners

 

Graziano Seghezzi brings nearly a decade of European venture capital investment experience to Sofinnova Partners, where he has been a partner focused on life sciences investment since joining the firm in 2006.

Graziano has been instrumental in targeting, investing in, and nurturing the growth of a number of Sofinnova Partners' portfolio companies, including: Creabilis Therapeutics (Italy), a specialty dermatology company developing products in multiple clinical areas such as psoriasis and atopic dermatitis; Crescendo Biologics (UK), a seed-stage company targeting the application of highly innovative antibody fragment technologies to the development of new therapeutics; GlycoVaxyn (Switzerland), a biotechnology company dedicated to the development of novel vaccines; and Omthera (USA), specialized in cardiovascular disorders with a best-in-class
omega-3 drug. Graziano is a board member of each company.

 

Prior to joining Sofinnova Partners' Paris-based team, Graziano was principal at Index Ventures in Geneva, Switzerland, where he invested in biotechnology and biopharmaceuticals companies. Before this, he worked for Sofinnova Partners, identifying new investment opportunities in Italian pharmaceutical and medical device companies out of Milan, Italy. Graziano began his career as a biomedical researcher at New York University's School of Medicine, where he gained five years of hands-on experience studying the molecular mechanism of angiogenesis in oncology and cardiovascular diseases.

 

Graziano has a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from the RSM, Erasmus University (Netherlands).

 

Chris Shelley, Partner, Manches 

 

Chris Shelley is a Partner specialising in IP law, advising on patents, copyright and database rights, trade marks and designs, and also in EC and UK competition law.

 

Nick Skaer, Chief Executive Officer, Orthox

 

Nick Skaer, CEO, Orthox Ltd. Nick founded Orthox Ltd. in 2008, securing £1.6 million seed funding from the Wellcome Trust, to commercialise regenerative cartilage and bone repair devices using a revolutionary silk biomaterial, Spidrex®. A bioscience graduate of Oxford and Strasbourg Universities, Nick developed Spidrex® with Oxford Biomaterials Ltd., the company of which he was CEO for the four years prior to founding Orthox. During this period, he raised over £3.5 million in private equity finance and public grants to fund the Spidrex® development programme, and was founding Director of two other equity financed Oxford Biomaterials spin out ventures, Neurotex Ltd. and Suturox Ltd.

 

Tim Sparey, Head of Business Development, Proximagen

 

Tim joined Proximagen in November 2009 as Head of BD to focus on the Company's commitment to deliver novel drugs and innovative new treatments for neurodegenerative disease and other CNS disorders, bringing new hope to patients and value to shareholders. His responsibilities include devising and executing the in- and out-licensing strategy.

 

Prior to joining Proximagen, Tim worked at Merck Serono in Commercial BD and prior to that spent 13 years with Merck & Co in the CNS drug discovery and Worldwide Licensing & External Research teams.

 

Sue Staunton, Business Services Partner, James Coweper

 

 

Sue Staunton is a business services partner. She also has a particular interest in working with technology businesses and their owners and, as such, heads our our technology team.
Sue works with clients on the development and implementation of their corporate strategies. She also has a great deal of experience in working with businesses in financial crisis to establish strategies to assist them to move forward successfully.

 

James Steel, Director of Corporate Finance, KBC Peel Hunt

 

James Steel is a director of corporate finance at KBC Peel Hunt, a leading middle market financial advisory and broking firm. Prior to joining KBC Peel Hunt in 2009 James was a senior investment banker within Piper Jaffray's European healthcare group and has considerable experience in advising both public and private companies on a wide range of corporate matters including financings and mergers and acquisitions.

 

Mark Sweetinburgh, Patent Attorney, Fry Heath & Spence

 

Mark is a UK and European Patent Attorney with extensive experience of drafting and prosecuting patent applications in the biotechnological, pharmaceutical and mechanical fields. Mark has particular expertise in relation to cases concerning biotechnology, stem cells, genetic marker technology, microbiology, enzymology, nutrition and plant breeding.

 

Douglas Thomson, Chief Executive Officer, Ixo Limited

Douglas has over 15 years experience in the biotech sector and is CEO of start-up Ixo Ltd. Douglas has senior executive and board level expertise in a number of biotech companies including Microscience Limited, SingVax Ltd and Aquapharm Biodiscovery with extensive experience in leading companies and commercialization of NBEs and NCEs. He has participated in the raising of significant equity and grant financing. Douglas originally trained and worked as an analytical chemist.

Rebecca Todd, Investment Manager, Oxford Capital Partners

 

Rebecca joined Oxford Capital Partners in 2007 and is responsible for investments in life sciences and healthcare. She is a Director on the Boards of Sirigen, Veryan and Microbial Solutions and an Observer to the Boards of Oxford BioTherapeutics and Exosect. Prior to becoming a venture capital investor, Rebecca was a marketing consultant, with a wide portfolio of clients, initially major pharmaceutical companies and latterly early-stage biotechnology companies. Rebecca has an MBA from the Saïd Business School, Oxford University, where she specialised in technology innovation and entrepreneurship, a PhD in Genetics from Nottingham University and graduated with first class honours in Biology from the University of York. Rebecca is also a member of the Investment Panel for the Mobius Life Sciences Fund. When the British climate allows, Rebecca is a keen rock climber.

 

Mark Tucker, Chief Executive Officer, g-Nostics

 

Mark co-founded g-Nostics Ltd in July 2004 around a genotyping technology to develop an enabling platform for clinicians and pharmacists to personalise medical prescribing.

During 2006/7 NicoTest® piloted in NHS pharmacies demonstrating statistically significant Clinical Utility. The Company has secured an exclusive strategic collaboration with GE Healthcare and a strong US distribution partner that reaches 90% of all US physicians.

Mark has five patents granted, or pending, to his name and has been involved with the smoking cessation sector since 1986. He helped commercialise and license the earliest transdermal product launches in this sector to a well known global brand.

 

Ena Vieira, Commercial Manager, SRG

 

With 10 years' recruitment and account management experience, Ena joined SRG in 2006 and has worked in a variety of roles since then, covering regional management responsibility for the South East, followed by a business development role covering four regions of the UK to the sector-focused commercial management role she has today.

In addition to having a successful history of working on recruitment projects for regional, national and managed service accounts in the UK, Ena has an established presence within the biotech sector with an in-depth understanding of the technical requirements of this marketplace.

 

Ian Wainwright, Principal, Corporate Broking, Piper Jaffray

Ian joins Piper Jaffray from Canaccord Adams, where he was a managing director, specialising in life sciences sales since November 2007. During his time at Canaccord Adams Ian has been instrumental in building the life sciences franchise. In both 2008 and 2009, Ian was ranked 4th in the Biotechnology Specialist Sales Extel Survey.

Prior to joining Canaccord Adams, Ian was in specialist biotech, medtech and pharma sales at Société Générale. Ian, who started his career at Ernst & Young, also worked in research for Goldman Sachs, Citigroup and as an analyst for Man Securities.

Ian has a degree in Natural Sciences from King's College, Cambridge.

 

Colby Walker, Life science insurance underwriter, CHUBB

Colby Walker, a life science insurance underwriter with CHUBB will present an underwriters view supported by FOCUS Insurance, the Oxford based speciality insurance broker for Life and Bioscience businesses who have designed and created this special scheme in conjunction with CHUBB.

Matthew Walls, Chief Executive Officer, Epistem

 

Matthew joined Epistem as Chief Executive Officer in February 2007 to lead the Company through the admission process to the LSE: AIM. Epistem has grown rapidly over the past few years since its admission. Matthew is an experienced CEO previously with Oxford BioSignals Limited where he led the strategic 'diagnostic' collaboration with Rolls Royce Plc and Covance Inc and completed the fundraising and repositioning of the medical diagnostic business to the United States. Matthew spent the early part of his career with ICI plc progressing through the executive development programme and several senior management positions. Matthew headed up the corporate financial and commercial development of plant biotechnology at AstraZeneca plc prior to its merger with Novartis to form Syngenta plc. Matthew has led the growth and development of several technology and biotechnology companies as CEO including Internexus Limited and Zylepsis Limited. Matthew holds a non-executive role at Riyada Oxford Investments Limited and is a chartered accountant and a member of CIMA.

 

 

Fintan Walton PhD, CEO and Founder of PharmaVentures

Dr Walton is the Founder and CEO of PharmaVentures. After completing his doctoral research on the genetics of cell proliferation at the University of Michigan (US) and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Although Dr Walton's main focus is his role as Chief Executive Officer of PharmaVentures, he is available for some consultancy assignments.

 

Sally Waterman, Chief Operating Officer, PolyTherics

Sally Waterman joined PolyTherics in October 2009. Her previous roles include Director of Research & Development at Protherics (now part of BTG) and KS Biomedix (acquired by Xenova), VP of Non-clinical Development at Vernalis and Director of Scientific Operations at Pharmakopius (since acquired by PRA). In each of these roles she has built the infrastructure and processes to support virtual R&D and align it with business objectives. She has been involved in numerous corporate transactions and has managed the due diligence process pre-deal and the integration process post-completion. Her early career was spent in regulatory affairs in several big pharma and she has retained oversight of this function throughout her career.

 

Peter Wighton-Smith, Chief Executive Officer, Oxford Immunotec

 

Dr.Wrighton-Smith started Oxford Immunotec after having spent 5 years at PowderJect Pharmaceuticals PLC, now part of Chiron Corporation. During his time there, he saw PowderJect grow to a global vaccines business with over 1,000 employees and immediately prior to founding Oxford Immunotec, he was Special Projects Director at PowderJect. Prior to that, he was Managing Director of PowderJect Diagnostics Ltd, a subsidiary of PowderJect, developing cellular immune based diagnostics. He has also held scientific & project management roles at major companies in both the healthcare and engineering fields, including posts in Switzerland and California. Peter has a Masters in Engineering, Economics & Management and a DPhil in Medical Engineering both from Oxford University. 

 

Speaker and Chair Biographies for 2009

Charlie Alexander
Andrea Alunni
Dr Mark Ashton
Chris Atterwill
Patrick Baddeley
Adam Barak
Dr John Beadle
Dr Richard Broadhead
Carlton Brown
John Burt
Kate Burt
Dr Christophe Chassagnole
David Colpman
Rod Cook
Jane Dancer
Paul Davies
John Dawson
James Dipple
Paul Drohan
Nick Dunster
Dr. Wolfgang Ebenbeck
Martin Edwards
Dr Mike Evans
Sam Fazeli
Professor Peter Friend
Denis Geffroy
Dr Regina Hodits
Dr J Nick Housby
Wills Hughes-Wilson
Dr Jackie Hunter
Simon Jones
Chris Jones
Dr Andrew Kelly
Simon Kiddle
Jim Kinnear Wilson
Dr David Knowles
Nicholas La Thangue
Andrew Lane
David Laskow-Pooley
Eddy Littler
Dr Anker Lundemose
Graeme Martin
Keith Martin
Dr Tony Maschio
Dr Melanie McCullagh
Bryan Morton
David Mott
Paul Murphy
Alasdair Naylor
Linda Naylor
Ian J. Nicholson
James Noble
James Noble
Dr Nigel Parkinson
Hadyn Parry
Rob Pinnock
Esteban Pombo-Villar
Ken Powell
Keith Powell
Robin Quirk
Dr Jon Rees
Allison Robbins
Bruce Savage
David Scales
Dr Richard Seabrook
Nigel Sheail
Nick Skaer
Dr. Candi Soames
Sue Staunton
Charles Swingland
Rebecca Tollervey
Chris Ullman
Fintan Walton
Mike Ward
Dr. Tom Weaver
Dr Malcolm Weirs
Dr. Kathleen Williams
Mike Wort
Professor Malcolm Young

Senior Business Development Manager, Shire Pharmaceuticals Group Limited

Charlie joined Shire in April 2007 with responsibilities including both in-licensing and out-licensing. His experience spans biotech, large pharma and consultancy. Immediately prior to joining Shire he worked as a consultant in providing strategic and commercial services to biotechs and mid-cap pharma. Before this his initial business development experience was with Xenova, a Slough-based biotech. Amongst other things he was responsible for seeking territorial deals for Xenovaís oncology portfolio and ultimately closed a deal for Xenovaís lead compound. He started his career at GSK spending a significant part of his time there working in New Product Development/Strategy.

 


 

 

 

Seed Investment Manager, Isis Innovation Ltd

Andrea joined Isis in August 2008 as Seed Investment Manager to help the University raise finance for progressing technology spin-outs. An electronics engineer by background, Andrea gained an MSc in Strasbourg (France-1994) in the field of Technology Transfer and an MBA in Rome (Italy-1995) focussing on finance. His professional experience spans 15 years in financing technology, from corporate finance in Telecom Italia, investment banking at Nomura and private equity at CDC Capital Partners. Andrea is the author of two books in the field of competitive acquisitions in the technology sector, published in Italy in 2006 and 2007.

 


 

 

 

Executive Vice President, Business Development, Evotec AG

Dr Mark Ashton joined Evotec in 1995. He has been Executive Vice President, Business Development since 2005 and is responsible for global commercial and marketing activities, discussing outsourcing needs with the worldís leading Pharmaceutical and Biotechnology companies. Prior to this he was President, Discovery Services, responsible for the Discovery division of Evotec: a division of over 250 chemists and biologists involved in projects ranging from high throughput screening, parallel synthesis and medicinal chemistry.
Dr Ashton has worked within the outsourcing industry for the past 14 years and is the author and co-author of various peer reviewed scientific publications and patents.

 


 

 

 

Scientific and Business Advisor to Capsant Technologies Ltd

Chris qualified as a pharmacist and gained his PhD at London University and having held MRC Fellowships at the Institute of Neurology & Oxford University, was appointed GSK Professor of Toxicology at the University of Hertfordshire where he pioneered Brain and Liver Spheroids as animal alternative drug screens. This technology was the forerunner of Capsantís human OrganDotTM technology.
Later positions included Director of Drug Safety at Roche UK. Chris served on the Home APC up to 2007. He has run Prognus Ltd since 2003, acting as Scientific Advisor to Capsant Ltd since it was founded.

 


 

 

 

Corporate Finance Partner, Manches LLP

An Oxford Graduate, Patrick joined Manches in 1984 and became a partner in 1987. A member of the Corporate Group, Patrick is involved in mergers and acquisitions, refinancing and other corporate transactions, particularly for clients in the life sciences field. He also advises on employee Share Schemes and is a member of the Share Schemes Lawyers Group. Patrick was a founder member of OBN Advisory Board, and is one of OBNís longest standing supporters.

 


 

 

 

Vice President of Boston Healthcare Associates (UK Office)

After an early career involving sales, marketing and pricing in the automotive industry with Vauxhall and General Motors Europe, Adam joined GlaxoWellcomeís International Pricing & Reimbursement division in 1996. In 1997 Adam became Head of European Pricing, managing the regional function and developing international pricing strategies for 4 of the 7 GW therapy areas, including European pricing strategies for CNS (including developing the European pricing strategy for epilepsy, depression and smoking cessation products), urology, metabolic, CNS, cardiovascular, oncology and anaesthesiology drugs.
Adam is a Chartered Marketer and a Member of the Chartered Institute of Marketing. In 2003 he has had articles on pharmaceutical pricing published in the International Journal of Medical Marketing and the Journal of Generic Medicines and has presented at international pharmaceutical conferences on pharmaceutical pricing strategies. Adam and BHA offer healthcare pricing and reimbursement training to the industry as well as other parties such as health ministers and distributors.

 


 

 

 

Chairman, Hybrid Systems Ltd

A successful biotech entrepreneur. Co-Founder and Chief Medical Officer of PowderMed, a DNA vaccine company sold to Pfizer in 2006. John has previously held roles at PowderJect, Pfizer and GlaxoSmithKline where he was VP of Global Medical Operations. He has expertise in the development of prophylactic and therapeutic vaccines for infectious diseases and oncology therapeutics.

 


 

 

 

Technical Sales Manager, Oxford Expression Technologies

Richard joined Oxford Expression Technologies in October 2008 as Technical Sales Manager. His experience spans both the academic and commercial spheres of science. Richard brings significant global, sales and marketing experience to the company, having previous experience in the field with Invitrogen and Flowgen. He also has extensive relevant technical experience acquired through laboratory research in the fields of proteomics and protein expression.

 


 

 

 

Chief Executive Officer, Immune Targeting Systems Limited

Carlton is a vet and holds an MBA from London Business School and has background in strategic marketing (SmithKline Beecham), corporate & business development (Cortecs Plc) & global healthcare investment banking (Dresdner Kleinwort Wasserstein). He was formerly Commercial Director & COO of a French vaccine company. He co founded ITS (2004) and successfully raised the Companyís Seed and £5.0m Series-A funding rounds. He strategically directed the innovation and development of the vaccine platforms from inception to permit the targeting of mutating viruses. Carlton is particularly interested in developing products capable of addressing key market needs with a specific focus on market disruption.

 


 

 

 

Founder & Chief Executive Officer, Thiakis

John Burt founded Thiakis in mid-2004 with Professor Steve Bloom (Imperial College London). Having raised £10 million in 2006 from a syndicate of investors led by Novo A/S, Advent Venture Partners and Imperial Innovations, Thiakis was acquired by Wyeth Pharmaceuticals for £100 million in December 2008. Prior to founding Thiakis, John was Head of Medical and Life Sciences at Imperial Innovations, the technology transfer office of Imperial College London, where he was instrumental in securing a number of significant licensing and collaborative research agreements. He also served as Imperial Innovationsí appointee director on the board of Sterix, leading up to its acquisition by Ispen in 2004.
Previously John had held business/corporate development and strategy positions with Glaxo Wellcome/GlaxoSmithKline and was responsible for R&D finance at Vanguard Medica (Vernalis), having qualified as a member of the Chartered Institute of Management Accountants whilst working in the management consultancy practice of Coopers & Lybrand. He has a first degree in Natural Sciences (Biochemistry) from the University of Cambridge and a D.Phil (Molecular Biology) from the University of Oxford.

 


 

 

 

Director, Commercial Alliances and Transactions, Worldwide Business Development, GlaxoSmithKline

Kate has a wealth of experience from working in GSKís business development and venture capital groups for the past seven years and has negotiated many of GSKís recent deals including the Strategic Alliances with Theravance, Epix, Cellzome, Dynavax and Regulus as well as a host of late stage licensing opportunities. Kate worked as a business consultant previously at GSK and Arthur Anderson and holds qualifications as both a molecular biologist and a Chartered Accountant.

 


 

 

 

Chief Operating Officer, Physiomics plc

Dr Christophe Chassagnole joined Physiomics in May 2004 as project leader to develop the cancer models of the company and since May 2007 he has served as Chief Operating Officer of Physiomics. He has been involved in Systems Biology projects during the last 15 years, with experience in both academic and industrial environments. He gained his PhD in biochemistry from Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University. Before Joining Physiomics Dr Chassagnole worked in France as a senior researcher for CRITT Bio-Industries (Toulouse) for 3 years in the field of metabolic engineering.

 


 

 

 

Senior Vice President, Business Development, Shire Pharmaceuticals Group Limited

David Colpman is a senior member of Shireís business development team with responsibility for building the global business through licensing and M&A. In the last nine years at Shire, David has completed around 10 licensing deals. In addition he has run numerous M&A, product divestment and acquisition projects. Specific achievements include in-licensing the GI product Lialda/Mezavant with sales potential of over $400M, leading the team that bought Transkaryotic Therapies for $1.6BN and in 2007 divesting a business to Almirall for $213M. In 2008 he won Shireís CSO award.
Prior to joining Shire he led GlaxoWellcomeís UK Business Development efforts and prior to that he was Head of Licensing and Alliances at Novo Nordisk in Denmark. David is a pharmacist by training; he spent part of his early career working in Japan and has a basic command of the Japanese language.

 


 

 

 

Partner, Biotech Personnel

Rod has over 30 years HR experience working in a variety of high technology companies. His last company role was as Head of Personnel for British Biotech, where he helped to grow a private company from 90 employees to over 330 in the FTSE 100.
Since the formation of Biotech Personnel a substantial client base of over 50 life science employers has been established. Assignments vary from Board level remuneration advice to a total interim HR service.

 


 

 

 

Vice President of Business Development, Cellzome

Since joining Cellzome at the beginning of 2008, she was involved in negotiating a major strategic alliance with GSK and extending and expanding Cellzomeís existing collaboration with Johnson and Johnson. Prior to joining Cellzome, Jane was at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) where she was responsible for negotiating in- and out-licensing agreements in relation to technology and products. She was also part of the team that negotiated the strategic alliance with AstraZeneca. Jane has a science background with a PhD from Cambridge in plant biochemistry and over ten years experience of research and project management in the agchem industry. She also has an MBA from Cambridge.

 


 

 

 

Chief Executive Officer, Cytox Group

Paul is an experienced business development specialist who has worked in the Biotechnolgy/Pharma/Healthcare sectors for over 30 years. He began his career in sales with Napp Laboratories and then moved to the Homecare sector with Caremark. In addition, he has worked for Amarin Pharmaceuticals, Roche Diagnostics, LCG Bioscience (CRO) and Pharmagene (now owned by Asterand). The latter of these specialised in providing pharmaceutical drug development teams with access to human tissue in a pre-clinical Phase Zero offering. He joined Cytox in a consultancy role in 2008 and will become a permanent member of the management team in 2009.

 


 

 

 

Chief Executive Officer, Oxford BioMedica

John Dawson joined Oxford BioMedicaís Board as non-executive director. In August 2008 and was later appointed CEO in October 2008. From 1996 to 2007 he held senior management positions in the European operations of Cephalon Inc., including from 2005, a management board position as CFO and Head of Business Development Europe.
In his time at Cephalon he led the many deals that built the European business to over 1,000 people, taking the business from having no sales in 1998 to a turnover of several hundred million US dollars. In 2005 he led the US$360 million acquisition of Zeneus by Cephalon.

 


 

 

 

Director, MEPC

James Dipple is Director of MEPC Ltd, Managing Director of Milton Park and of Leavesden Park and is also Head of Development and Construction. He also heads up the activities at Callaghan Square, Cardiff. From 2004-2008, James was Development Director of Easter Group and before that, Director of Hines UK Ltd. James has actually returned to MEPC having previously been Managing Director of Milton Park and Head of Development from 1997-2002, when he was largely credited with taking Milton Park into the modern era in which it sits today. Prior to that, James was a Partner with Strutt & Parker where his principle clients were Arlington and British Aerospace. Outside work his interests include rugby, skiing and the arts.

 


 

 

 

Vice President and General Manager, Genzyme UK and Ireland

Paul Drohan joined Genzyme Corporation, in July of 1996. He is currently the General Manager & Vice-President of Genzyme UK & Ireland. In this position, Mr. Drohan is responsible for companyís financial success in UK & Ireland through his management of Sales & Marketing, Finance, Operations, Medical & Regulatory Affairs, Public & Government Affairs and Legal Affairs. Paul has been in this current role since April 1. 2005. Prior to assuming responsibility for the Genzyme UK & Ireland, Paul was the General Manager & Vice President of Genzyme Canada. Working to establish Genzyme in his native land, he worked with patients, healthcare professionals and government to provide access to Genzymeís novel therapeutics. These activities culminated in working to establish a new approach for access of ultra-orphan diseases with, and within, both the provincial and federal governmentsí healthcare responsibilities. Paul is a Director of Genzyme Therapeutics Ltd and is a member of the UKSC (UK Steering Committee) and the EMC (European Management Committee).

Prior to joining Genzyme Canada, Mr. Drohan held the position of Group Product Manager at Pharmacia & Upjohn. In 10 years at Upjohn, Mr. Drohan moved through sales & marketing function beginning in sales, specialty sales, medical sciences liaison, product management, product director and finally group product manager. He served as a consultant to the College of Family Physicians of Canada and worked with the Royal College of Physicians & Surgeons to implement the MOCOMP (Maintenance of Competency Programme) with Canadian specialists. During his tenure in the pharmaceutical / biotechnology industry he has successfully led the launch of 7 products into the Canadian and UK/Ireland markets. He has led the negotiation and execution of two successful co-marketing agreements. His increasing level of responsibility has provided him with the insight into managing an overall operation and he was an architect of the resent DoH-NCG agreement for NCG sustainability. A critical requirement to success in any healthcare system is the responsibility for companies and their personnel to work with Government in the establishing a positive and progressive relationship that is beneficial to patients. Paul is married and a father of 4 girls. An active cyclist, tennis player and downhill skier provide challenges outside of his on-going career.

 


 

 

 

Senior Business Analyst, The Wellcome Trust

Nick joined the Trust in 2005 and is responsible for contract negotiations, due diligence and IP issues. He monitors existing investments in drug discovery, vaccine trials, medical devices and platform technologies, and holds two Board Observer positions. He obtained a first degree in biochemistry from the University of Bristol, a PhD from Cambridge and has six years' experience in the biotech industry with focus on cancer, immunology and anti-infective preclinical drug discovery.

 


 

 

 

Head of Fluorine Team, Saltigo

Dr. Wolfgang Ebenbeck joined Saltigo GmbH, a globally operating custom manufacturer and a wholly owned subsidiary of Lanxess AG, in 2004. He was appointed as Head of Saltigoís Fluorine Team, a dedicated custom research service provider in the field of organofluorine chemistry, which supports the activities of life science customers from drug discovery to preclinical programs providing versatile fluorinated building blocks and scalable fluorination methods.
Prior to the formation of Saltigo GmbH, Dr. Wolfgang Ebenbeck was Research Manager in the Fluorine Group at Bayer AG, Central Research Department. This group played a pivotal role in the development of numerous fluoro-containing pharmaceutical and agrochemicals products at Bayer. Before joining Bayer in 2001, Dr. Wolfgang Ebenbeck received his PhD at the University of Regensburg and undertook Post Doctoral Research at the Research School of Chemistry in Canberra/Australia.

 


 

 

 

Senior Partner, Novo Ventures

Dr Martin Edwards is Senior Partner in Novo A/S where he has worked since 2003. Martin represents Novo on the Boards of Funxional Therapeutics Ltd, Logical Therapeutics Inc, Serentis Ltd, Symphogen A/S, and Vantia Ltd. Prior to this Dr Edwards was CSO of ReNeuron Ltd taking the company public in 2000. Martin has spend most of his career in drug development and was SVP and world wide head of Novo Nordisk drug development between 1993 and 1998, SVP of Medical Affairs for Novo Nordisk in Princeton, and SVP and CMO for Zymogenetics Inc. Martin originally trained in medicine at Manchester and worked in the NHS for 5 years before joining the pharmaceutical industry. He is a Member of the Royal College of Physicians, Member of the Royal College of General Practitioners and Fellow of the Faculty of Pharmaceutical Medicine. He also holds an MBA from Warwick University.

 


 

 

 

Chief Executive Officer, Oxford Gene Technology

Dr Mike Evans joined Oxford Gene Technology in March 2005. Prior to this he spent 16 years at GE Healthcare, formerly Amersham plc. Dr Evans most recently held the position of Executive Vice President, Marketing and Strategy, Amersham Discovery Systems Division, and was previously Executive Vice President of the Bioassays Business. In 2000 Dr Evans joined Ascot Fine Chemicals as Managing Director, responsible for two businesses within the Ascot plc group and was a member of Ascot's Executive Committee. Dr Evans holds a BA, MA and DPhil from the University of Oxford.

 


 

 

 

Head of European Equity Research, Piper Jaffray Ltd

Sam Fazeli is a managing director, head of European research, and senior research analyst focused on European biopharmaceutical stocks. Fazeli joined Piper Jaffray in 2005. Fazeli and his team cover 20 UK and Continental European stocks. Fazeli has 13 years' experience in the biopharmaceutical sector. Previously, he was at Nomura where he was part of a team that was ranked No. 1 in the U.K. in the September 2004 Institutional Investor Survey of U.K. Small Cap Fund Managers. In 2008, Fazeli was ranked 3rd in the Extel Biotech Survey of UK institutions. Fazeli has a PhD in Pharmacology and seven years' post-doctoral experience.

 


 

 

 

Director of the Oxford Transplant Centre and Professor of Transplantation in the Nuffield Department of Surgery at Oxford University, Vice President of the British Transplantation Society, Oxford Transplant Centre and Clinical Trial Service Unit

Professor Friend was trained at the University of Cambridge and St Thomas' Hospital and carried out his postgraduate training in surgery mainly in Cambridge. After a secondment as Visiting Assistant Professor at the Indiana University medical Centre, he returned to Cambridge as Lecturer in Surgery (Honorary Consultant). He took up his present post as professor of Transplantation in Oxford in 1999. He is also Director of the Oxford Transplant Centre and Programme Director for specialist training in general surgery for the Deanery.

 


 

 

 

Senior Business Manager, Almac Sciences Ltd

Denis completed his academic qualification in organic chemistry at Sussex University, UK (1989-1993). He then moved directly into a business development role. Over the years, Denis has developed strong knowledge in early clinical development projects including API synthesis, radiolabelling, polymorph screening, formulation development and drug product manufacture. Denis has held a range technico-commercial roles, working for Chiroscience/ChiroTech from 1997-2000, then Synetix Chiral Technologies, part of ICI (2000-2004) and since 2004 in his current role at Almac.

 


 

 

 

Partner, Atlas Venture

Regina Hodits is a Partner in the life sciences group. She joined Atlas Venture in 2004 and focuses on investments across Europe. She began her career in venture capital in 2000 with Apax Partners in Munich, where she was responsible for life science investments and closely involved with Apaxí investments in Genmab, Silence Therapeutics, Astex and Wilex. Prior to Apax Partners, she was an industry specialist for pharmaceutical and biotech companies at McKinsey & Company focusing on building new businesses, spin-offs and mergers in the sector.
Regina serves on the boards of Atlas companies Fibrex, f-star, and Jenavalve, where she was a founding investor. In addition, she sits on the boards of portfolio companies Egalet and NovaMed and is a board observer on Nitec. Regina was on the board of Atlas investment U3 Pharma which was acquired by Daiichi Sankyo Co., Ltd. in 2008.
Regina holds a Ph.D. in Biochemistry, a Master of Science from the Technical University in Vienna, Austria and she did her post-doctoral research at MRC in Cambridge, UK. She has been the recipient of a number of scientific awards and research grants, and has published in several journals, including Nature Biotech and JBC.

 


 

 

 

Chief Scientific Officer, Novolytics

Nick was the founding CSO of Novolytics and has been responsible for all aspects of the business with current responsibility for operations and business development. In this time he has created successful linkages for Novolytics which are currently being progressed in preparing for clinical trials. Nick has raised over £1.0 million of funding for Novolytics in both grants and equity finance. Prior to Novolytics Nick gained commercial management experience at Oxagen Limited (UK) which was followed by a business development role in the technology transfer office of the University of Warwick where he was involved with assessment of ideas for commercialisation and set up several small biotech companies including Novolytics. Nick has also worked at the University of Manchester Incubator Company as a business consultant and formed and headed up the business development capabilities at Warwick HRI, a department of the University of Warwick.

 


 

 

 

Senior Director, Health Policy Europe, Genzyme (US)

Wills Hughes-Wilson is Senior Director, Health Policy Europe at Genzyme, working on Genzymeís policy development in the European Union. She is Chair of the Advanced Therapies Working Group at EuropaBio, the European Association of Bioindustries and member of the EBE, the European Biopharmaceutical Enterprises group, a specialised group representing the interests of biopharmaceutical companies operating in Europe. The working groups bring together companies active in the sector, to develop consensus-based contribution to the European law-making procedure in the field of Advanced Therapies.
Prior to joining Genzyme, Wills was Executive Manager at EBE, and previously at the European Federation of Animal Health, representing veterinary medicine R&D companies. Wills graduated in Law & Politics from the University of Durham in the UK and is a member of both the International Association of Business Communicators (IABC) and the Society of European Affairs Practitioners (SEAP).

 


 

 

 

Senior Vice President, Science Environment Development, GlaxoSmithKline

Dr Jackie Hunter has worked in the pharmaceutical industry for over 20 years. Most recently, as head of the Neurology Centre of Excellence for Drug Discovery at GlaxoSmithKline, she led the discovery and development of new therapeutics for neurological and gastrointestinal disorders. This resulted in potential new treatments for multiple sclerosis, Alzheimerís disease and GI disorders.
In 2008 she became the Senior Vice President & Head of Science Environment Development with a remit to develop a more open and transparent global R&D architecture. This includes new ways of working with academia and other publically funded bodies. She is a member of the Innovative Medicines Initiative and Board.

 


 

 

 

Chief Financial Officer, Glide Pharma

Following a degree in physics, Simon joined Ernst and Young where he qualified as a Chartered Accountant. He joined Glide Pharma in early 2005 and together with Glide Pharmaís CSO, Simon is focussed on fundraising and corporate development, he also supports the companyís in-licensing and out-licensing activities as well as managing the day-to-day financial and infrastructural operations. Simon was previously CFO at Oxonica, the AIM-listed nanomaterials company, between 2000 and 2005, and has also served on the Board of industrial biotechnology company, Green Biologics.

 


 

 

 

Chief Executive Officer, Glysure

Mr. Jones has over 19 years of experience in the medical device and diagnostic industry. He joins Glysure from Tensys Medical, where he was CEO from 2005 through 2008; taking over a turnaround venture backed company and leading development of the first clinically-acceptable, continuous, non-invasive blood pressure monitor. Prior to joining Tensys, Mr. Jones spent 9 years with Nellcor Inc, a division of Tyco International Ltd, most recently as VP of Marketing responsible for the pulse oximetry and critical care businesses. He spent six years in sales and marketing management positions at BioGenex Laboratories. Mr. Jones is a graduate of Yale University with a Bachelor of Science Degree in Molecular Biophysics and Biochemistry.

 


 

 

 

Chief Scientific Officer, Biotecnol

Andrew Kelly was one of the two founders of Biotecnol back in 1997, together with Pedro Pissarra. Since then he has been active in developing the company from a consultancy to a biopharmaceutical company providing product development services for clients, including clinical trial products; for the development of the companyís antibody pipeline, and also for developing the companyís platform technologies.
In addition to directing all scientific activities within Biotecnol, he is also responsible for the management of the IP portfolio, a significant part of the companyís ongoing business development and has lectured at the University of Newcastle on "Business for the Bioscientist.î

 


 

 

 

Partner, Mewburn Ellis LLP

Simon joined Mewburn Ellis LLP in 1991 and joined the partnership in 1997. Simon handles patent work in chemical, biotechnology, pharmaceutical and nanotechnology fields, in particular protein engineering, peptide therapeutics, enzymes, microarrays, microfluidic devices, nanoparticles and proteomics.

 


 

 

 

Partner, Manches LLP

Jim graduated in biochemistry from the University of Aberdeen, and progressed to an MSc in biochemical engineering from the University of Birmingham before converting to law. He was articled at the niche intellectual property firm, Bristows Cooke & Carpmael. He spent 5 years with City law firm McKenna & Co, before joining NabarroNathanson in October 1993. He joined Manches from Nabarros in May 2003, as a Partner in the Technology & Media Department in the Thames Valley office.
Jim has specialised in intellectual property since admisssion in 1987, conducting disputes relating to patents, copyrights, trade marks, confidential information and designs.

With his technical background he has also advised a number of science and engineering based clients on the protection and exploitation of their IP rights through R&D agreements, licensing, sales and acquisitions, especially for clients in the pharmaceutical, biotechnology, agri-bio, medical device and veterinary medicines sector. His clients range from academics and university technology transfer offices, through growing companies to those listed on the London and New York stock exchanges.

 


 

 

 

President and Chief Scientific Officer, CellCentric. Ex-Chief Scientific Officer and Development Director, Piramed Ltd

David worked for over 20 years in major pharmaceutical companies both in Europe and the US and established an international reputation in anti-infectives R&D. In 1999, he joined the UK biotech sector, simultaneously taking on various executive, non-exec and advisory roles in an attempt to learn rapidly about the business environment. As CSO of RiboTargets plc, he successfully transformed the scientific basis of the company from one based on the discovery of anti-infective molecules targeting discreet RNA structural motifs into one predominantly focused on the discovery and development of anti-cancer agents. Following the merger of RiboTargets and British Biotech, he became Director of R & D for the combined organization and then, prior to his departure, oversaw the merger of British Biotech with Vernalis. David was subsequently appointed CSO and R&D Director of Piramed Ltd, based in Slough. Piramed signed a lucrative pre-clinical deal with Genentech in November 2005 and was subsequently acquired by Roche in May 2008. David left Roche at the end of November 2008 and is currently President CSO of CellCentric Ltd and a non-executive director of Procarta Ltd.
David is a past Member of Council of the American Society for Microbiology and on the editorial board of Current Opinions in Microbiology. He continues to serve on various biotech Scientific Advisory Boards.

 


 

 

 

Founding Director, Celleron Therapeutics

Nicholas has over 20 years of experience in biotechnology and healthcare. He founded Prolifix in 1995, a successful spin-out from the UK Medical Research Council, focussed on cancer drug discovery and was CSO until its merger with the Scandinavian oncology company TopoTarget. He acted as Chief Business Development Officer in TopoTarget, and was responsible for completing a number of significant deals with both large and mid size companies. Nick has extensive scientific, commercial and financing experience derived from the biotechnology sector. He is Professor of Cancer Biology at the University of Oxford, and was previously Cathcart Professor of Biochemistry at the University of Glasgow. He is a Fellow of the Royal Society of Edinburgh, a Fellow of the Academy of Medical Sciences and a Member of EMBO. He has authored over 150 publications, is an inventor on an extensive number of granted patents, and has consulted extensively in the biotechnology sector. He is a Founding Director of Celleron Therapeutics, focussed on developing targeted cancer medicines.

 


 

 

 

Managing Director, MorphoSys UK

Andrew gained a PhD relating to antibody immunotherapy from the University of Southampton in 1989, when the current applications of antibody based therapeutics could only be imagined. After a spell in a regional diagnostic laboratory with the NHS he joined Serotec in 1994 to set up their internal QC systems. Since then he has progressed within the company to take responsibility for manufacturing and new product development. Following the acquisition of Serotec by MorphoSys in 2006 Andrew has been responsible for Scientific Affairs within the AbD Division, and was appointed Managing Director of MorphoSys UK in June 2008.

 


 

 

 

Managing Director, PharmaFor Ltd

David, a pharmacist by profession, founded Pharmafor ltd, a company providing specialist assistance to small and emerging enterprises in the life science sector. Having successfully been responsible and involved in several spin-outs and start-ups he now has focused this knowledge and experience into assisting multiple start-ups and growth companies. Prior to this he has held a number of director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life Technologies, OSI, Bilcare and Surface Therapeutics. These have spanned the full range of activities ranging from discovery, through manufacturing to sale of pharmaceutical products, diagnostics and devices. He is a non executive director of Venturefest Ltd, a member of the advisory board of OBN and an independent Governor of Oxford Brookes University. He is heavily involved with ensuring academic inventions are progressed to commercialisation through rapid innovation.

 


 

 

 

Chief Executive Officer, Domainex

Eddy joined Domainex in May 2007. Since joining Domainex he has led the company through a finance round and restructured the company to a site at Cambridge. His experience covers large pharma including Wellcome and GlaxoWellcome and biotechs including Medivir. Immediately before joining Domainex he worked as a consultant providing strategic guidance and experience in anti infectives to a variety of pharma and biotechs. Before this he was Head of the UK site and Director of Lead Discovery for Medivir. Amongst other things he was a key player in Medivirís outlicensing activities, including deals with J&J (Tibotec), Roche, Boerhinger and GSK. After a period of time in academic research he began his industrial career at the Wellcome Research labs eventually becoming Head of Gene Targets with projects in virology and gene therapy of cancer. Post acquisition he joined GW as Head of Antiviral Research. Eddy is a member of the MRC Infection and Immunity Board and Translational Research Group.

 


 

 

 

Executive Vice President, OSI Pharmaceuticals Inc. and President, Prosidion

Anker Lundemose is a biotech entrepreneur and has co-founded several companies including Symphogen, Santaris Pharma and Prosidion. He has an extensive background spanning academia, large pharma as well as biotech and has held positions within R&D, Business Development as well as Executive Management. Anker has been Executive Vice President and President (Prosidion) of OSI Pharmaceuticals (NASDAQ:OSIP) since April 2005 when OSI successfully acquired Prosidion Limited of which Anker was then CEO. Today Prosidion constitutes the UK subsidiary of OSI Pharmaceuticals and undertakes all of OSIís type 2 diabetes & obesity R&D activities. Prosidion currently has several programs in clinical development including the glucokinase activator PSN010 which is partnered with Eli Lilly. Prosidion further capitalizes on a portfolio of medical use patents covering the diabetes target DP-IV and the income from several non-exclusive licenses contributes to the profitability of OSI. Prosidion employs approximately 100 people in Oxford covering all aspects of R&D from early discovery to Phase II/III clinical trials. Anker Lundemose has previously held positions at Novo Nordisk and has served as member of the Board of Directors for Symphogen and for Display Biotech Systems which was acquired by Neurosearch in 2001. Currently he is a Director of Prosidion Limited & OSI Pharmaceuticals UK Limited and further sits on the Advisory Board to Oxfordshire Bioscience Network.

 


 

 

 

President & Chief Exceutive Officer, Takeda Research Investment Inc.

Dr. Martin is President and CEO of TRI with day-to-day responsibility for operations. He brings more than 28 years of pharmaceutical R&D experience, primarily in multinational Pharmas (Wellcome; Glaxo Wellcome: Hoffman La Roche). He was responsible for the discovery and preclinical development of Zomig®, marketed worldwide for the acute treatment of migraine. More recently, Dr. Martin served as Chief Technical Officer at Telik Inc. with responsibility for technology and business development before establishing a Bay Area biopharmaceutical consulting operation, Discovery-Insight. Dr. Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK.

 


 

 

 

Chief Executive Officer, Apitope

Keith is a director and entrepreneur with a successful 30 year career in R&D, corporate & business development and biotech start-up with both executive and non-executive Board, management and leadership roles in England, Belgium, USA & Japan. Keith has raised more than Euro 15 million for biotechs and developed products from bench to market and completed high value licensing deals. Experienced in venture investment, he began his career as a Wellcome Trust Research Fellow in Mental Health at University of Nottingham Medical School and received a NATO Exchange Fellowship to Princeton University.

 


 

 

 

Partner, Edwards Angell Palmer & Dodge Innovations LLP

Dr. Tony Maschio has extensive experience in biotechnology patenting and specialises in advising companies in strategy and value generation using Intellectual Property Rights. He has acted before the European Patent Office representing many clients in complex Opposition and Appeal proceedings. His success has been individually recognised in the Legal 500, which provides independent advice to clients seeking the best attorneys for their work. He has also been individually recognised by Chambers & Partners who have been publishing their world-famous guides to the legal profession since 1990 and said "Tony Maschio is renowned for his biotech work". Tony specializes in immunology and biotechnology, including RNAi technology.

 


 

 

 

Business Development Director, Biotica

Melanie McCullagh joined Biotica as Business Development Director in April 2008. She was previously at Antisoma (London, UK), an LSE listed cancer drug development company. There she was instrumental in the 2007 licensing of ASA404 to Novartis in a deal worth $890m, and was also responsible for bringing new investigational cancer drugs into the company through in-licensing and collaborations. Prior to Antisoma, Melanie led the Strategy Analysis group in Datamonitor Healthcare (London, UK), providing insight to leading pharmaceutical and biotechnology clients into areas such as forecasting, licensing, M&A and portfolio management

 


 

 

 

President and Chief Scientific Officer, EUSA Pharma Inc

Bryan Morton is the Founder, President and Chief Executive of EUSA Pharma Inc, a rapidly growing transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care. Prior to founding EUSA in 2006, Bryan was the CEO of Zeneus Pharma, which he founded following the $120m acquisition of Elanís European business. Zeneus was subsequently acquired by Cephalon in late 2005 for $360m after two highly successful years of rapid growth and profitable trading.

Bryanís entrepreneurial success is built on 30 years of commercial, business development and general management experience in the pharmaceutical industry, spent largely with Merck & Co Inc. and Bristol Myers Squibb. He has extensive international experience, particularly in the US and Europe, having held senior positions, including at Board and SVP level, in America, the UK, Belgium and Australia.
In addition to his role leading EUSA Pharma, Bryan is a Non-executive Director of the stem cell company ReNeuron, a Director of the medical device business Aircraft Medical Ltd and sits on the Global Advisory Board at Pilgrim Software Inc, which is focused on the life sciences sector. Bryan holds an MBA from Durham University in the UK, a BSc in Pharmacology from Aberdeen University in Scotland and is a graduate of the INSEAD European Management Programme.

 


 

 

 

Co-Founder and Investment Director, Oxford Capital Partners

David Mott is the co-founder and Investment Director of Oxford Capital Partners and has been investing in emerging technology companies since 1999. His investment experience covers a range of sectors, from new media to renewable energy and from medical devices to novel materials. The Oxford Capital Partners healthcare is focused on investments in medical devices, medical instruments, drug discovery, personalized medicine and pandemics. The portfolio includes companies such as Glide Pharma, OrthoMimetics, Oxford BioTherapeutics, Oxitec, Scancell, Sirigen, Sphere Medical and Veryan Medical. In 2006, he was named Young Venture Capital Personality of the Year at the Investor Allstars Venture Capital Awards and has been cited as one of the rising stars of the UKís venture capital industry.

 


 

 

 

Chief Technical Officer, Eykona Technologies

Paul joined Eykona earlier this year, after more than 20 years with multinational wound care companies KCI and Smith and Nephew. The teamís vision is to make Eykona the gold standard in wound assessment, and Paulís experience in major geographical markets, in business and strategic planning, in new product development, launches and growth, and in key opinion leader relationships will contribute to realising our goal

 


 

 

 

Head of Research, Solace Pharmaceuticals

Alasdair joined Solace Pharmaceuticals in October 2007 as Head of Research. In this role he is responsible for moving preclinical projects through key milestones. Prior to Solace, Alasdair was at Pfizer for 18 years, most recently as Research Head of the Genitourinary therapeutic area. A Neuroscientist by training, he gained a BSc in Pharmacology from Aberdeen University and a PhD in Neuroscience from the University of Calgary.

 


 

 

 

Head of Technology Transfer Group, Isis Innovation

Before moving to Isis in July 2002, Linda was based at the University of York where she was manager of Bioincubator York Ltd and was responsible for the commercialisation of Bioscience research either through company start-up or licensing. Linda was also part of the White Rose Biotechnology Consortium which was established to exploit the possible synergies between the Universities of York, Sheffield and Leeds to maximise the commercial potential of life science research from the three Universities. Linda has had over 20 years experience in the Life Science industry with Zeneca plc / ICI plc during which time she was responsible for managing the biology research within developing life science businesses covering the pharmaceutical, agrochemical, biopolymer, chemical and food business. Linda has a BA in Biological Sciences and an MBA from the Saïd Business School, Oxford.

 


 

 

 

Chief Executive Officer, Chroma Therapeutics Limited

Ian Nicholson joined Chroma Therapeutics Limited in September 2004. Prior to joining Chroma, he was Senior Vice President of Business Development for Celltech Group plc, responsible for all global licensing activities and additionally held the position of Acting CEO, Oxford GlycoSciences plc following its acquisition by Celltech in 2003.
Prior to Celltech, Mr Nicholson was Commercial Director at Oxford Asymmetry International plc and has held a variety of senior commercial positions with Lonza AG and Amersham International plc. Mr Nicholson serves as a member of the board of directors of the Biotechnology Industry Association (BIA) and also serves as a non-executive director of Symphogen A/S and BioVentix Limited. Ian holds a BSc (Hons) degree from University College, London and an MBA from Boston University.

 


 

 

 

Chief Executive Officer, Adaptimmune Ltd.

James Noble is CEO of Adaptimmune Ltd. As the former CEO of Avidex Ltd and now Immunocore Ltd, James has in-depth knowledge of Adaptimmuneís technology as well as a wealth of prior experience in the international biotech community. Former CFO of British Biotech prior to leading Avider for 7 years, James also sits as a non-executive director on the Boards of GW Pharmaceuticals plc and Evolve Capital plc (both listed on AIM) and of Courage Corporation (listed on NASDAQ) plus privately held Axles Limited

 


 

 

 

Chief Executive Officer, Immunocore Limited

James Noble is CEO of Immunocore Limited. As the former CEO of Avidex Limited, James has in-depth knowledge of Immunocoreís mTCR technology as well as a wealth of prior experience in the international biotech community. Former CFO of British Biotech prior to leading Avidex for 7 years, James also sits as a non-executive director on the boards of GW Pharmaceuticals plc and Evolve Capital plc (both listed on AIM) and of Curagen Corporation (listed on NASDAQ) plus the privately held Axellis Limited. He is also CEO of Adaptimmune Limited.

 


 

 

 

Account Manager, Aptuit Ltd

Nigel joined Aptuit in 2008 to help increase API business within the Aptuit network. His experience covers large pharma process R&D, pilot plant operations, and cGMP manufacturing up to commercial scale for a Contract Manufacturing Organisation. Prior to joining Aptuit, Nigel worked for Shasun, as head of R&D in the UK, supporting all aspects of process design and scale-up. He started his career at Rhone-Poulenc Rorer in Dagenham initially working as a process research chemist, is happily married and has 2 children.

 


 

 

 

Chief Executive Officer, Oxitec

Hadyn joined Oxitec as CEO in November 2008. Hadyn has an extensive background in the Life Science sector. During his fifteen year career at Zeneca / Syngenta he held various positions, including General Manager of Zeneca Plant Sciences and European Director and Global Head of R&D for Advanta, one of the worldís largest seed companies. More recently he was CEO of MNL Pharma, a company that was focused on pioneering a novel approach in immunology. Mr Parry is also Chairman of Help for Heroes, a charity that was founded in 2007 to support wounded British soldiers.

 


 

 

 

Director, Licensing and External Research, Merck, Sharp Dohme (UK subsidiary of Merck & Co. inc.)

Robís remit since joining Merck's licensing team in Sept 2007 is to identify partnering opportunities in the UK & Irish Republic. He spent a period in Biotech between 2004-6, advancing programs in CV, metabolic disease & pain from concept to clinic. Previously he held positions of increasing seniority in Parke Davis Cambridge, UK, until their acquisition by Pfizer. He moved to their research laboratories in Ann Arbor, Michigan, as senior director for CNS Molecular Science in 2001. Collaborations were an important part of Robís mandate at Parke-Davis / Pfizer, proving to be a critical factor in the success of the projects he was involved with.
Before he joined the pharmaceutical industry Rob trained in biochemistry & physiology, followed by postgraduate study at Southampton & several years of fellowships at the University of Cambridge. He is also an associate investigator in the Cambridge University Centre for Brain Repair.

 


 

 

 

Head of Strategic Alliance Management, Europe Novartis Institutes of BioMedical Research

Dr Esteban Pombo-Villar CChem FRSC is Head of Strategic Alliance Management at the Novartis Institutes of BioMedical Research. His group within Strategic Alliances is responsible for managing the portfolio of current alliances with the Institutes. Prior to 2003 he was External Collaborations Manager for Nervous System Research, after gaining over 12 years experience in leading medicinal chemistry drug discovery projects in the same area. Dr Pombo-Villar obtained his PhD from Warwick University in the UK.

 


 

 

 

Former Chief Executive Officer, Arrow Therapeutics

Ken Powell is Executive Chairman of Q-Chip a Cardiff based life science company and an advisor to VC funds. Throughout his career he has developed life science research into successful commercial ventures. Immediately prior to his current role Ken was a founder and CEO of Arrow Therapeutics Ltd a wholly owned subsidiary of Astra Zeneca PLC (Arrow was acquired by Astra-Zeneca PLC for $150 million in February 2007).
With over 30 yearsí international experience in the pharmaceutical industry and academia, his previous posts have included Head of Antiviral Research and Head of Biology at the Wellcome Foundation. He was Professor of Virology and Cell Biology at the Wolfson Institute for Biomedical Research (UCL) where he was also deputy director from 1996 to 2002. During his time at WIBR Ken set up Inpharmatica (now part of Galapagos NV) and Ark Therapeutics (now LSE listed) in addition to Arrow Therapeutics which he founded with five colleagues in 1998. Powell is well known for attracting venture capital investment; his portfolio of backers have included high calibre groups from the US, Europe and Japan.

 


 

 

 

Chief Executive Officer, Polytherics

Dr Keith Powell graduated with a PhD in The genetics of haem synthesis. After working on vitamin B12 synthesis at Glaxo, he joined the University of Newcastle to work on DNA repair. He then moved to ICI and worked on many projects including single cell protein and microbial plastics. Moving on to Zeneca, he led many groups including ìDiscoveryî, introducing high throughput screening , ìBiotechnologyî and ìEnvironmental Scienceî; his final position was as ìHead of Intellectual Propertyî. Keith then spent several years in California as Head of the Chemistry business of Maxygen. When he returned to the UK, he joined the Bloomsbury Bioseed Fund as Entrepreneur in Residence, becoming CEO of several companies.
Keith is now Chairman of Domainex Ltd and CEO of Polytherics Ltd. He is also a Partner in Longbow.

 


 

 

 

Chief Operating Officer, RegenTec Ltd

Robin Quirk is COO and a co-founder of RegenTec Ltd. A spin-out from The University of Nottingham, the company has developed materials that support the regeneration of functional tissue using via a new minimally-invasive approach. A registered pharmacist with experience spanning community, hospital, and industrial sectors of the profession, Rob has a PhD in biomaterials research and has worked for over ten years within the fields of tissue engineering and regenerative medicine.

 


 

 

 

Chief Executive Officer, OBN

Dr. Jon Rees is CEO of OBN, having taken over the direction of the network's activities in July 2005, taking the organisation to financial self-sustainability, diversifying its business, and leading the spin-out of OBN from the University in July 2008. As executive director, Dr. Rees sits on the 5-member Board of OBN, developing strategy for the organisation as well as Business Planning. He is responsible for the day-to-day operational management of OBN, including co-ordination the work of outside contractors and consultants, implementation of strategy, project management, fundraising, and business development.
Dr. Rees has several yearsí background in Project Management, which he moved into after having worked as a post-doctoral research officer in the Dept. of Plant Sciences (Univ. Oxford).

Dr. Rees conceptualized and delivered BioTrinity, now OBN's flagship one-to-one biotechnology partnering conference and company showcase of the South East most promising biotechs which attracted 400 delegates in its first year - and at which over 500 partnering meetings were held. BioTrinity became the largest biopartnering meeting in South East England (SEEDA) region in its inaugural year. Dr. Rees also instigated OBN's Group Purchasing Scheme which is expected to save OBN Member companies up to £1m over its first two years.

 


 

 

 

Senior Associate, Genzyme Ventures

Allison leads the investment process for Genzyme Ventures and manages its portfolio. She previously held a position within Genzymeís Transactions & Partnering group and played a key role in the recent Osiris Therapeutics transaction. Prior to joining Genzyme, Allison covered the biotechnology sector as a financial research analyst for Paramount Capital, a life-science focused hedge fund. She has also had experience within the fixed-income trading group of Goldman Sachs & Co., Pfizerís European Business Development group, and the Investment Banking division of ING Barings. Allison received her MBA with honors from the Wharton School of the University of Pennsylvania with a focus on Finance and Health Care Management. She also received her BA in Biochemistry and Economics from Dartmouth College, where she graduated Summa Cum Laude. Ms. Robbins is a CFA charterholder.

 


 

 

 

Chief Executive Officer, CMP Therapeutics

Bruce is a serial entrepreneur with experience in the biosciences sector. He started a biosciences company called Cytocell in 1991, and in 2002 started up a University of Oxford spin-out company called BioAnaLab, where he was part time CSO until 2003. He is co-founder and CEO of CMP Therapeutics Ltd a company founded on Medical Research Council technology that originated in a unit in the University of Oxford that has novel compound for treatment of allergies and infectious diseases in pre-clinical development.
After graduating from London University he spent 6 years in Roche as a research biochemist. He then moved into sales and marketing positions in the medical diagnostics industry. During his time at Porton International, Bruce was involved with the commercialisation of a number of specialised therapeutics before starting a diagnostic business for them. He is a special professor at the University of Nottingham business school, entrepreneur in residence at the Cass Business School, London and North Oxfordshire Enterprise hub, Hub Champion.

 


 

 

 

Chief Executive Officer, GlycoForm

David has more than 20 years experience in large pharmaceutical companies, having held a senior international position in research and development within GlaxoWellcome . He moved into the biotechnology sector in 2000 working as R&D director for Strakan Ltd (now ProStrakan Group), Charterhouse Therapeutics Ltd and Antisoma PLC before becoming CEO of Cerogenix Ltd. He was a non-executive director of BIBRA International, Enhance Biotech Inc, sat on the board of the UK Public Health Laboratory Service and has been a consultant in the life sciences practice of Spencer Stuart. He joined Glycoform as CEO in July 2008.

 


 

 

 

Head of Business Development, Technology Transfer, Wellcome Trust

Richard is a founding member of Technology Transfer, Wellcome Trust, where he is Head of Business Development. He is also an advisor to the Wellcome Trust Sanger Institute and Genome Research Limited. Richard has extensive experience with early-stage funding of life science technologies, commercial transactions and intellectual property management, Board, SAB and government agency advisory roles.

 


 

 

 

Vice President, Global Head Licensing - Pharma Partnering, Roche Pharmaceuticals Division

Mr. Nigel Sheail, based in Basel, Switzerland, leads the Global Licensing group in the Pharma Partnering department of Roche Pharmaceuticals. Pharma Partnering is department responsible for identifying, accessing, evaluating and pursuing opportunities with external partners. Mr. Sheail has been responsible for a broad range of deals from research technology collaborations through to phase 3 product licensing opportunities. He was also involved in the establishment of two ìspin-offî organizations, BioXell and Basilea.
Academically trained as a molecular biologist, Mr. Sheail is a qualified Chartered Accountant and has held a number of functions within the Pharmaceutical industry both with Roche and GlaxoSmithKline (GSK). Prior to joining Pharma Partnering, Nigel worked as the Global Controller for Research and was Finance Director responsible for the establishment of Rocheís operations in China which included the establishment of five joint venture operating companies and a holding company. Mr. Sheail was a founding member of the Swiss Pharma Licensing Group.

 


 

 

 

Chief Executive Officer, Orthox

Nick founded Orthox Ltd in 2008, securing £1.6 million seed funding from the Wellcome Trust, to commercialise regenerative cartilage and bone repair devices using a revolutionary new biomaterial, Spidrex®. A bioscience graduate of Oxford and Strasbourg Universities, Nick developed Spidrex® with Oxford Biomaterials Ltd., the company of which he was CEO for the four years prior to founding Orthox. During this period, he raised over £3.5 million in private equity finance and public grants to fund the Spidrex® development programme, and was founding Director of two other equity financed Oxford Biomaterials spin out ventures, Neurotex Ltd. and Suturox Ltd.

 


 

Chartered & European Patent Attorney, Partner, Edwards Angell Palmer & Dodge Innovations LLP

 

 

Dr. Candi Soames' practice has focused for some time on Biotechnology and Immunology. She has a first degree in Biochemistry and a D.Phil from the University of Oxford. Her strength in Immunology is reflected in her D.Phil work on complement regulation and subsequent post doctoral research on the basis of intracellular signalling in immune molecules. Candi is a standing member of the UK Chartered Institute of Patent Attorneys biotechnology committee. She also lectures frequently on European patent law and practice and writes for journals including Nature Drug Discovery on intellectual property issues.

 


 

 

 

Business Services Partner, James Cowper LLP

Sue Staunton has a particular interest in working with technology businesses and their owners and, as such, heads our technology team.
Sue works with clients on the development and implementation of their corporate strategies. She also has a great deal of experience in working with businesses in financial crisis to establish strategies to assist them to move forward successfully.

 


 

 

 

Deputy Chairman, Circassia Limited

Charles co-founded Circassia in May 2006. Immediately prior to establishing Circassia, Charles was a Director and General Counsel of Zeneus Pharma where he oversaw the companyís transactions, including the in-licensing of several products. Before this he was Executive Director, General Counsel and Company Secretary of PowderJect Pharmaceuticals Plc which he joined in 1996. While at PowderJect he was responsible for all legal, intellectual property and compliance matters, and managed the legal aspects of several major acquisitions and fundraisings, including the eventual sale of the company to Chiron for $1 billion in 2003. Prior to this, Charles practised as a corporate lawyer in the City of London for over 15 years.

 


 

 

 

Partner, Patent Attorney, Edwards Angell Palmer & Dodge Innovations LLP

Rebecca Tollervey is a partner at Mewburn Ellis LLP, working in the firmís Bristol office. She joined the Mewburn Ellis in 2000 and became a partner in 2008. Rebecca works in the firmís biotechnology group, and particularly in the fields of molecular and cellular biology, diagnostics and micro-arrays, and therapeutic biomolecules.

 


 

 

 

Chief Scientific Officer, Isogenica Ltd.

Chris joined Isogenica Ltd. in 2002 and has been developing the companyís platform technology, CIS Display, for the discovery of polypeptides as research reagents, diagnostic tools and therapeutics. He has also been involved in research and licensing deals with several pharma companies during his time with the company. Previously, he was Team Leader at Gendaq Ltd. (Sangamo Biosciences Inc.), which was a biotech spin out from the Laboratory of Molecular Biology, Cambridge, that developed customised transcription factors using engineered zinc finger DNA binding proteins.

 


 

 

 

Chief Executive Officer and Founder of PharmaVentures

Dr Walton is the Founder and CEO of PharmaVentures. After completing his doctoral research on the genetics of cell proliferation at the University of Michigan (US) and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).br /> Since 1992, his businesses have conducted over 450 consultancy assignments with pharmaceutical and biotechnology companies in more than 20 countries. These assignments have encompassed all aspects of deal transaction activities, including business and corporate strategy, strategic alliances, business development, technology valuations, business and financial modelling, due diligence, expert reports for IPOs, commercial assessments and market research.
Although Dr Waltonís main focus is his role as CEO of PharmaVentures, he is available for some consultancy assignments.

 


 

 

 

Senior Editor, Europe, BioCentury

Based in the U.K., Mike has been a commentator and analyst of the biotech industry for more than 20 years. After first joining BioCentury in 1997, Mike moved into the investment banking community in 2000 and was a sellside analyst for two investment banks. In 2002 he co-founded the business intelligence group Critical I Ltd. He rejoined BioCentury in 2005. In 2006, Mike was shortlisted by Nature Biotechnology in its 10th anniversary issue for making a significant contribution to biotech in the past 10 years. Mike, who graduated in biochemistry and chemistry from the University of London, formerly was Editor of both European Chemical News and Performance Chemicals.

 


 

 

 

Director of Mary Lyon Centre, MRC Harwell

Dr. Weaver joined MRC Harwell in Sept 08. Previously he was the Commercial Director of Medical Solutions, plc, a provider of pathology and diagnostic services to the UK healthcare industry. He was the CEO of Geneservice Limited, a genomics service provider that he founded as a spin-out from the UK MRC genome project. Before this Dr. Weaver worked as a Director of Technology Development for INCYTE Plc and Hexagen, Ltd. He has a PhD in Oncology from the University of Wisconsin Medical School.

 


 

 

 

Founder and Chief Executive Officer, Heptares Therapeutics

Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company. Inpharmatica was sold to Galapagos NV in 2006. He joined MRC Technology in 2006 in order to establish Heptares Therapeutics Ltd in July 2007, as Founder and CEO. Malcolm was elected Visiting Professor of Biochemistry at Imperial College, London in 1997, and to the Council of the UK Biotechnology and Biological Sciences Research Council in 2004.

 


 

 

 

Registered US Patent Attorney, Partner Edwards Angell Palmer & Dodge LLP

Kathleen advises biotech and pharmaceutical clients on strategic legal issues relating to intellectual property, including helping companies avoid roadblocks and laying the groundwork for new commercial efforts. She provides advice to clients on patent portfolio creation and management, patentability and freedom to operate legal opinions, patent prosecution, and intellectual property due diligence for investments. Kathy works closely with companies to ensure that intellectual property is effectively protected and/or avoided in their business deals. Her clients include start-up biotech companies, as well as mature biotech/pharma companies, and research institutions. Her work, in synergy with her European Patent Attorney colleagues, assists in growth of the biotech and pharmaceutical industries and commercialization of new drugs and disease treatments on a global basis.

 


 

 

 

Managing Director, De Facto Communications.

Mike specialises in both life sciences communications and in healthcare financial communications. A trained microbiologist, he has worked in a number of senior sales, marketing and technical roles for Glaxo, SmithKline and Wellcome in the UK and overseas.
An expert in financial communications, Mike has managed more than 10 IPOs raising well in excess of £200 million, worked on secondary and follow-on offerings raising in excess of £2.4 billion, consulted on a number of mergers and acquisitions of products and companies in the life science sector, developed disaster recovery programmes for SME companies, and conducted due diligence on products companies and facilities for acquisition purposes.
Mike also worked with Deutsche Bank to raise money to privatise the Bulgarian pharmaceutical industry. As the CEO of Balkanpharma, he led the consolidation of the three pharmaceutical facilities in Bulgaria into one cohesive organisation. Balkanpharma remains the core of the Actavis Group the US$ 1.4 billion market capitalization generics manufacturing company.

 


 

 

 

Chief Executive Officer, e-Therapeutics plc.

Malcolm has been a Royal Society Research Fellow at the RIKEN Institute, and at Oxford University, Director of the Institute for Neuroscience, Provost of Science and Engineering, and Pro-Vice Chancellor at Newcastle University. His research focuses on understanding how function arises from structural aspects of complex biological systems, using complex systems analysis and informatics. Outputs include 6 publications in Nature and Science, and 6 new drug candidates, 2 of which are entering Phase III. He is one of eighteen scientists worldwide nominated by the Sunday Times as the "Brains behind the 21st Century.î

 


 

 

 

 

 

 

Previous Biographies

 

John March, Chief Executive Officer & Chief Scientific Officer, Big DNA

I am the founder and Chief Executive of BigDNA Ltd, a vaccines development company (both platform & products) utilising a patented technology using bacteriophages (viruses of bacteria) as DNA vaccine delivery vehicles. I bring perhaps a slightly unconventional approach to biotech commercialisation (the company is named after my car number plate!), and I have been involved in all stages of the research and commercial development to date, morphing from scientist to businessman. BigDNA is fully funded for the next 3 years and has grown to 14 employees. We are targeting a major pharma trade sale within 3 years, by which time we expect to have completed phase I/II trials of our lead product.  

 

 

 

 

 

 

 

Charlie Alexander

 

Professor Malcolm Young

 

Mike Wort

 

Dr. Kathleen Williams

 

Dr Malcolm Weirs

 

Dr. Tom Weaver

 

Mike Ward

 

Fintan Walton

 

Chris Ullman

 

Rebecca Tollervey

 

Charles Swingland

 

Sue Staunton

 

Dr. Candi Soames

 

Nick Skaer

 

Nigel Sheail

 

Dr Richard Seabrook

 

David Scales

 

Bruce Savage

 

Allison Robbins

 

Dr Jon Rees

 

Robin Quirk

 

Keith Powell

 

Ken Powell

 

Esteban Pombo-Villar

 

Rob Pinnock

 

Hadyn Parry

 

Dr Nigel Parkinson

 

James Noble

 

James Noble

 

Ian J. Nicholson

 

Linda Naylor

 

Alasdair Naylor

 

Paul Murphy

 

David Mott

 

Bryan Morton

 

Dr Melanie McCullagh

 

Dr Tony Maschio

 

Keith Martin

 

Graeme Martin

 

Dr Anker Lundemose

 

Eddy Littler

 

David Laskow-Pooley

 

Andrew Lane

 

Nicholas La Thangue

 

Dr David Knowles

 

Jim Kinnear Wilson

 

Simon Kiddle

 

Dr Andrew Kelly

 

Chris Jones

 

Simon Jones

 

Dr Jackie Hunter

 

Wills Hughes-Wilson

 

Dr J Nick Housby

 

Dr Regina Hodits

 

Denis Geffroy

 

Professor Peter Friend

 

Sam Fazeli

 

Dr Mike Evans

 

Martin Edwards

 

Dr. Wolfgang Ebenbeck

 

Nick Dunster

 

Paul Drohan

 

James Dipple

 

John Dawson

 

Paul Davies

 

Jane Dancer

 

Rod Cook

 

David Colpman

 

Dr Christophe Chassagnole

 

Kate Burt

 

John Burt

 

Carlton Brown

 

Dr Richard Broadhead

 

Dr John Beadle

 

Adam Barak

 

Patrick Baddeley

 

Chris Atterwill

 

Dr Mark Ashton

 

Andrea Alunni

 

 

Jim Kinnier-Wilson, Head of Life Sciences, Manches

Jim Kinnier Wilson is Head of Life Sciences at Manches LLP. He is a biochemist with an MSc in Biochemical Engineering and has specialised in intellectual property, advising many life sciences clients since qualifying in 1987

 

 

 

 

 

 

Dr Spragg gained a first class honours degree in microbiology and PhD in marine biotechnology from Heriot-Watt University. Dr Spragg developed the company whilst holding a Royal Society of Edinburgh Enterprise Fellowship in biotechnology/

Aquapharm is a leading marine biotechnology company pioneering the discovery, isolation and development of novel bio-chemicals isolated from the biological diversity of marine microbes. The company is developing these natural products as new anti-infectives as well as further high value products for use in other commercial sectors such as natural cosmetic ingredients, nutraceuticals and industrial applications.

Since founding the business, Dr Spragg has successfully raised over £10M in equity finance. D Spragg is the recipient of the 2007 Gannochy Innovation Medal from the Royal Society of Edinburgh for achievements in biotechnology & innovation. In 2008, Dr Spragg's entrepreneurial achievements were recognised through winning the Ernst & Young Entrepreneur of the year 2008 in Health Care for Scotland. 

 

Linda McCausland, Head of Physical Sciences, Almac Group Drug Development Services





BioTrinity 2014 highlights
1,014 delegates from 32 countries
624 companies
184 speakers
107 company showcase presentations
2,462 one-to-one meetings
130+ investor delegates from 12 countries
61 exhibitors
80 global pharma/corporate venture delegates
33 global pharma/medical technology corporates